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A B S T R A C T
Background
Financial incentives, monetary or vouchers, are widely used in an attempt to precipitate, reinforce and sustain behaviour change,
including smoking cessation. They have been used in workplaces, in clinics and hospitals, and within community programmes.
Objectives
To determine the long-term effect of incentives and contingency management programmes for smoking cessation.
Search methods
For this update, we searched the Cochrane Tobacco Addiction Group Specialised Register, clinicaltrials.gov, and the International
Clinical Trials Registry Platform (ICTRP). The most recent searches were conducted in July 2018.
Selection criteria
We considered only randomised controlled trials, allocating individuals, workplaces, groups within workplaces, or communities to
smoking cessation incentive schemes or control conditions. We included studies in a mixed-population setting (e.g. community, work-
, clinic- or institution-based), and also studies in pregnant smokers.
Data collection and analysis
We used standard Cochrane methods. The primary outcome measure in the mixed-population studies was abstinence from smoking at
longest follow-up (at least six months from the start of the intervention). In the trials of pregnant women we used abstinence measured
at the longest follow-up, and at least to the end of the pregnancy. Where available, we pooled outcome data using a Mantel-Haenzel
random-effects model, with results reported as risk ratios (RRs) and 95% confidence intervals (CIs), using adjusted estimates for cluster-
randomised trials. We analysed studies carried out in mixed populations separately from those carried out in pregnant populations.
Main results
Thirty-three mixed-population studies met our inclusion criteria, covering more than 21,600 participants; 16 of these are new to this
version of the review. Studies were set in varying locations, including community settings, clinics or health centres, workplaces, and
outpatient drug clinics. We judged eight studies to be at low risk of bias, and 10 to be at high risk of bias, with the rest at unclear risk.
Twenty-four of the trials were run in the USA, two in Thailand and one in the Phillipines. The rest were European. Incentives offered
included cash payments or vouchers for goods and groceries, offered directly or collected and redeemable online. The pooled RR for
quitting with incentives at longest follow-up (six months or more) compared with controls was 1.49 (95% CI 1.28 to 1.73; 31 RCTs,
adjusted N = 20,097; I2 = 33%). Results were not sensitive to the exclusion of six studies where an incentive for cessation was offered
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at long-term follow up (result excluding those studies: RR 1.40, 95% CI 1.16 to 1.69; 25 RCTs; adjusted N = 17,058; I2 = 36%),
suggesting the impact of incentives continues for at least some time after incentives cease.
Although not always clearly reported, the total financial amount of incentives varied considerably between trials, from zero (self-
deposits), to a range of between USD 45 and USD 1185. There was no clear direction of effect between trials offering low or high total
value of incentives, nor those encouraging redeemable self-deposits.
We included 10 studies of 2571 pregnant women. We judged two studies to be at low risk of bias, one at high risk of bias, and seven
at unclear risk. When pooled, the nine trials with usable data (eight conducted in the USA and one in the UK), delivered an RR at
longest follow-up (up to 24 weeks post-partum) of 2.38 (95% CI 1.54 to 3.69; N = 2273; I2 = 41%), in favour of incentives.
Authors’ conclusions
Overall there is high-certainty evidence that incentives improve smoking cessation rates at long-term follow-up in mixed population
studies. The effectiveness of incentives appears to be sustained even when the last follow-up occurs after the withdrawal of incentives.
There is also moderate-certainty evidence, limited by some concerns about risks of bias, that incentive schemes conducted among
pregnant smokers improve smoking cessation rates, both at the end of pregnancy and post-partum. Current and future research might
explore more precisely differences between trials offering low or high cash incentives and self-incentives (deposits), within a variety of
smoking populations.
P L A I N L A N G U A G E S U M M A R Y
Can rewards help smokers to quit in the long term?
Background
Smoking is the leading cause of disease and death worldwide. Most smokers want to quit, but stopping smoking can be very challenging.
Quitting smoking can greatly improve people’s health. Rewards, such as money or vouchers, can be used to encourage smokers to quit,
and to reward them if they stay stopped. Such schemes can be run in workplaces, in clinics, and sometimes as community programmes.
Study types
We conducted our most recent search for studies in July 2018.
General trials: We found 33 trials, covering more than 21,600 people, that tested different rewards schemes to help smokers to quit.
Two studies included smokers from mental health clinics, two from primary care clinics, two from head-and-neck cancer treatment
clinics, two from colleges or universities, and one in Thai villages. Twenty-four of the trials were run in the USA. All the trials followed
up participants for at least six months. Those who had quit were checked by testing their breath or bodily fluids. Rewards were cash
payments, vouchers, or the return of money deposited by those taking part.
Pregnancy trials: We looked at studies in pregnant women separately. We found ten trials, nine based in the USA and one in the UK,
covering 2571 pregnant women who smoked. Rewards were vouchers that were sometimes increased in value, depending on how long
the woman had managed to stay quit.
Key results
General trials: Six months or more after the beginning of the trial, people receiving rewards were more likely to have stopped smoking
than those in the control groups. Success rates continued beyond when the incentives had ended. Studies varied in the total amounts
of rewards that were paid. There was no noticeable difference between trials paying smaller amounts (less than USD 100 (US dollars))
compared to those paying larger amounts (more than USD 700).
Pregnancy trials: Combining data from nine trials showed that women in the rewards groups were more likely to stop smoking than
those in the control groups, both at the end of the pregnancy and after the birth of the baby.
Quality of the studies
Some of the studies did not provide enough data for us to fully assess their quality. Taking out the lowest-quality trials from the analysis
did not change the results. Our certainty in our main findings is high. Our certainty in our findings in pregnant women is moderate,
as some studies were of lower quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Smoking cessation: incentives compared to no incentives in mixed populations
Patient or population: Adult smokers
Setting: Mixed
Intervention: Incent ives for smoking cessat ion
Comparison: No incent ives
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*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOverall we rate the quality of evidence as high, despite some of the included studies being considered at high risk of bias.
This is because when analyses were restricted to only those studies at low risk of overall bias there was st ill a signif icant
ef fect in favour of the intervent ion. Sim ilarly, when we removed studies at high risk of bias f rom analyses, leaving only those
at low and unclear risk of bias, there remained an ef fect est imate clearly in favour of the intervent ion. We are therefore very
















































































B A C K G R O U N D
Description of the condition
Smoking is the leading cause of preventable death and disease
worldwide. Most adults who smoke wish to quit, but quitting is
challenging and despite the presence of effective evidence-based
cessation methods, quit rates remain low. Quitting smoking can
lead to substantial health gains, even later in life. The earlier some-
one quits smoking, the more they reduce their risk of developing
smoking-related diseases (WHO 2018).
Description of the intervention
There is interest and support for incentive-based programmes
to change unhealthy behaviours, including smoking, weight loss,
and alcohol consumption, and to increase levels of physical ac-
tivity (Giles 2014; NICE 2010). However, financial incentives
to promote behaviour change are controversial. Qualitative re-
search demonstrates that public acceptability of incentives varies
(Giles 2015), perhaps due to misinformation or a lack of education
(Robertson 2018), and a concern about commissioning (fund-
ing of ) incentive-based schemes. There has also been a concern
that incentive schemes may only be effective for the duration of
time that incentives are offered. There may be cultural variation
in acceptability, such that implementation of incentive-based pro-
grammes may prove more difficult in some settings (Berlin 2018).
Many developing countries, particularly in Latin America, op-
erate conditional national or regional cash transfer programmes
of monetary rewards for behaviour change or compliance, often
targeting improvements in child and maternal health (Lagarde
2009; Paes-Sousa 2011; Powell-Jackson 2011). In the UK, in-
centive schemes often focus on encouraging pregnant women to
quit smoking, with well-established programmes such as ’Give It
Up For Baby’ (Ballard 2009; Radley 2013), conducted in Tayside
(Scotland) and awarding grocery vouchers for verified abstinence.
A series of studies included in the last update of this review, con-
ducted in the USA (Donatelle 2000a; Donatelle 2000b; Donatelle
2002; Heil 2008; Higgins 2004; Higgins 2014) and a large ran-
domised trial in the UK (Tappin 2015a) also attest to the tobacco
control community’s interest in the feasibility of rewarding preg-
nant women who smoke for achieved abstinence.
How the intervention might work
Incentives and rewards (terms used interchangeably in studies con-
tributing to this review) routinely feature in smoking cessation
programmes. Theory suggests they might work according to be-
havioural processes of operant conditioning (positively reward-
ing the desired behaviour), or by providing short-term gain for
behaviour change that ultimately results in long-term gain, but
is perceived as less proximal to the individual (delay discount-
ing) (Gneezy 2011; Miglin 2017). Incentives can be used to en-
courage recruitment into the programme, to reward compliance
with the process, and to reward cessation achieved at predefined
stages, usually contingent on production of a biochemically-con-
firmed cessation outcome. A variety of rewards have been used for
these purposes, including cash payments, vouchers exchangeable
for goods (excluding alcohol and cigarettes) or leisure activities,
salary bonuses, or promotional items such as T-shirts, pens and
bags.
Rewards can be given for attendance at the programme and at
follow-up appointments, irrespective of subsequent smoking sta-
tus (i.e. guaranteed or non-contingent), or can be paid and scaled
relative to the participant’s success in smoking cessation (i.e. con-
tingent) (Higgins 2002). Recent trials and systematic reviews have
explored variations in the type, the scale, and the scheduling of re-
wards (Adams 2014; Crossland 2015; Giles 2014; Jochelson 2007;
Leeks 2010; Sigmon 2012b), and in their acceptability as a mech-
anism for behaviour change (Hoddinott 2014; Thomson 2014).
This review focuses on rewards for abstinence (as opposed to at-
tendance, etc.).
Why it is important to do this review
This updated review is a modified version of our previous review
(Cahill 2015). Over the thirteen-year lifetime of this review, the
debate about incentive-based smoking cessation programmes has
shifted from their feasibility (i.e. can they work?) to their effec-
tiveness (i.e. do they work?), relative success or limitations of the
mechanisms deployed (Higgins 2012; Promberger 2012), the mer-
its of rewards (’carrots’) versus penalties (’sticks’) (Adams 2014;
Lynagh 2013; Volpp 2014), the extent to which achieved changes
can be maintained (Jochelson 2007; Strickland 2014), the pos-
sibilities of unintended consequences (Marteau 2009; Thomson
2014), and the acceptability and implementation of incentive-
based programmes (Berlin 2018). Although many of the older in-
cluded studies may not address these issues, our review contributes
to a growing evidence base that defines the rationale for incentive-
based programmes and identifies areas for further investigation. In
this update we also explore the use of incentives in sub-populations
of participants, consider the longevity of effects of incentives, and
the cumulative value of incentives optimal for cessation outcomes.
O B J E C T I V E S
To determine the long-term effect of incentives and contingency
management programmes for smoking cessation. We address the
following questions:
1. Do incentives reduce the prevalence of smoking at longest fol-
low-up?
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2. What is the optimal amount and type of incentives that might
be offered to impact on cessation outcomes?
3. What are the cost implications of incentives, to employers and
to the community?
4. How great is the risk of disbenefits arising from the use of
incentives, e.g. false claims, ineligible applicants?
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) or cluster-RCTs allocating
individuals, communities, workplaces or groups within work-
places to intervention or to control conditions.
Types of participants
Adult smokers, of any gender, in any setting, including trials con-
ducted in pregnant women who smoke. We have not included
trials aimed exclusively at adolescents, as they are covered by a
separate Cochrane Review (Fanshawe 2017).
Types of interventions
Incentive schemes to reward participants for validated cessation
and abstinence in smoking cessation programmes. We have not
included reports of the effectiveness of incentives or rewards to
healthcare workers (physicians, nurses) for the delivery of smoking
cessation interventions, or of reimbursement to participants for
smoking cessation treatment costs, as these are covered in another
Cochrane Review (Van den Brand 2017). We include in this re-
view studies which offered entry into prize draws alongside other
guaranteed incentives, but studies which offer only non-guaran-
teed rewards (e.g. raffle only) are covered by a separate review of
’Competitions for smoking cessation’ (Fanshawe 2019).
Control groups could be usual care or a smoking cessation inter-
vention similar to that provided in the experimental group, but
without incentives. Studies comparing two interventions provid-
ing incentives, but which varied by the amount or type of incen-
tive, were also eligible.
Types of outcome measures
The primary outcome for this review is long-term smoking ces-
sation. This could be measured as point prevalence, sustained or
continuous abstinence; however, where multiple measures were
used in one study we took the most stringent measure. For tri-
als in mixed populations abstinence had to be assessed at a mini-
mum of six months from the start of the intervention. For trials in
pregnant women, we extracted smoking cessation outcomes at the
closest follow-up to end of pregnancy, and also at longest follow-
up post-partum if reported. We did not require the minimum six-
month follow-up period for pregnant smokers because of the time-
limited nature of pregnancy. Abstinence could be self-reported or
biochemically validated, but we preferred biochemically validated
over self-reported rates.
We also looked at disbenefits and costs, where reported.
Search methods for identification of studies
We ran the most recent literature searches on 30th July 2018. For
this update we searched the Cochrane Tobacco Addiction Group
Specialised Register, using the search strategy in Appendix 1. The
Specialised Register includes studies identified by systematic elec-
tronic searches of multiple databases, handsearching of specialist
journals, and ’grey’ literature, i.e. conference proceedings and un-
published reports not normally covered by most electronic index-
ing systems. At the time of the search the Register included the
results of searches of the Cochrane Central Register of Controlled
Trials (CENTRAL), issue 1, 2018; MEDLINE (via OVID) to up-
date 20180726; Embase (via OVID) to week 201836; PsycINFO
(via OVID) to update 201800820. See the Cochrane Tobacco
Addiction Group website for full search strategies and a list of
other resources searched.
We also conducted searches of the trial registers, clinicaltrials.gov,
and the WHO International Clinical Trials Registry Platform (IC-
TRP). We checked reference lists of eligible papers, and consulted
with experts in the field to identify any relevant forthcoming or
unpublished research. We have contacted the authors of ongoing
and included studies where necessary, and have recorded their co-
operation in the Acknowledgements section.
Data collection and analysis
Selection of studies
Two review authors (CN and SG) independently screened all
search results (titles and abstracts) for possible inclusion, resolv-
ing any discrepancies through discussion. The same two review
authors then independently assessed the full text of potentially
relevant studies, again resolving discrepancies through discussion
or through referral to a third review author (JHB). We noted rea-
sons for the non-inclusion of key studies, and report these in the
Characteristics of excluded studies tables.
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Data extraction and management
Two review authors independently extracted and summarised
study data for each study, using a tailored data extraction form
(CN, JHB, SG, CM). We resolved any discrepancies through
discussion or referral to a third review author. Where available,
we recorded the following information in the Characteristics of
included studies table:
1. Methods: study design, study name (if applicable), study
recruitment period, country, number of study centres, study
setting, study recruitment procedure.
2. Participants: N (intervention/control), definition of smoker
used, specific demographic characteristics (e.g. age, gender),
mean cigarettes per day, mean Fagerström Test for Nicotine
Dependence (FTND), inclusion criteria, and any relevant
exclusion criteria.
3. Interventions: Description of intervention(s) (treatment,
dosage, regimen, behavioural support, duration of intervention,
monetary value of incentives), description of control (treatment,
dosage, regimen, behavioural support); what comparisons were
constructed between which groups, and any concomitant
interventions received by intervention and control groups.
4. Outcomes: primary and secondary outcomes specified and
collected, time points reported, biochemical validation,
definitions of abstinence, adverse events, costs.
5. Notes: we recorded trial funding and declarations of interest
of trial authors where reported.
Assessment of risk of bias in included studies
We evaluated each included study for risks of bias, using the meth-
ods described in the Cochrane Handbook for Systematic Reviews of
Interventions (Cochrane Handbook, Higgins 2017, Chapter 8). The
domains examined for this review include:
1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Biochemical validation of abstinence (detection bias)
4. Incomplete outcome data (attrition bias)
5. Other potential risks of bias
Two review authors independently rated each domain as being at
low, unclear, or high risk of bias, with quotations from the study
report and reasons to justify our judgements. We have summarised
the consensus-agreed ’Risk of bias’ judgements across different
studies for each of the domains listed, and display the summary
results in a ’Risk of bias’ figure. As blinding of participants is
not feasible due to the nature of intervention, we do not assess
performance bias, as in the standard methods of the Cochrane
Tobacco Addiction Review Group.
Measures of treatment effect
We report results as risk ratios (RRs) with 95% confidence inter-
vals (CIs), calculated as (number quit in intervention group/num-
ber randomised to intervention group)/(number quit in control
group/number randomised to control group).
Unit of analysis issues
Several mixed-population studies were cluster-randomised, i.e. al-
located by group, community, or workplace. We have used the in-
traclass correlation coefficient (ICC) reported by Martinson 1999
(unadjusted ICC for percentage quit smoking in a worksite) to
obtain an adjusted estimate of the effect size for the studies that
were cluster-randomised and that contributed to our analyses.
Dealing with missing data
We contacted investigators or study sponsors in order to verify
key study characteristics and to obtain missing numerical outcome
data where possible (e.g. when a study is reported as abstract only).
Where possible, we conducted an intention-to-treat analysis, in-
cluding all smokers randomised. Where possible we have treated
participants who dropped out or who were lost to follow-up after
randomisation as being continuing smokers. We note the propor-
tion of participants for whom the outcome was imputed in this
way, and whether there was either high or differential loss to fol-
low-up between the groups.
In trials of pregnant women, we have followed the convention ob-
served in most of the trials, and not included in the denominator
women whose pregnancies were uncompleted because of termina-
tion or foetal death.
Assessment of reporting biases
As there are a sufficient number of included studies (10 or more
contributing to the outcome), we have created a funnel plot for
the analysis in mixed-population studies to assist in identifying
possible publication bias, methodological flaws, or small-study
effects. We have searched for and report on studies we know to
have been completed, but for which results are unavailable.
Data synthesis
For our primary outcome of smoking cessation, we have combined
eligible studies using a Mantel-Haenzel random-effects model. We
have combined studies carried out in mixed populations separately
from those carried out in pregnant women. In both cases we in-
clude an analysis with smoking cessation at longest follow-up as
the outcome. For the pregnancy studies we also include an analysis
with smoking cessation at end of pregnancy as an outcome.
We have not combined data on costs or disbenefits, as this in-
formation was sparsely and heterogeneously reported. Where re-
ported, we summarise results narratively in the text.
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Subgroup analysis and investigation of heterogeneity
We have used the I2 statistic to assess statistical heterogeneity,
given by the formula ((Q - df )/Q) x 100%, where Q is the Chi
2 statistic and df is its degrees of freedom (Higgins 2003). This
describes the percentage of the variability in effect estimates that
is due to heterogeneity rather than to sampling error (chance). A
value greater than 50% may be considered to indicate substantial
heterogeneity.
Nine included studies involved participants who misused sub-
stances. We included this group in the mixed-population analyses,
but we also investigated them separately through subgroup analy-
sis, new to this version of the review, as they have been shown to
have different barriers and facilitators to smoking cessation from
the general population (Gentry 2017).
We analysed nine pregnancy trials separately from the studies in
mixed populations, due to different outcome data. These analyses
did not require six-month follow-up and explored smoking cessa-
tion at longest follow-up, and at least until the end of pregnancy.
For this update, we also ran an exploratory meta-regression com-
paring incentive amount to effect estimate.
We conducted sensitivity analyses removing studies at high risk
of bias and removing studies where incentives were provided at
longest follow-up.
’Summary of findings’ tables
We have created ’Summary of findings’ tables using the following
outcomes:
• Mixed-population studies: smoking cessation at longest
follow-up (Summary of findings for the main comparison).
• Pregnancy trials: smoking cessation at longest follow-up
(post-partum where available) (Summary of findings 2).
We have used the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness, and publication
bias) to assess the quality of the body of evidence as it relates to the
studies which contribute data to the prespecified outcomes. We
have used methods and recommendations described in Chapter 11
of the Cochrane Handbook (Schünemann 2017), using GRADE-
pro software. We justify all decisions to down- or upgrade the
quality of the evidence using footnotes, and have made comments
to aid readers’ understanding of the review where necessary.
R E S U L T S
Description of studies
We included RCTs, allocating individuals, workplaces, groups
within workplaces, or communities to experimental or control
conditions. Included trials recruited from diverse populations, in-
ternationally, using a broad range of incentive interventions, from
self-incentives/deposits to modest or large-value financial incen-
tives.
Results of the search
For this update we screened the titles/abstracts of 279 studies, and
129 full texts. We included 19 new studies in this update, giving
a total of 43 studies, across all populations. We excluded four
studies included in the previous review update because they were
not randomised (three mixed population studies: Paxton 1980;
Paxton 1981; Paxton 1983, and one pregnancy study: Higgins
2004), and one because it did not evaluate guaranteed incentives
(Crowley 1995, which is now covered in Fanshawe 2019). We
identified 27 ongoing trials. The flow of studies for this update is
recorded in Figure 1.
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Figure 1. Study flow diagram for 2019 update
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Included studies
Interventions in mixed populations
We retain 17 studies which had met our inclusion criteria and
were included in the 2015 version of this review. The previous
version of the review included non-randomised studies, which
we exclude for this update of the review (Paxton 1980; Paxton
1981; Paxton 1983). From our latest searches, we included 16
new trials recruiting mixed populations. These include four fur-
ther community-based studies (Cheung 2017; Etter 2016; Fraser
2017; White 2018), four trials recruiting from substance misusing
populations (community or residential settings) (Ainscough 2017;
Cooney 2017; Rohsenow 2015; Rohsenow 2017), three work-
place-based studies (Halpern 2018; Romanowich 2015; Van den
Brand 2018), four recruiting via clinics (mental health, head and
neck cancer or primary care) (Brunette 2017; Ghosh 2016; Lasser
2017; Rettig 2018), and one trial recruiting an online community
population (Dallery 2016). We include White 2018, which was
not published at the time of conducting our searches, because the
authors kindly provided data. Romanowich 2015 was borderline
include, as the trial initially recruited smokers willing to quit, but
randomisation did not take place until a brief incentivised five-day
abstinence phase had been completed (’Early success’ participants
were randomised to the trial). As this may have skewed results, we
excluded the study from our meta-analysis in a sensitivity analysis,
which did not substantially alter the findings, hence our decision
to include the study despite the strict inclusion criteria of ’smokers’
not being met. In total, we included 33 mixed-population studies
(21,627 participants) for this update. We identified 78 excluded
studies (from all versions of the review), three ongoing studies in
published protocols and 19 ongoing studies from trials registries.
Settings
Five studies were set in community settings (Cheung 2017; Etter
2016; Fraser 2017; Giné 2010; White 2013), with one additional
study recruiting a community sample but delivering online-only
support (Dallery 2016). Six studies delivered smoking cessation
support in clinics (mental health, head and neck cancer, or pri-
mary care) (Brunette 2017; Gallagher 2007; Ghosh 2016; Lasser
2017; Rettig 2018; Volpp 2006), and eight delivered interven-
tions in substance misuse clinics, representing a large subgroup
(Ainscough 2017; Alessi 2014; Cooney 2017; Drummond 2014;
Rohsenow 2015; Rohsenow 2017; Secades-Villa 2014; Shoptaw
2002). Type of substance misuse was mixed where specified. Three
of the older studies delivered the intervention in an academic insti-
tution (Ledgerwood 2014; Tevyaw 2009; Windsor 1988), and the
rest were delivered in worksites, including White 2018. Twenty-
four of the trials were run in the USA, two in Thailand (White
2013; White 2018), one in the Phillipines (Giné 2010) and one
in Hong Kong (Cheung 2017). Five were European.
Incentives
Approximately half of studies (16 in total) offered cash for absti-
nence (contingent rewards), or monetary incentives in the form of
vouchers (seven studies). Four studies used entry into a prize draw
alongside a guaranteed reward (Cheung 2017; Glasgow 1993;
Hennrikus 2002; Ledgerwood 2014). Two studies used self-de-
posited money as the reward incentive (Dallery 2016; Giné 2010)
and a further four studies used a combination of deposit arms
with cash rewards or mixed-rewards arms for abstinence at fixed
time points (Halpern 2015; Halpern 2018; White 2013; White
2018). Seven studies included more complex payment schedules,
especially with a ’reset’ option, meaning that a non-abstinent bio-
chemically-confirmed outcome at any time point would reset the
escalating schedule of reinforcement to a lower level, thus rein-
forcing continued abstinence (Ainscough 2017; Cooney 2017;
Drummond 2014; Rohsenow 2017; Secades-Villa 2014; Shoptaw
2002; Tevyaw 2009).
Most of the studies (Ainscough 2017; Alessi 2014; Cooney 2017;
De Paul 1994; Drummond 2014; Etter 2016; Gallagher 2007;
Ghosh 2016; Giné 2010; Glasgow 1993; Hennrikus 2002; Lasser
2017; Rettig 2018; Secades-Villa 2014; Shoptaw 2002; Van den
Brand 2018; Volpp 2006; Windsor 1988) compared the incentive
intervention arm to ’usual care’, or to another intervention arm
with different support options (non-incentives). We combined
these controls in our analyses. White 2013 and White 2018 ex-
amined different arms offering deposits and varying schedules of
bonus payments (individual and team bonuses).
Brunette 2017 compared ’usual care’ to quitline support or cogni-
tive behavioural therapy (CBT). Approximately half within each
experimental group received incentives. As exact numbers could
not be calculated from reported results, we excluded this study
from our analysis.
Nine studies (Dallery 2016; Fraser 2017; Ledgerwood 2014; Rand
1989; Rohsenow 2015; Rohsenow 2017; Romanowich 2015;
Tevyaw 2009; Volpp 2009) compared non-contingent incentives
against contingent (outcome-related) incentives.
Cheung 2017 compared ’usual care’ with two incentive groups -
those who were ‘early informed’ about the incentive intervention,
and those who were ‘late informed’, so were not initially aware
they would receive rewards for abstinence.
Halpern 2015 compared ’usual care’, including non-contingent
rewards, to individual rewards, as well as to collaborative awards
(where rewards were given for peer/buddy abstinence in addi-
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tion to individual abstinence) and to deposits and team deposits.
Halpern 2018 compared ’usual care’ and text message support to
rewards and redeemable deposits.
Cessation methods
Only one trial did not deploy any kind of cessation support pro-
gramme (Glasgow 1993). Most of the trials included self-help
support of brief advice at a minimum for the usual-care con-
trol group. Eleven trials included nicotine replacement therapy or
pharmacotherapy to support their participants (Ainscough 2017;
Brunette 2017; Cooney 2017; Gallagher 2007; Halpern 2015;
Halpern 2018; Rohsenow 2015; Rohsenow 2017; Romanowich
2015 Shoptaw 2002; Volpp 2006). The most recent published
trial also offered an electronic cigarette option to some participants
as part of the smoking cessation intervention (Halpern 2018).
Most of the included studies used some form of multicomponent
support programme, by combining, for example, self-help and
brief advice, with pharmacotherapy. Dallery 2016 and Etter 2016
offered online support, and Halpern 2018 used motivational text
messages to offer digital support to trial participants. De Paul 1994
combined self-help with a buddy system. Drummond 2014 pro-
vided motivational feedback on ’lung age’ to promote cessation.
Van den Brand 2018, White 2013, and White 2018, which were
workplace or community-based studies, used group intervention
including group-based ’pledges’ for abstinence or peer pairing,
thus employing peer pressure/motivation as part of the interven-
tion. However, White 2018 reported that the size of the worksites
did not lend itself to the strategy for pairing teammates. Many
teammates did not know each other, and did not interact during
the study period.
Outcomes
All the included studies rewarded smoking cessation, either alone
or in combination with recruitment, participation or both (see the
Characteristics of included studies table for full details).
As reported in the previous review update, raw outcome data, par-
ticularly in the older studies, were often difficult to extract. For
this update we found the new included trials to be more clearly
reported. Fifteen trials followed up participants for a maximum of
six months (Ainscough 2017; Alessi 2014; Cheung 2017; Cooney
2017; Dallery 2016; Drummond 2014; Fraser 2017; Ghosh 2016;
Ledgerwood 2014; Rand 1989; Romanowich 2015; Secades-Villa
2014; Tevyaw 2009; Volpp 2006; White 2013), one for nine
months (Gallagher 2007), 12 for 12 months (Brunette 2017; Giné
2010; Halpern 2015; Halpern 2018; Lasser 2017; Rettig 2018;
Rohsenow 2015; Rohsenow 2017; Shoptaw 2002; Van den Brand
2018; Windsor 1988; White 2018), two for 18 months (Etter
2016; Volpp 2009), and three for 24 months (De Paul 1994;
Glasgow 1993; Hennrikus 2002). Most of the more recent studies
included 12-month follow-up as the standard primary outcome
time point.
Few studies formally reported on harms or costs; where reported,
we present them narratively below.
Interventions in pregnancy
We include trials conducted in pregnant women as a separate
group. We retain eight of the nine studies included in the last
update (Cahill 2015), with Higgins 2004 now excluded as it was
not randomised. We identified 10 excluded studies (from all ver-
sions of the review), two ongoing studies in published protocols
and three ongoing studies from trials registries. IN our updated
searches we found two new completed pregnancy trials that met
our inclusion criteria (Baker 2018; Harris 2015). Baker 2018 is
the largest pregnancy trial of incentives for cessation in pregnancy
yet reported, recruiting 1014 US pregnant women, and so con-
siderably contributes to the growing evidence base. We include a
total of 10 trials recruiting pregnant smokers (2273 women) in
this update.
Settings
Nine studies were conducted in the USA, mostly in public or pri-
vate antenatal clinics, obstetric practices, and community ante-
natal programmes. One trial (Tuten 2012) in methadone-main-
tained pregnant women, was conducted in the Center for Addic-
tion and Pregnancy in Baltimore. The only included UK-based
study (Tappin 2015a; the Cessation in Pregnancy Incentives Trial)
with 612 participants, was mediated through the pregnancy refer-
ral pathway to the UK NHS stop-smoking service.
Incentives
The largest pregnancy trial (Baker 2018) provided cash payments
as the incentive. In all other cases the rewards were vouchers
for goods or services. Three trials (Donatelle 2000a; Donatelle
2000b; Donatelle 2002) delivered monthly rewards contingent
upon proven abstinence. Four trials evaluated the allocation of
incremental rewards, with the voucher reset to baseline value in
the case of relapse or missed visits, but restored to previous levels
if abstinence was re-established (Harris 2015; Heil 2008; Higgins
2014; Tuten 2012). Ondersma 2012, using a computer-based in-
tervention, shifted the onus of testing to the participants, who
could present themselves as often as they wished for verification
of abstinence, and could win up to five USD 50 gift cards over
the course of the programme. Harris 2015 also offered the op-
tion of web-based confirmation of biochemical validation of ab-
stinence. Tappin 2015a awarded vouchers up to a value of GBP
350 (pounds sterling) for achieving staged cessation targets, and
a further GBP 50 for engaging with the programme and setting
a quit date. Donatelle 2000a also rewarded a social supporter,
in tandem with the participant smoker. Non-contingent rewards,
roughly equivalent to the value available to the intervention group,
were given to control participants in three trials (Baker 2018; Heil
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2008; Higgins 2014), while Tuten 2012 incorporated a group on
a schedule of non-contingent rewards generated from an earlier
pilot study. Donatelle 2000a gave a USD 5 voucher to all partici-
pants for each of three attendances during the trial. Tappin 2015a
gave all participants in both arms of the trial a GBP 25 shop-
ping voucher for supplying primary outcome information (34 to
38 weeks gestation) and a biological sample for those who self-
reported as quitters.
Cessation methods
All the trials offered a programme of practical cessation support,
in addition to the routine care delivered by the host clinics. Three
trials (Donatelle 2000b; Donatelle 2002; Ondersma 2012) used
the 5As approach (Ask, Advise, Assess, Assist, Arange), while five
trials offered self-help materials. Tuten 2012 also included a brief
motivational interviewing feedback session for all participants.
Harris 2015 offered a web-based smoking cessation programme
in addition to telephone support. The UK trial (Tappin 2015a)
referred all participants to UK stop smoking services, that routinely
conducted a one-hour cessation session, four weekly phone calls,
and provided free NRT if the women chose to use it.
Outcomes
All the included studies reported abstinence at the end of preg-
nancy, with seven of the 10 tracking participants into the post-par-
tum stage. Two trials (Donatelle 2000b; Donatelle 2002) referred
simply to “abstinence”, without further definition of the type or
duration. In all cases, rewards were available only for biochemi-
cally-verified abstinence. Two trials rewarded smoking reduction
as well as complete abstinence, with Tuten 2012 setting percent-
age reduction targets to be met for rewards, while Higgins 2014
allocated higher-value vouchers for breath samples below 4 ppm
rather than 6 ppm in the early stages of the trial. Our primary out-
come of interest for this group is abstinence at the longest available
assessment point (which allows us to be the most inclusive in terms
of studies included in the analysis); we also report abstinence rates
at or around the end of pregnancy for all the trials which had these
data.
Few studies formally reported on harms or costs; where reported,
we describe these below.
Excluded studies
We list 90 excluded studies in the Characteristics of excluded
studies table. The main reasons for exclusion were ineligible study
design, not meeting our definition of the intervention, or not
following up participants for at least six months.
Risk of bias in included studies
Overall, we judged eight studies to be at low risk of bias (low risk
of bias across all domains) and 10 studies to be at high risk of bias
(high risk of bias in at least one domain), with the remaining stud-
ies at unclear risk of bias. Assessments of the risk of bias domains
for each study are shown in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Mixed-populations studies
In the mixed-population studies, we judged eight studies to be
at low risk of bias and seven to be at high risk of bias, with the
remaining 18 at unclear risk of bias.
Selection bias
Of the 33 mixed-population studies, we judged 13 to be at low
risk of selection bias (low risk of both random sequence generation
and allocation concealment). We judged four to be at high risk of
selection bias, due to issues with either random sequence genera-
tion, allocation concealment, or both (Brunette 2017; Gallagher
2007; Ghosh 2016; Giné 2010). We judged the remainder to be
at unclear risk of selection bias, due to insufficient information on
which to judge.
Detection bias
Of the mixed-population studies we rated 30 at low risk of detec-
tion bias, because biochemical measures were used to verify ab-
stinence. Because of the explicit mechanism of rewards, most of
the reported trials did not attempt to blind participants, trialists
or assessors. In Ainscough 2017, major study problems were en-
countered and no participants were followed up at the primary
endpoint. Hennrikus 2002 did not validate the abstinence of all
participants claiming abstinence. We judged these two trials to be
at high risk of bias for this domain. We judged Ghosh 2016 to be
at unclear risk, as limited detail was provided on the method of
validation used.
Incomplete outcome data
In our analysis of all of the included studies, we treated programme
dropouts and losses to follow-up as continuing smokers, whether
or not the trial reported results in this way, and conducted the
analyses on an intention-to-treat basis, i.e. the denominator in-
cluded all persons randomised at the start of the trial in their orig-
inal groups. Of the mixed-population studies, we considered 22
to be at low risk of bias for this domain.
In accordance with standard Cochrane Tobacco Addiction Group
methods for assessing attrition bias, we rated five studies at high
risk of bias in this domain, due to high or differential rates of
dropout (Ainscough 2017; De Paul 1994; Ghosh 2016; Halpern
2018; Rand 1989), and six as unclear, as there were not sufficient
details available on which to make a judgement for this domain
(Brunette 2017; Giné 2010; Halpern 2015; Secades-Villa 2014;
Volpp 2006; Windsor 1988).
Other risk of bias
We judged two studies to be at high risk of other biases. We rated
Ghosh 2016 at high risk of bias due to inconsistent reporting of
length of follow-up, and Hennrikus 2002 at high risk of bias as
group dropouts were not followed up.
In order to test the robustness of the cessation interventions we
have included in our review only those studies which followed
up participants for at least six months from the beginning of the
intervention. Six of the trials, however, (Drummond 2014; Fraser
2017; Gallagher 2007; Ghosh 2016; Lasser 2017; Van den Brand
2018) delivered their final cessation rewards at the same time point
as the end of the designated follow-up period, thereby potentially
confounding the intervention rewards with testing at the longest
follow-up. A sensitivity analysis considering these trials separately
made no relevant difference to the overall combined outcomes.
Pregnancy studies
In the pregnancy studies, we judged two studies to be at low risk
of bias, one at high risk of bias, and seven at unclear risk of bias.
Selection bias
Of the included pregnancy studies, we judged two to be at low risk
of selection bias (low risk for both random sequence generation
and allocation concealment). We judged the remainder to be at
unclear risk due to insufficient detail reported.
Detection bias
We judged all of the studies of pregnant women to be at low risk
of detection bias, because each study used biochemical validation
of abstinence.
Incomplete outcome data
Of the included pregnancy studies, we rated six at low risk of bias
for incomplete outcome data. Two were unclear due to insufficient
detail. We ranked Donatelle 2000a at high risk of attrition bias,
as it had lost 36% of the intervention group by two months post-
partum, and 52% of the control group, although the authors report
that this level of depletion was not unusual for the antenatal clinic
in question.
Although we routinely prefer to conduct an intention-to-treat
analysis (including all participants randomised), for these trials we
have excluded from the denominators any predefined withdrawals
due to termination or foetal demise, where these were reported.
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Tappin 2015a excluded three control participants from the de-
nominator, as they had withdrawn immediately after randomisa-
tion and had withheld their data from inclusion in analyses; we
have adjusted our calculations accordingly.
Other risk of bias
We found no other risks of bias in the included pregnancy studies.
Effects of interventions
See: Summary of findings for the main comparison Incentives
vs no incentives for smoking cessation in mixed populations;
Summary of findings 2 Incentives vs no incentives for smoking
cessation in pregnant women at longest follow-up
Mixed populations
Cessation
Details of the results for the 33 mixed-population included studies
in this review are tabulated in Table 1, and are displayed graphically
where data were available in Analysis 1.1. In our analyses results for
the two intervention arms (early- and late-informed incentives) of
Cheung 2017 are collapsed and compared with the control arm.
Results of two incentive groups in Halpern 2018 are collapsed
and compared to a control group. Results of incentives arms in
Romanowich 2015 are also collapsed and compared to a control
group.
We conducted a meta-analysis of 30 of the included studies for
which there were sufficient data (33 comparisons) (Analysis 1.1).
We excluded Ainscough 2017, Brunette 2017,and Hennrikus
2002 from formal analyses because no extractable data were avail-
able on programme participants at follow-up.The primary result
at longest follow-up (six months or more) gave an RR for quitting
with incentives compared with controls of 1.49 (95% CI 1.28 to
1.73; 30 RCTs (33 comparisons), adjusted N = 20,097, I2 = 33%).
We also present this analysis in Summary of findings for the main
comparison, with a grading of the certainty of the evidence.
To explore the effect of incentives offered up until the long-term
follow-up point (six months or more) compared to those where
longest follow-up occurred after the incentive schedule had ended,
we carried out a subgroup analysis. There was no significant dif-
ference in the results found between groups (P = 0.25, I2 = 24%,
Analysis 1.1). Restricting results to only those studies which fol-
lowed up beyond the provision of incentives yielded a statistically
and clinically significant effect in favour of the intervention (RR
1.40, 95% CI 1.17 to 1.69; 28 RCTs; adjusted N = 17,058; I
2 = 36%), suggesting that the impact of incentives continues for
at least some time after incentives are no longer provided. In the
group of studies where incentives were provided at longest follow-
up, the result was similar (RR 1.66, 95% CI 1.33 to 2.07; 6 RCTs;
adjusted N = 3039; I2 = 20%).
In a subgroup analysis of trials recruiting participants in substance
misuse treatment, results also suggested a favourable benefit of
incentives for smoking cessation at longest follow-up (no signif-
icant subgroup difference (P = 0.38; I2 = 0%; RR in substance
abuse subgroup 1.24, 95% CI 0.81 to 1.89; 8 studies; N = 1055;
I2 = 0%; Analysis 1.2.1). Although confidence intervals are wide,
this reflects the smaller number of studies and participants in this
group; the point estimate was consistent with the overall meta-
analysis which found a beneficial effect of the intervention.
Although not always clearly reported, the financial amounts of in-
centives varied between trials, from zero (self-deposits), to a range
of between USD 45 up to USD 1185. There was no clear direction
of effect between trials offering low or high total amounts of incen-
tives, nor those encouraging redeemable self-deposits. We ran an
exploratory meta-regression and found no significant association
between the outcome and the total value of financial incentive (P
= 0.180, Figure 3). Any such indirect comparison is particularly
crude in this context, due to differences in the cultural significance
of financial amounts (e.g. USD 50 might have different signifi-
cance in different contexts).
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Figure 3. Exploratory meta-regression testing association between incentive amount and effect estimate
Cheung 2017, a large trial recruiting from a community sample
in Hong King as part of the ’Quit to win’ contests, specifically ex-
amined the effect of small-value financial incentives. They tested
incentives where participants were ’early informed’ against a group
of participants who were ’late informed’ about the incentive offer.
There was no statistically significant difference in biochemically-
validated abstinence rates between the early-informed and late-in-
formed groups. Overall there was a beneficial effect of the small fi-
nancial incentive offer across both intervention groups when com-
pared to a control group who were not offered an incentive.
The two largest trials included in this review update specifically
evaluated financial incentives against deposit-based incentives.
Halpern 2018 found both deposits and incentives to be effective
for long-term smoking cessation, but no significant differences be-
tween the two forms of incentivisation (2% in the rewards group
(95% CI 1.2 to 2.8) versus 2.9% in the redeemable deposit group
(95% CI 2.0 to 3.8)) and a very high loss to follow-up. Simi-
larly, White 2018 found that both were effective and reported that
“Deposit programs had a negligible effect on abstinence compared
with no-deposit programs” (reporting a 1.1 point increase, P =
0.53).
By far the largest trial among the included studies is White 2018,
a nine-arm cluster-RCT recruiting 4190 participants drawn from
employees at large workplaces in the Bangkok metropolitan area
(101 worksites from 84 Bangkok area companies). The interven-
tions were individual bonuses, team bonuses, self-deposits and
deposits plus bonuses (individual and team). The total incentive
available varied by arm, and was equivalent to USD 20 (TBH 600
(Thai baht)) in arms that offered a smaller bonus (including the
arm that combined a smaller bonus with deposits), and USD 40
(THB 1200) in the arms that offered a larger bonus (including
the arm that combined a larger bonus with deposits and the arms
with a team bonus). Bearing in mind that Thailand is a middle-
income country, the amounts given were relatively small compared
to some of the other studies. Incentives were provided up until the
end of the three-month intervention period. All incentive arms did
significantly better than the usual-care control group at the study’s
12-month primary endpoint of validated sustained abstinence. As
there were no significant differences between the individual- and
group-based arms, and no significant differences between deposit-
or reward-based arms, we combined the eight intervention arms
into two groups (incentives versus control) for our analyses.
We conducted a sensitivity analysis removing studies at high risk
of bias from the overall meta-analysis for mixed populations. This
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resulted in an RR of 1.48 (95% CI 1.25 to 1.76; 25 RCTs; adjusted
N = 13,986; I2 = 37%), which still clearly favours incentives.
Removing both those studies at high and at unclear risk also yielded
a statistically significant benefit in favour of the intervention (RR
1.97, 95% CI 1.57 to 2.57; 8 studies; adjusted N = 5037; I2 =
34%).
We constructed an exploratory funnel plot for the main meta-
analysis (Figure 4; Analysis 1.1, abstinence at longest follow-up),
but did not detect indications of publication bias, i.e. that small
studies with negative findings might be under-represented.
Figure 4. Funnel plot of comparison: 1 Incentives in mixed populations, outcome: 1.1 Smoking cessation
(subgrouped by when incentives were provided).
Costs
Few studies reported on costs. Among all participants in Halpern
2015 achieving sustained abstinence at six months, the average
cost per quitter ranged from USD 800 to USD 890. The trial-
ists compared this outlay, even without any deposit contribution
from the participant, to the estimated USD 5816 additional cost
to employers of hiring a smoker rather than a non-smoker in the
USA (Berman 2014), and rated the intervention highly cost-ef-
fective. Volpp 2009 offered no comment on potential cost bene-
fits of incentive programmes, other than to report an estimate of
savings per quitter to an employer (USD 3400 per year, MMWR
2002). White 2013 reported that the intervention, if rolled out
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to the smoking population in the study area, could translate to
a decrease in smoking prevalence of 2% to 5%, and offered an
incremental cost-effectiveness analysis. The authors estimate that
the cost per quitter from the intervention was USD 281 (95% CI
USD 187 to USD 562), compared with quitting with nicotine
gum (USD 1780, 95% CI USD 1414 to USD 2401) or with
varenicline (USD 2073, 95% CI USD 1357 to USD 4388) in
Thailand. The authors note that the intervention complies with
the World Health Organization’s ranking of “very cost-effective”
in Thailand, i.e. less than gross domestic product (USD 8600,
purchasing power parity-adjusted in 2011; World Bank 2012).
Fraser 2017 reported that the overall cost per quitter for control
group participants was on average USD 4268.26 while incentive
group participants averaged USD 3601.37 per quit. Halpern 2018
reported the cost per successful quitter to be USD 7797.52 where
free cessation aids were provided, compared to USD 3623.13 per
quitter for the incentive group participants, and USD 3461.47 for
the redeemable deposit group. Rettig 2018 did not report formal
cost-effectiveness data, but reported that “Over-the-counter nico-
tine replacement therapy was provided for free (estimated cost per
participant USD240)” compared with low-cost overall incentives
(exact cost not reported).
Harms, disbenefits
Few studies formally evaluated harms or disbenefits of incentives
specifically. Potential harms evaluated were attributable to smok-
ing cessation itself or judged not attributable to the intervention.
Gallagher 2007, reporting on an intervention in 180 people with
schizophrenia or other serious mental illness, briefly considered
whether smoking cessation may have worsened the participants’
psychiatric symptoms, but found no evidence for this at end of
intervention or at 36-week follow-up, using the Brief Symptom
Inventory. However, the authors caution against placing too much
weight on this finding, because of low power within the study
to detect such differences. Alessi 2014 reported one participant
was hospitalised for alcohol-related heart, liver and lung problems,
considered by the trialists not to be associated with the interven-
tion programme. Brunette 2017, recruiting from a community
mental health clinic, reported that 25 participants (4%) experi-
enced a serious adverse event: 16 were hospitalised for psychiatric
exacerbations, seven were hospitalised for medical reasons (pneu-
monia, lung cancer, and heart attack), and five study participants
died. However it is not clear whether these events were related
in any way to the intervention. Cheung 2017 speculated that in-
centive-based interventions leading to ’cheating’ or ’gaming’ by
participants may have occurred, in an attempt to ‘play the sys-
tem’ to receive financial rewards. They suggest that ’loose’ inclu-
sion criteria for the study might have led to the inclusion of low-
rate/non-daily/light smokers who might simply stop smoking for
a day in order to win. Such ’cheating’ was possible, but was not
evaluated. None of the other included studies reported on any
harms, unintended consequences or adverse events associated with
the interventions; however, we consider in the Discussion section
the implications of systematic deception in participants seeking
to obtain unmerited rewards for abstinence, and other potential
disbenefits of incentives interventions.
Pregnancy
Cessation
Details of the results at longest follow-up (up to 24 weeks post-
partum) for nine of the 10 included studies in pregnant women in
this review are tabulated in Table 2, and are displayed graphically
where data were available in Analysis 2.1; Figure 4. One trial could
not be included in the meta-analysis: the MISS Project (Donatelle
2002) reported interim results only, i.e. for 298 women from a
projected total of 600. We were unable to obtain further informa-
tion on final numbers, or on quit rates achieved at any point.
The trials demonstrated a clear benefit for the incentives groups
over the controls. Taken together, nine trials in pregnant smokers
(eight conducted in the USA and one in the UK) delivered an
RR at longest follow-up (up to 24 weeks post-partum) of 2.38,
95% CI 1.54 to 3.69; 9 RCTs; N = 2273; I2 = 41%) in favour of
incentives. This effect persisted in a sensitivity analysis removing
the one study at high risk of bias (Donatelle 2000a) (RR 2.22,
95% CI 1.37 to 3.59; 8 RCTs; N = 2068; I2 = 41%).
We were unable to ascertain with any certainty whether the size
of the rewards made a difference to outcomes, due to a paucity
of relevant data. Three trials addressed the question of whether
contingent rewards were more effective than non-contingent fixed
payments (Heil 2008; Higgins 2014; Tuten 2012). In these trials,
scaled payments were given only as a reward for validated absti-
nence (contingent), while fixed payments were guaranteed pro-
vided that the participant attended and gave a biological sample,
irrespective of her smoking status. All three trials favoured condi-
tional over non-conditional payments, with an RR of 3.33, 95%
CI 0.97 to 11.38; 3 RCTs; N = 225; I2 = 18%; Analysis 2.3.
None of the included trials compared an incremental with a fixed
schedule, but with both payable only for validated abstinence, i.e.
testing the role of variable rewards rather than contingency.
Costs
While confirming that they had not conducted a cost-benefit anal-
ysis, Heil 2008 reported that the average cost of the incentives per
participant was USD 334. Tappin 2015a reports that the short-
term incremental cost per quitter was GBP 1127, with an incre-
mental cost per quality-adjusted life year of GBP 482. The NHS
lower threshold is GBP 20,000, designated by the National Insti-
tute for Health and Care Excellence (NICE 2018) as an indicator
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of cost effectiveness (Tappin 2015b), suggesting that “financial in-
centives for smoking cessation in pregnancy are highly cost-effec-
tive” (Boyd 2016). The remaining included studies in pregnancy
did not report on costs.
Harms, disbenefits
None of the included pregnancy trials reported on harms or unin-
tended consequences of the interventions, although Tappin 2015a
offered some evidence on the likelihood of the participants ’gam-
ing’ to receive unmerited rewards. We consider this further in the
Discussion section below.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Smoking cessation: incentives compared to no incentives in pregnant women
Patient or population: Pregnant women who smoke
Setting: Antenatal clinics
Intervention: Incent ives for smoking cessat ion
Comparison: No incent ives













Follow-up: 10 to 24
weeks post-partum








1 included study did not
contribute to the analy-
sis because of lack of
usable data
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: Conf idence interval; RR: Risk rat io; OR: Odds rat io;
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aOverall we rate the quality of evidence as moderate, as we judged only two of the included studies to be at low risk of bias
(one study at high risk; the rest at unclear risk). When we restricted analyses to only those studies at low risk of overall


















































































D I S C U S S I O N
Summary of main results
Overall there is high-certainty evidence that incentives improve
smoking cessation rates at longest follow-up in mixed-population
studies (Summary of findings for the main comparison). With
moderate-certainty evidence, the nine trials in 2273 pregnant
women contributing to the meta-analyses confirmed the efficacy
of incentives at longest follow-up, at or around the end of preg-
nancy (Summary of findings 2).
Previous reviews of incentive-based interventions for smoking ces-
sation have expressed concerns that the effect of incentives may
be time-limited. This would conform to a learning theory-based
explanation, that rewards are effective when consistently offered,
but that the effect of the reward may be ’extinguished’ when re-
wards cease. With regard to smoking cessation, where individuals
may initially find quitting difficult but may adapt over time to this
change, offering rewards that can initiate cessation seems to sug-
gest that the long-term effect overall may be maintained. This is
plausible, because the incentives serve to support the initial, most
difficult weeks (or months) of a quit attempt and the risk of re-
lapse reduces over time. Findings from our meta-analysis in mixed
populations suggest that incentives continue to have a significant
impact on sustained smoking cessation, even after they have fin-
ished. In our next update, when we anticipate further evidence
will be available and therefore contribute further data points, we
plan to conduct an analysis comparing quit rates at last incentive
point to quit rates at subsequent follow-ups where incentives are
not provided; this would provide a more direct test of the lasting
effect of incentives.
In our updated searches we identified four new trials that recruited
people who misused substances (Ainscough 2017; Cooney 2017;
Rohsenow 2015; Rohsenow 2017). This suggests that there is
increasing focus and attention being paid to the importance of
smoking cessation for this population, and incentives may offer a
promising intervention strategy for this group in whom smoking
rates remain high (Gentry 2017). Together with the four older
trials recruiting from this population, our subgroup analysis sug-
gested a positive benefit of incentives; confidence intervals were
wide but results were consistent with the overall finding of a posi-
tive effect. However, we report these findings with caution, as the
analysis is likely to be underpowered and more studies are needed.
We explored narratively the value of incentives offered across stud-
ies, and considered subgroup analysis. We concluded that this
would not be possible, as the amounts offered varied considerably,
and it was not possible to broadly group trials into ’low value’ or
’high value’ incentives, as the diverse cultural settings of studies
and the ’meaning’ of the total amount of incentives offered to
participants can not be predicted. Even a small financial incentive
offered to a factory worker in rural Thailand may be highly valu-
able and meaningful to individual participants. From the available
evidence, we cannot conclude whether the value of the financial
incentive has a discernible impact on the effectiveness of the in-
tervention; this is therefore a question that future iterations of this
review should seek to explore further. A possible approach would
be to evaluate incentive size as a percentage of mean study partici-
pant income, but the most valuable data would come from studies
directly comparing different incentive amounts, as then the pop-
ulation would not be a confounder.
The deposit-refund trials merit particular attention, in the light
of the discussions that have emerged from the Volpp 2009 study
about whether the programme could be implemented in a real-
world setting. If implementation of an incentives programme is
compromised by the costs incurred, then the model of participants
depositing and forfeiting their own money is likely to be more at-
tractive to employers and institutions seeking affordable behaviour
change interventions. Although effect estimates appear to be con-
sistent between deposit-based and traditional reward schemes, low
uptake rates compared with reward-based interventions may limit
the appeal and efficacy of such programmes (Volpp 2014). White
2013 reports a participation rate of 10.5% among eligible smok-
ers, while Giné 2010 reports a rate of 10.6%. Halpern 2015 di-
rectly compares interventions funded entirely from trial resources
to those funded partly by the participants themselves (USD 150).
As discussed above, uptake rates proved to be a barrier, with 90%
of those offered rewards accepting the intervention compared to
only 13.7% of those required to put up a deposit, obliging the
trialists to develop an adaptive model of randomisation in order to
populate the deposit-based arms. On an intention-to-treat basis,
the rewards arms consistently delivered significantly more quitters
than the deposit arms at all time points; however, in instrumen-
tal variable analysis which accounts for different rates of uptake
(equivalent to a per protocol analysis), among participants pre-
pared to accept either intervention the deposit arms outperformed
the rewards arms, with six-month quit rates of 53.4% and 17.1%
respectively, and 12-month quit rates of 18.5% and 8.8% respec-
tively.
White 2013 used community-based health workers to support
smokers attempting to quit in a region of Thai villages, using
a deposit-refund intervention. The six-month success rates were
impressive, at 44.3% for the intervention group compared with
18.8% among the controls; however, the unusually high quit rate
for the control group suggests that this population may have rep-
resented ’low-hanging fruit’ (easy quitters who may never have
received support to stop smoking before), and that these findings
are not readily generalisable to areas with longstanding and es-
tablished tobacco control programmes. The two largest trials in-
cluded in this review update specifically evaluated financial incen-
tives against deposit-based incentives. White 2018 and Halpern
2018 found both deposits and incentives to be effective for long-
term smoking cessation, but no significant differences between the
two forms of incentivisation. This suggests that although it may be
more difficult to recruit smokers into deposit-based programmes,
once they are in they appear to be strongly committed to the pro-
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cess and can achieve high quit rates.
While the findings of this review are encouraging, it is important
to note that there may be substantial barriers to implementing
incentives in routine care or as part of mainstream services. Pub-
lic opinion regarding incentives is often negative (Berlin 2018;
Giles 2015; Hoddinott 2014) with incentives seen as ‘rewarding’
behaviour change for a ‘habit’ that is perceived as self-inflicted
(smoking). This may limit the extent to which trial results can
inform changes in policy and practice. An additional challenge
is resource constraints. Real-world implementation requires fun-
ders (such as the NHS or local government in the UK who fund
smoking cessation services) to prioritise these schemes over other
approaches to smoking cessation. For further consideration are the
possible harms and disbenefits of incentives schemes. Those who
relapse to smoking and do not receive a financial incentive may
conceivably disengage from subsequent cessation attempts. This
potential harm warrants monitoring in future trials.
Deception
Only six of the included trials tested for smoking status at base-
line, with cotinine or exhaled carbon monoxide (CO) (Brunette
2017; Cheung 2017; Etter 2016; Halpern 2015; Harris 2015;
Romanowich 2015). Halpern 2015 only tested eligibility in a 5%
sample of enrolled participants, who were paid USD 100 for sup-
plying a cotinine assay. Of those asked to submit a baseline sample,
nine (6%) returned a negative assay and 21 (14%) did not return
a sample, suggesting that up to 20% of participants could have
been non-smokers. However, as the rates were comparable across
all arms of the trial, and sensitivity analyses adjusting for this pos-
sible level of deception made no difference to effect estimates, we
conclude that biochemical validation of smoking status at baseline
may not impact on overall trial outcomes, since deception about
baseline smoking status is likely to be equally distributed through
randomisation.
It was a condition for inclusion in this review that studies used
some form of biochemical verification to confirm the smoking
status of those claiming abstinence when rewards were due. This
procedure is the recommended gold standard for good trial de-
sign in smoking cessation studies (SRNT 2002). It may also be
particularly important that quitters in an incentives-based trial are
shown to be truly abstinent at the evaluation points, since de-
ception may be a justifiable critique to be directed at incentive-
based interventions. Volpp 2006 addressed the likelihood of par-
ticipants modifying their smoking behaviour in anticipation of be-
ing contacted for follow-up assessment and cotinine testing, and
concluded that this was unlikely, since although participants knew
that they would be biologically tested, they were unaware of how
long nicotine metabolites would be detectable or the exact date
on which they would be checked. Where reported, most included
studies demonstrated good correspondence between self-reported
claims of abstinence and biochemical verification. As incentives
were contingent upon biochemically-confirmed abstinence, and
our review outcome of longest follow-up was robust to the removal
of studies without biochemical verification at longest follow-up
(e.g. studies at high risk of detection bias), it is unlikely that de-
ception impacted our findings.
Work on incentives for pregnant smokers trying to quit has been
concerned with directing attention to the risks of deception or
’gaming’, particularly the likelihood of delaying a quit attempt to
coincide with a rewards programme, and the likelihood of mis-
representing smoking status, either to gain admission to an incen-
tive programme or to receive unmerited rewards for abstinence
(Marteau 2013). Ierfino 2015, in a longitudinal cohort study of
239 pregnant smokers, found no evidence of gaming to enter an
incentives programme, but detected a 4% level of deception to win
vouchers for abstinence (e.g. falsely reporting abstinence). Tappin
2015a used residual routine blood samples (i.e. taken for non-
study-related purposes) collected from the final 200 women en-
rolling in their study, to cross-check the smoking status of self-
reporting quitters. Residual bloods were available for 18 of the 69
intervention women who self-reported abstinence at 34/38 weeks,
and had this confirmed by saliva or urinary cotinine; 78% of these
samples (14/18) confirmed their non-smoking status. Similarly,
five residual samples for the 26 control participants with confirmed
abstinence at 34/38 weeks corroborated 80% (4/5) of the results.
While this suggests some overestimation of the true quit rates, the
level of deception appeared to be similar across both groups, and
confirmed the veracity of 80% of the self-reported quitters. A large
pregnancy trial included in this new update of the review (Baker
2018) reported that “It is possible that some participants quit or
reduced their smoking just prior to the 6-month visit. Breath CO,
which was used in this trial, has a relatively brief half-life; serum
cotinine might have been more sensitive to detecting temporally
remote smoking”’ A much smaller pregnancy trial (Harris 2015)
more robustly combined both CO and urinary cotinine testing to
confirm abstinence. Taken together, these results suggest that the
likelihood of deception in the pregnancy incentives trials is also
low.
Overall completeness and applicability of
evidence
This review includes a number of studies from diverse cultural
settings (White 2018 recruited from worksites in Bangkok, Giné
2010 approached people smoking in the street in Philippines cities,
Van den Brand 2018 recruited from workplaces in the Nether-
lands, Etter 2016 recruited a community sample in Switzerland,
and Fraser 2017 contributes new evidence from 1900 US com-
munity-based smokers), suggesting that the impact of incentives
can be considered to be generalisable across these populations, al-
though more evidence is needed from low- and middle-income
countries. Future reviews might consider analysis of outcomes by
population setting. Comparison of clinical versus community-
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based populations may be meaningful, as different populations
may be more or less motivated to quit, and have differential access
to adjunctive support. Population setting may also have relevance
for scalability of incentive-based interventions.
We have followed standard Cochrane methods to identify and
evaluate the studies contributing to this review, and are confident
that we have not missed any significant published trials. We have
sought missing or incomplete data, and have contacted authors
where possible to clarify our interpretation of their work. The in-
creased diversity of populations included within this review, from
diverse cultural settings, across different healthcare systems, and
including unique populations such as pregnant women and those
in treatment for substance misuse and distinct clinical popula-
tions has extended the applicability of this review, in line with re-
cent trends in public health approaches to incentivising behaviour
change.
Certainty of the evidence
Mixed-population studies:
We rated the overall certainty of the evidence in this group of
trials as high (see Summary of findings for the main comparison).
Although there were concerns about risk of bias, particularly in
older trials, our sensitivity analyses excluding trials at high risk of
bias and excluding studies at both high and unclear risk of bias did
not change the positive effect of incentives on abstinence rates. We
upgraded the quality of evidence from the previous version of this
review, suggesting that we can have increased confidence in our
reported findings and the estimate of effect. Due to the inclusion of
several high-quality large RCTs which detected significant effects
in favour of the intervention, the estimate of effect has increased
overall.
Pregnancy studies:
The included trials covering pregnant smokers are rated as being of
moderate certainty (Summary of findings 2), suggesting that the
true effect is likely to be similar to what we have found, although
further research may have an impact on the estimate of effect.
Certainty was limited by concerns about risk of bias, with most
studies judged to be at unclear risk. All the trials were conducted
within the last 19 years, and have benefited from advances in trial
methodology and reporting expectations. Only four trials (Baker
2018; Harris 2015; Ondersma 2012; Tappin 2015a) were deemed
to have reported adequate randomisation procedures.
Potential biases in the review process
We followed standard Cochrane methods which are designed to
reduce risks of bias. Our funnel plot for the main analysis in mixed
populations did not suggest evidence of asymmetry. We searched
trial registries, but we cannot rule out the possibility that we may
have missed unpublished, unregistered studies.
Agreements and disagreements with other
studies or reviews
A number of systematic reviews addressing incentives for smoking
cessation have been published in recent years. Two reviews address
smoking among other public health interventions based on incen-
tives: Giles 2014 evaluated 16 studies of incentivised health be-
haviour change, 10 of which focused on smoking cessation. Using
most of the same studies as in previous versions of our review, they
demonstrated a benefit for smoking cessation up to six months
follow-up (RR 2.48, 95% CI 1.77 to 3.46) and at later follow-
up (more than six months) (RR 1.50, 95% CI 1.05 to 2.14), but
with high heterogeneity (I2 = 76%). Two further reviews were con-
fined to smoking cessation only: Leeks 2010 demonstrated a 4.4%
benefit at a median of 12 months follow-up for worksite-based
cessation programmes which included incentives or competitions.
Sigmon 2012b explored incentive programmes within particular
high-risk population subgroups, including substance abusers, ado-
lescents and young adults, and people diagnosed with pulmonary
disease, and also highlighted the use of shaping procedures for
hard-to-treat smokers, the promise of developing technologies for
delivery of the intervention, and varying the scale of the incentive.
We are aware of two reviews which synthesise evidence on incentive
schemes in pregnant women. Higgins 2012 summarised a series of
six trials of incentives in pregnant smokers, conducted by two US-
based research groups and particularly addressing birth outcomes.
Findings are similar, stating that such interventions “hold promise”
as a mechanism for increasing cessation rates in this population of
smokers. As highlighted above, however, studies suggest that im-
plementing incentives may be difficult, regardless of the evidence.
Our results in pregnant women are similar to those reported in the
Pregnancy and Childbirth Cochrane Review (Chamberlain 2017),
but there are some key differences. The Chamberlain 2017 review
assessed effectiveness of psychosocial interventions for smoking
cessation in pregnancy, and included a subset of studies using in-
centives. Their primary outcome was abstinence around the end
of pregnancy, while ours is at longest follow-up, i.e. post-partum
where available. Unlike in our review, they did not exclude pre-
specified withdrawals (termination, foetal demise) from the de-
nominator. The Chamberlain 2017 meta-analysis included only
data comparing contingent incentives with alternative interven-
tions. They identified insufficient data for comparisons with usual
care and substantial heterogeneity (I2 = 93%) when assessing in-
centives compared with less intensive interventions, precluding
pooling of data. We include six trials which do not appear in the
Chamberlain 2017 meta-analysis. Their main result (incentives
versus alternative interventions for smoking abstinence around the
end of pregnancy) covers 212 women, giving a risk ratio of 2.26
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(95% CI 1.36 to 4.09) (Chamberlain 2017). Our own analysis of
the same (secondary) outcome in 1244 women delivers an RR of
2.79 (95% CI 2.10 to 3.72) (Analysis 2.2).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
• There is high-certainty evidence that incentives boost long-
term cessation rates (six months or more) in mixed-population
studies. This effect appears to persist following their
discontinuation, suggesting that even a short incentivised
intervention may have long-term benefits.
• There is moderate-certainty evidence that incentives also
boost the long-term cessation rates of pregnant women who
smoke, which continues post-partum.
• Low- to moderate-value incentives appear to achieve
sustained success rates beyond the end of the reward schedule,
suggesting that even modest incentive schemes may be effective
at encouraging long-term smoking abstinence.
• Deposit-refund trials may be prone to low rates of uptake
compared to reward-based programmes; however, people who do
sign up and contribute their own money achieve comparable or
higher quit rates than reward-only participants.
• Although concern has been expressed about incentive-based
interventions attracting smokers motivated more by the material
rewards than by the desire to quit, there was little evidence that
levels of deception varied between experimental and control
participants, or that rates of disconfirmation were unacceptably
high. The motivation for entering an incentive-based cessation
scheme may be less important than eventual engagement in
promoting smoking cessation.
Implications for research
• Evaluation of different incentive reward schedules for
smoking cessation is needed.
• Further large, well-conducted trials are needed on the
effectiveness of using incentives for smoking cessation in low-
and middle-income countries and in pregnant women.
• Trials are needed that directly compare high- and low-value
incentives to assess whether there is a difference in effect. A
possible approach would be to evaluate incentive value as a
percentage of mean study participant income.
• The affordability and cost effectiveness of incentive
programmes should be tested in real-world settings, as part of the
evaluation process.
• Implementation and acceptability of incentives in real-
world settings should be formally evaluated, including directly
comparing or assessing the value of incentives alongside other
smoking cessation interventions.
• Trials in pregnant women should explore the effect of
financial versus deposit-based incentives.
• Potential disbenefits and harms of incentives interventions
require monitoring in future trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Ainscough 2017
Methods Randomised pilot study
Country: UK
Setting: Outpatient drug addiction treatment centre
Participants 37 smokers aged 18+ undergoing pharmacological treatment for opioid addiction
Intervention n = 19, control n = 18
Mean CPD = 10. women n = 12 (32%). Mean age, ethnicity, not reported
Interventions Both groups received standard smoking cessation treatment (manualised behavioural
support and NRT according to NCSCT and NICE guidance over 6 weeks)
Experimental Group(s): Contingency management for abstinence. Following an escalating
with reset schedule, where rewards increase in a set increment value for each successive
verified display of the desired behaviour. When the desired behaviour is not observed, no
reward is given, and the reward value for the next verified display of the desired behaviour
is reset to that of the initial reward. Reward values then begin to rise again in the same
way as before. The desired behaviour in the experimental group is smoking abstinence,
defined as breath CO reading of < 10 ppm
Control Group: Contingency management for attendance. The intervention followed an
escalating with reset schedule as described above, but the incentives were for attendance
at smoking cessation treatment at the clinic that week, not abstinence
Theoretical basis for intervention: not reported
Duration of intervention: 5 weeks in total, starting in week 2 of the standard stop-smoking
services treatment and ending in week 6
Length of follow-up: 6 months
Outcomes Point prevalence abstinence at 6 months. Aimed to CO-verify with cut off at < 10 ppm
Notes New for 2019 update
Trial encountered many problems and only 1 person was followed up at 6 months.
Unpublished study, author provided outcome data by personal correspondence
Funding: “This work was funded as part of TSA’s PhD studentship by the Medical Re-
search Council and the Institute of Psychiatry, Psychology and Neuroscience (MRC/IoP
Excellence Studentship). LSB is funded by a Cancer Research UK (CRUK)/BUPA Foun-
dation Cancer Prevention Fellowship (C52999/ A19748). LSB and AM are members
of the UK Centre for Tobacco and Alcohol Studies, a UK Clinical Research Collabora-
tion Public Health Research: Centre of Excellence. Funding from the Medical Research
Council, British Heart Foundation, Cancer Research UK, Economic and Social Re-
search Council and the National Institute for Health Research under the auspices of the
UK Clinical Research Collaboration is gratefully acknowledged 35 (MR/K/K023195/1)
. Neither the funding bodies nor study sponsors had any role in study design; collection,
management, analysis and interpretation of data; writing of the report and the decision
to submit the report for publication.”
Decarations of interest: “JS has contributed to UK guidelines which include considera-
tion of the potential role of contingency management in the management of addiction
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problems (NICE, 2007; chaired by JS), and JS also chaired the broader scope pan-UK
working group preparing the 2007 and 2017 editions of the ‘Orange Book’ (‘Guide-
lines on the Management of Drug Misuse & Dependence’) for the UK Departments
of Health, providing guidance on management and treatment of drug dependence and
misuse, which include guidance on possible inclusion of contingency management. JS’s
institution has received support and funding from the Department of Health (England)
and National Treatment Agency (England), and JS and JS’s institution have provided
funded consultancy advice on possible novel addiction treatments, products and formu-
lations to a range of pharmaceutical companies but these do not have any connection to
the intervention being investigated in this paper. JS’s employer (King’s College London)
has registered intellectual property on a novel buccal naloxone with which JS is involved,
and JS has been named in a patent registration by a pharmaceutical company as inventor
of a potential novel concentrated nasal spray, but these do not have any connection to
the work being reported in this paper. A fuller account of JS’s interests is at http://www.
kcl.ac.uk/ioppn/depts/addictions/people/hod.aspx. JS is supported by the National In-
stitute for Health Research (NIHR) Biomedical Research Centre for Mental Health at
South London and Maudsley NHS Foundation Trust and King’s College London and
is an NIHR Senior Investigator”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Randomisation will be performed
by the principal investigator (PI), using the
service provided by the company ‘sealed
envelope’, 25 and will be performed us-
ing random permuted blocks within strata.
Randomisation will be stratified based on
participants’ current smoking frequency
(between 10 and 20 per day, and more than
20 per day).”
Allocation concealment (selection bias) Unclear risk Not discussed
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcome not biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk Only one participant was successfully fol-
lowed up
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Methods Randomised controlled trial
Country: Connecticut, USA
Setting: Residential substance use disorder clinic
Participants 45 smokers, aged 18+, smoking 10+ CPD. All participants were men
Intervention n = 24, control n = 21. Mean age 37, ethnicity 84% non-Hispanic. Mean
FTND 3.8. Mean CPD 18.6
Interventions All participants: 2 quit-smoking preparation sessions, i.e. in session 1: 2 x CO samples,
30-minute counselling session and a self-help quit guide; then in session 2 (4 days later)
review of progress and obstacles, quit plan updated and TQD set
Participation rewards: Everyone got USD 15 for intake, USD 25 per follow-up, and
a USD 1 gift certificate or item (snacks and gum) for each CO and cotinine sample,
irrespective of smoking status
Control Group: Monitoring only; 2 x CO samples a day Monday to Friday for 4 weeks,
plus brief individualised support/feedback (5 mins) from research staff. CPD tracked at
every session; cotinine tested on Mondays
Experimental Group: As Controls, + incentives: In week 1 a “guaranteed prize” bowl with
70 cards, of which 64 had a USD 1 prize, e.g. toiletries, sports drink, gum, 5 worth a
USD 20 prize, e.g. exercise weights, portable games, Barnes and Noble gift cards, and 1
for USD 100 (linens, TV, and DVD player). Week 1 started with 1 draw for an abstinent
CO test, rising by 1 for each consecutive abstinent test, capping at 5. A positive test or
unexpected missed sample reset back to 1
In weeks 2 to 4, standard prize bowl contained 500 cards, 50% worth a prize; 219 were
USD 1 prizes, 30 were USD 20 prizes, and 1 USD 100 prize. A cotinine-negative test
gave 5 bonus draws. Participants could earn 150 draws from this bowl for negative CO
samples and 15 draws for negative cotinine samples. Increased draw entitlements from
week 1 carried over to weeks 2 to 4
CM participants could earn up to 190 draws for negative CO tests, with average expected
maximum earnings of USD 426.56, and 15 draws for negative cotinine tests, averaging
USD 46.43
Outcomes % reduction in CPD; 7-day PPA at 4, 8, 12 and 24 weeks
Biochemical verification: twice daily (Monday to Friday) CO < 6 ppm; weekly (Monday)
cotinine < 30 ng/ml
Notes Additional information supplied by the author
Funding: ”This study and the preparation of this report were funded by National
Institutes of Health grants R21-DA021836; R21-DA029215; R01-DA013444; R01-
DA027615; R01-DA024667; P30-DA023918 and P50-DA092410
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomization to one of two con-
ditions occurred using an urn procedure”
and “stratifying on at least one CO ≤ 6
ppm during baseline”
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Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Very few losses; 2 participants left the treat-
ment centre before completion
Baker 2018
Methods 2-group randomised clinical trial. 2012 to 2016
Country: USA
Setting: A perinatal support programme (First breath (FB)). Private and community
health clinics providing perinatal healthcare services across Wisconsin as part of the FB
programme
Participants 1014 pregnant women, aged 18+, smoking daily (at least 1 CPD each day for at least 1
week) at some time within the last 6 months, enrolled in Wisconsin Medicaid (Badger-
Care Plus or Medicaid SSI)
Intervention n = 505, control n = 509. Mean age 26, ethnicity: % white CG: 47.2%
IG: 45.4%, black or African American CG: 36.9% IG: 39.8%, Asian CG: 0.8% IG:
0.2%, American Indian/Alaska Native CG: 2.0% IG: 1.0%, ’Other’ CG: 2.8% IG: 1.
0%, Refused/do not know/missing CG: 7.5% IG: 8.5%, Hispanic CG: 5.3% IG: 4.8%,
Non-Hispanic CG: 81.7% IG: 81.8%, Refused to answer/missing CG: 13.0% IG: 13.
5%
Education % Less than high school CG: 3.7% IG: 4.2%, Some high school CG: 20.
6% IG: 20.6%, High school or GED CG: 34.2% IG: 34.3%, Some college or 2-year
degree CG: 25.55 IG: 22.0%, College degree CG: 3.0% IG: 5.4%, Refused to answer/
missing CG: 13.0% IG: 13.7%. CPD: 1 to 10 CG: 39.3% IG: 38.4%; 11 to 20 CG:
39.1% IG: IG: 39.4%; 20+ CG: 17.5% IG: 19.4%; Refused to answer/missing CG: 4.
1% IG: 2.8%
Interventions Control Group: The study compensated all participants USD 40 for study registration/
enrolment and USD 40/visit for attendance at post-birth Visit 1 (1 to 3 weeks post-birth)
and post-birth Visit 4 (at month 6). Participants attending visits 1 and 4 completed
CO testing to biochemically verify self-reports of abstinence from smoking; participants
with CO test values of 7 ppm were considered to be abstinent. Thus, control condition
participants could receive up to USD 120
Experimental Group(s): Incentive condition participants received a further USD 25/visit
for any of the 6 pre-birth visits they completed, USD 25/visit for attendance at post-
birth visits 2 and 3, USD 20/call for completion of 5 post-birth calls, and USD 40/
visit for biochemically-confirmed abstinence at post-birth visits 1 and 4. Thus, incentive
condition participants could receive up to USD 500 for meeting all payment criteria
Theoretical basis for intervention: not reported
Duration of intervention: 6 months post-birth
Length of follow-up: 6 months post-birth
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Outcomes PPA at 6 months with cut-off CO < 7 ppm. Number of post-birth home visits and phone
calls taken; biochemically-confirmed abstinence at the post-birth week 1 visit; and self-
reported smoking status at the 2- and 4-month visits
Engagement in treatment and cost effectiveness also cited on NCT record but not
reported
Notes New for 2019 update’
Previously listed as ongoing
Funding: not reported
Decarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk FB staff used randomisation tables pre-
pared by the UW-CTRI to randomise
women upon consent. Separate computer
determined randomisation tables were cre-
ated based on race (white/non-white) and
county with proportional randomisation
(1:1) into the incentive and control condi-
tions
Allocation concealment (selection bias) Unclear risk Allocation not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Results were CO-verified
Incomplete outcome data (attrition bias)
All outcomes
Low risk For the primary outcome, 316 of 509 (37.
9%) control condition participants had
missing data; 145 of 505 (28.7%) incentive
condition participants had missing data.
Participants with missing data for the pri-
mary outcome were counted as smoking
(ITT)
Other bias Unclear risk 6-month follow-up stated for primary out-
come, but Table 2 results reports “4-6
months” follow-up
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Brunette 2017
Methods 3-arm RCT, 2012 to 2018
Country: USA
Setting: 10 New Hampshire community mental health clinics
Participants 661 community-dwelling adult Medicaid beneficiaries (low income) with a mental illness
diagnosis who were receiving services at a community mental health clinics (CMHC)
. 22% schizophrenia, 23% bipolar, 24% major depression, 31% anxiety and other dis-
orders. Average 17 CPD at baseline. Intervention: Prescriber visit (PV) plus quitline
(PV+Q) n = 303, PV+ CBT n = 212; Control (PV) only n = 146. Mean age 46. 426
women (64%). Ethnicity: n = 610, 93% white. Employment: n = 545, 82% not em-
ployed. Education: n = 549 high school graduate (83%)
Interventions Control Group: Usual care prescriber visit for smoking cessation. All conditions included
a visit with participants’ existing CMHC psychiatrist or nurse practitioner to discuss
cessation medications and NRT and to obtain a prescription if they decided to use phar-
macotherapy (PV). CMHC prescribers were trained with a yearly 45-minute session of
group training in safety, efficacy, and techniques for providing brief tobacco cessation
counselling with evidence-based pharmacotherapy tailored to smokers with mental ill-
nesses. NRT (single product) and cessation medications (varenicline and bupropion)
were covered by Medicaid. All participants received a participation reward of USD 30
Experimental Groups:
PV+Q: PV plus facilitated quitline counselling (PV+Q). Participants met with their pre-
scriber as described above, for which USD 15 was provided, and received a supported
referral to the New Hampshire Tobacco Helpline, which provides an average of 3 man-
ualised telephone counselling sessions to help smokers quit and to support abstinence.
Participants’ cellphone records or helpline staff verified participation, enabling rewards
for up to 3 calls (USD 20 each)
PV+CBT: Participants met with their prescriber as described above for which a USD
15 participation reward was provided. Programme co-ordinators explained how to use
telephone counselling and forwarded a referral to the telephone CBT therapist, who
initiated the first call. The CBT used was a manualised adaptation of the 12-session
Freedom From Smoking programme for people with severe mental illnesses provided by
experienced tobacco treatment specialists. Participants received a USD 5 participation
reward for each completed session, confirmed by counsellors’ records
Incentives for smoking abstinence. Within each intervention, half of participants were
randomly assigned to receive monetary incentives contingent upon abstinence during 1
x 4-week cessation attempt. Programme co-ordinators explained how to use the absti-
nence incentive intervention. Participants agreed to come in to the clinic for abstinence
confirmation after they initiated a quit attempt. Participants in the abstinence rewards
conditions received USD 50 in cash for verified abstinence on Mondays, Wednesdays,
and Fridays in the first 2 weeks of the quit attempt. The incentives were contingent on
breath CO of 6 ppm on the first day and 4 ppm on subsequent days and urine cotinine
sample, 100 ng/mL in the second week for those not using NRT. Participants could
return in the third and fourth weeks for additional incentives (i.e. USD 75 for verified
abstinence with the same criteria). Participants could earn up to USD 450 during the 4
weeks after quitting
Theoretical basis for intervention: Behavioural reinforcement theory. CBT
Duration of intervention: 1 month
Length of follow-up: 12 months
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Outcomes 12-month PPA confirmed by CO breath test and urinary cotinine. Expired breath CO
≤ 4 ppm and urine cotinine < 100 ng/mL (or solely breath CO if participant was using
NRT). Treatment programme participation, medications
Notes New for 2019 update
Half of participants in each intervention group randomised to receive incentives. N
randomised to incentives not reported. 25 participants (4%) experienced a serious adverse
event: 16 were hospitalised for psychiatric exacerbations, 7 were hospitalised for medical
reasons (pneumonia, lung cancer, and heart attack), and 5 study participants died
Funding: “This research received financial support from the Centers for Medicare and
Medicaid Services (Medicaid Incentives for the Prevention of Chronic Diseases grant
1B1CMS330880) and from the New Hampshire Department of Health and Human
Services (NHDHHS).”
Decarations of interest: “Dr. Brunette reports receipt of research funding from Alkermes.
The other authors report no financial relationships with commercial interests.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Quote: “equipoise randomization that al-
lowed participants to opt out of one of the
cessation treatment conditions or allowed
randomization to any of the three options.
This strategy is recommended for compar-
ative effectiveness trials that include more
than two treatments. Randomization strata
were defined by conditions to which the
participant was willing to be randomly as-
signed. Within the stratum, a participant
was then randomly assigned with equal
probability to the selected treatment con-
dition options. Computer-generated tables
for each strata within each site were used for
random assignment. In addition, partici-
pants were randomly assigned to receive in-
centives for biologically verified abstinence
or no incentives. After randomization, par-
ticipants were encouraged to initiate their
assigned interventions, but interventions
could be accessed for the one year study pe-
riod.”
Quote: “Within each intervention, half of
participants were randomly assigned to re-
ceive monetary incentives contingent upon
abstinence during one four-week cessation
attempt”
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Allocation concealment (selection bias) Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Full results not reported - unclear how
many participants randomised to incen-
tives/no incentives, values for the primary
outcome only presented as % in a figure
Cheung 2017
Methods 3-arm RCT. 2013 to 2016.
Country: Hong Kong
Setting: Shopping malls and public areas in all 18 districts in Hong Kong
Participants 1143 participants in the Hong Kong 4th QTW Contest in 2013. Adult daily smokers
who smoked at least 1 CPD in the past 3 months with exhaled CO ≥ 4 ppm. Intervention
groups: early-informed (EI) n = 379, late-informed (LI) n = 385; Control group: 379
Mean age 45. 208 (16.4%) women. Mean 15.2 CPD at baseline. Had secondary edu-
cation (64.1%). Ethnicity not reported. Monthly household income (HKD) (USD 1 =
HKD 7.8) Below 10,000 EI: 94 (24.8) LI: 108 (28.0) CG: 115 (30.3), 10,000 - 19,999
EI: 128 (33.8) LI: 129 (33.5) CG: 116 (30.6) 20,000 or more EI: 140 (36.9) LI: 131
(38.4) CG: 124 (32.8)
Interventions All groups offered cash incentive if biochemically validated quit rate at 3 months (HKD
500/USD 64)
Control Group: The control group was not informed about the incentive at any telephone
follow-up, but the validated quitters at either 3- and 6-month follow-up received the
incentive at 6-month follow-up
At 3-month follow-up, validated quitters participated in a lucky draw organised by the
Council on Smoking and Health (COSH), in which each of the 5 winners obtained a
gift voucher of HKD 10,000 (USD 1282). All participants were informed about this
grand prize at the enrolment
To ensure fairness, all quitters received the incentive, and once only
All participants received brief smoking cessation advice based on the AWARD protocol
at enrolment, 1-week and 1-month follow-up, a pocket-sized self-help education card
and a 12-page self-help booklet
Experimental Groups:
Early informed group - At 1-week and 1-month telephone follow-up, the early-informed
group was informed about the incentive, which was offered to the validated quitters at
3-month follow-up
Late informed group - At 3-month follow-up, the late-informed group was informed
that they would receive the incentive if they quit and passed the biochemical validation
at 6-month follow-up
Theoretical basis for intervention: Health Action Process Approach (HAPA) model
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Duration of intervention: 6 months
Length of follow-up: 6 months
Outcomes Point prevalence abstinence at 6 months follow up, verified by exhaled CO ≤ 4 ppm
and saliva cotinine level ≤ 10 ng/ml. Quit attempts (longest duration and number of
quit attempts (no smoking for at least 24 hours)); cessation aids
Notes New for 2019 update
‘loose inclusion criteria for the study might have led to the inclusion of low-rate/nondaily/
light smokers who might simply stop smoking for a day in order to win. Such “cheating”
was possible’
Funding: “This work was supported by the Hong Kong Council on Smoking and Health
(COSH).”
Decarations of interest: “Prof. Tai-hing Lam is the principal investigator of the FAMILY
project, which was funded by the Hong Kong Jockey Club Charities Trust. All other
authors do not have connection with the tobacco, alcohol, pharmaceutical or gaming
industries, and nobody was substantially funded by these organizations.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomisation was used to individu-
ally and randomly allocate the participants
recruited on each recruitment day into 3
RCT groups. One investigator (YTCD)
used random.org to generate random per-
mutations of the 3 RCT groups and allo-
cated these permutations to the blocks with
a size equal to 3, 6 or 9. These blocks of
permutations were assigned to the partici-
pant lists on each recruitment day. Other
research staff conducted the telephone call
and the intervention based on the alloca-
tion list at 1-week and 1-month telephone
follow-up
Allocation concealment (selection bias) Low risk All participants and recruitment staff were
prevented from knowing the allocation
procedures at enrolment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data completion at 6 months above 50% in
all arms and no substantial between-group
differences: Early informed: n = 228, 60.
2%; Late informed: n = 221, 57.4%; Con-
46Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cheung 2017 (Continued)
trol group: n = 228, 60.2%
Other bias Unclear risk Participants took part in a Quit and win
contest (and may have already been ran-
domised as part of that study) before being
randomised to this trial. Potentially already
motivated sample (incentivised by compe-
tition)
Cooney 2017
Methods RCT. Dates not reported
Country: USA
Setting: US. Department of Veterans Affairs (VA) intensive outpatient substance use
treatment programme
Participants 83 adults age 18+. Met DSM-IV criteria for alcohol abuse or dependence with last drink
occurring within 90 days, reported current cigarette smoking of 10 or more CPD with
at least a 3-year smoking history, substance detoxification when necessary was completed
prior to randomisation. If history of recent cannabis use, required to have negative urine
toxicology screen for cannabis at time of enrolment
Intervention group: n = 42; Control group: n = 41.
Mean age 49.9. Mean 20 CPD at baseline. Women n = 3 (2.4%). Ethnicity: 67% white:
CBT + NRT: Hispanic n = 3 (7.3%), white n = 26 (63.4%), African American n = 11
(26.8%), Other n = 1 (2.4%)
CBT plus NRT plus CM: Hispanic n = 0 (0%), white n = 30 (71.4%), African American
n = 12 (28.6%), Other n = 0 (0%). Socioeconmic status:
Homeless 38.6%, employed: CBT + NRT n = 11 (26.8%) CBT + NRT + CM n = 16
(30.1%). Other drug use diagnosis (CG) 15 (36.6%) (CM) 18 (42.9%)
Interventions Control Group: CBT + NRT: 3 x 40-minute sessions (120 minutes total) at weekly
intervals, focused on preparation to quit smoking, coping with nicotine withdrawal, and
relapse prevention. All prescribed an 8-week course of nicotine patch therapy beginning
on TQD with 21 mg dose for 4 weeks, then 14 mg for 2 weeks, then 7 mg for 2 weeks
Experimental Group(s): CBT + NRT + CM: same behavioural content and strategies
as CG, but delivered across 12 shorter daily10-minute sessions (120 min total) to cor-
respond with daily CM sessions. Escalating financial incentives for biochemically-con-
firmed smoking abstinence following TQD. Readings of 5 ppm or less were reinforced
with a progressive monetary incentive, along with a reset condition for tobacco lapse.
Participants were eligible to receive financial reinforcements twice daily from session 5
through 12. Reinforcement began with USD 5 at the beginning of day 1, USD 5.50 at
the end of day 1, USD 6 and USD 6.50 on day 2, USD 7 and USD 7.50 on day 3 and
so on, up through USD 12 and USD 12.50 on day 8, totaling a potential maximum of
USD 140 in financial reinforcement for 8 days of tobacco abstinence. Reinforcement
was withheld for CO ≤ 5 ppm and was reset to USD 5 for the first CO ≤ 5 ppm after
a smoking lapse. Vouchers for financial reinforcements were given to participants by the
study therapist
Theoretical basis for intervention: CBT
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Duration of intervention: 8 weeks (12 days CM but 8 weeks NRT)
Length of follow-up: 6 months
Outcomes PPA at 6 months. CO “Readings of ≤ 5 parts per million (ppm) were considered
corroboration of smoking abstinence”. Smoking at 1½ weeks after quit date, 1 month.
Alcohol use, drug use
Notes New for 2019 update
Funding: not reported
Decarations of interest: “Judith Cooney has worked as a promotional speaker for Pfizer,
Inc”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Urn randomisation computer programme
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk High retention rates
Other bias Unclear risk Quote: “Design with an experimental con-
dition that integrated CM within 12 brief
CBT sessions compared with a more con-
ventional, three-session CBT without CM
treatment schedule. This design does not
allow us to dismantle the effects of fre-
quently scheduled CBT from the effects of
CM procedures”
Dallery 2016
Methods RCT. 2010 to 2016
Country: USA
Setting: community smokers, recruited online
Participants 94 adult community smokers, motivated to quit, with at least a 2-year history of daily
smoking. Mean age 36, mean CPD at baseline = 17. Submission-contingent group (SC)
n = 46; abstinence-contingent group (AC) n = 48. 56% women. Ethnicity: AC: European
American 77%; Hispanic American 4%; African American 15%; native American 0%;
Asian 4%; More than 1 race 0%. SC: European American 71%; Hispanic American 7%;
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African American 7%; Native American 4%; Asian 9%; More than one race 2%. SES:
AC: Less than high school 2%; High school degree, no college 8%; Some college 44%;
Associate professional degree 13%; Bachelor’s degree or higher 37%. SC: Less than high
school 2%; High school degree, no college 0%; Some college 48%; Associate professional
degree 13%; Bachelor’s degree or higher 37%
Interventions Control Group: submission-contingent (SC) group: financial incentives based on sub-
mitting CO samples (regardless of abstinence status)
Participants could earn a maximum of USD 480 in incentives based on abstinence or
CO submissions. Participants in both groups were provided with the same CO-based
goals. The only difference between groups was the target behaviour to receive incentives:
the AC group had to meet video-verified CO cut-points and the SC group had to submit
videos. A USD 50 deposit was required from all participants. Deposits were made to
PayPal via debit, credit card or direct bank transfer. The first USD 50 earned went
toward reimbursement for the initial deposit incentive. Participants were loaned a CO
monitor (Bedfont piCO+ Smokerlyzer; Bedfont Scientific Ltd, Maidstone, UK) and a
web-camera. Each participant’s homepage consisted of a graph of CO sample results,
voucher earnings history, a ‘post video’ button and a display showing their previous
sample’s date/time, and the earliest date/time at which they could provide their next
sample
Experimental Group(s): abstinence-contingent (AC) group: financial incentives based on
abstinence
Tapering: For participants in the AC group, the average CO during baseline was cal-
culated and every predetermined reduction from this value resulted in USD 3.00. The
reductions were calculated for each participant such that the last day of this phase would
serve as their quit day, with a target CO ≤ 4 ppm
Induction: For participants in the AC group, CO samples were judged as either positive
or negative (≤ 4 ppm.). A USD 3.00 incentive was awarded for the first negative sample,
and increased by USD 0.25 for each consecutive negative sample. In addition, every
third consecutive negative CO resulted in a USD 5.00 bonus
Theoretical basis for intervention: not reported
Duration of intervention: total length of intervention appears to be 49 days. 7 weeks
stated in abstract
Length of follow-up: 6 months
Outcomes PPA CO-verified by video at 6 months. CO ≤ 4 ppm. PPA at week 4 and 3-month
follow-up. Treatment acceptability, behavioural change
Notes New for 2019 update
Funding: “Research and preparation of this paper was supported by Grants
R01DA023469 (Principal Investigator: J.D.) and P30DA029926 (Principal Investiga-
tor: L.M.) from the National Institute on Drug Abuse.”
Decarations of interest: none reported by authors
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Quote: “Randomization was automated by
an Excel macro that coded each participant
based on smoking severity and gender, and
then assigned the participant to the group
with a lower number of participants with
that combined smoking severity and sex
code. If smoking severity and gender dis-
tributions were equal, then the participant
was assigned randomly to a group”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated by online video
(participant takes CO test and videos re-
sults to research team)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low and similar rates of attrition in each
arm
De Paul 1994
Methods Cluster-randomised 3-arm controlled trial
Country: USA
Setting: 63 Chicago worksites, stratified on size and type of business
Participants 844 smokers (280 self-help (SH), 281 incentives (I), 283 Group (G)),
Mean age 37.8, 37% women, mean % black 20.5, mean years education 13.8, mean
years smoking 19.9, mean CPD 21.5. Sex and race differed across conditions and were
controlled for in all analyses
Interventions 1. SH (also = M) 5-day cessation TV programme ’Smoke-free in the 90s’ + 8-page
newspaper supplement, self-help ALA manual Freedom from smoking in 20 days
2. I (also = IM) as SH, plus USD 1 per day for each day abstinent up to 6 months
(maximum USD 175)
3. G (also = GIM) as I, plus group meetings twice a week for first 3 weeks, + 14 ’booster’
meetings over 6 months; programme included a ’buddy’ system, and tips in booster
sessions on living with a smoker, weight control, exercise and stress management
Outcomes Baseline, post-test (3 weeks), and at 6, 12, 18 and 24 months. Lottery system used to
boost follow-up return rates. CO samples at all assessments, + cotinine at 6 months. ICC
calculated (no significant between-firm effects detected)
Notes Only groups SH and I are used for the comparison, to isolate the effects of the incentives.
Results extrapolated from percentages
Additional information supplied by the authors
Study was funded by the National Institute of Heart, Lung, and Blood
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Stratified by size and type and then ran-
domised. Method not stated
Allocation concealment (selection bias) Unclear risk Method not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk 1/63 companies dropped out before in-
tervention, 1/62 during intervention, 3/61
during first 6 months
Only Grps I (SH only) and II (SH + incen-
tive) used for this review; attrition by post-
test was SH: 32.3%, Incentives: 23.3%; 6
months SH: 43.3%, Incentives: 46.5%; 12
months SH: 52.5%, Incentives: 47.2%; Al-
though losses by 12 months are high, there
was no significant difference in levels of
missing data between the 2 groups. Across
groups, those who were younger, heavier
smokers, with lower health ratings, less ef-
fort to quit, more confident of quitting and
with less helpful coworkers were more likely
to drop out
Other bias Unclear risk Allocation was by worksite, but analysis by
individual participant. The last scheduled
rewards were paid out to coincide with the
final assessment, and may therefore have
confounded that result
Donatelle 2000a
Methods Study design: RCT, conducted June 1996 to June 1997; data collection completed
January 1998
Country: USA
Setting: 4 Oregon Women, Infants, and Children (WIC) programme sites
SOS (Significant Other Supporter) Programme I
Participants 220 women smokers (112 intervention, 108 control)
Aged 15+, ≤ 28 weeks gestation, literate in English; withdrawal criteria included termi-
nation and foetal death
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Interventions All participants received a USD 5 participation voucher at each of 3 assessments. Everyone
at baseline was given verbal and written advice on importance of smoking cessation by
WIC- or SOS-trained staff, + self-help kit A pregnant woman’s guide to quit smoking
Experimental Group(s): Each participant was asked to designate a social supporter, prefer-
able female non-smoker. Both were eligible for vouchers if participant quit.
Participant was phoned monthly (up to 10 months) to report smoking status. If she
reported quit and supplied confirmatory saliva sample, she got a USD 50 voucher, and
“their social supporter received a voucher as well” (i.e. USD 50 for 1st quit month,
USD 25 for other quit months, and USD 50 for final quit month). Vouchers were
funded by contributions from 10 local ’community partners’ (businesses, foundations
and healthcare organisations)
Control Group: Baseline advice and quit kit, + monthly phone calls to determine smoking
status
Outcomes 7-day PPA at 8 months gestation, and at 2 months post-partum
Biochemical validation by salivary cotinine < 30 ng/ml, and salivary thiocyanate < 100
mg/ml
Notes New for 2015 update
Funding: grant from Robert Wood Johnson Foundation Smoke-Free Families Program,
+ support from local businesses and healthcare facilities
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk Relatively high, but comparable with non-
participant attenders at the WIC clinic
Losses: Intervention: 32% at 8 months
gestation, 36% at 2 months post-partum;
Control: 51.5% at 8 months gestation,
52% at 2 months post-partum
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Methods Study design: RCT, dates not stated
Country: USA
Setting: 8 Oregon Women, Infants, and Children (WIC) programme counties
SOS (Significant Other Supporter) Programme III
Participants Probably similar to Donatelle 2000a;
186 pregnant smokers, randomised to E1 (N = 67); E2 (N = 59); Controls (N = 60)
Interventions All participants received a 5As intervention (Ask, Advise, Assess, Assist, Arrange)
E1 group: USD 25 voucher (local department store) for each month achieving validated
abstinence
E2 group: USD 25 voucher (local department store) for achieved abstinence + immediate
feedback on risks to the foetus associated with CO results. CO ≤ 5 ppm confirmed
monthly abstinence
Outcomes Abstinence at end of pregnancy
Biochemical validation by salivary cotinine < 30 ng/ml. CO < 5 ppm monthly
Notes New for 2015 update
Minimal information; emails to the author elicited no responses
Funding not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information
Donatelle 2002
Methods Study design: RCT, 3-group design; interim report on data from August 2001 to Septem-
ber 2002
Country: USA
Setting: 9 Oregon private practice prenatal clinics
The MISS project
Participants 298 “predominantly low-income, high risk pregnant women”, smoking “even a puff” in
the last 7 days, aged 15+, < 29 weeks gestation, literate in English
79% had Medicaid or Oregon Health Plan insurance; 24% had private insurance; mean
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age 24.1 years, mean education years 11.9
Target enrolment was 600
Interventions All participants received a 5As intervention (Ask, Advise, Assess, Assist, Arrange), + a
copy of A Pregnant Woman’s Guide to Quit Smoking, + local cessation resource guide
E1 group (102 women): USD 25 voucher (local department store) for each month
achieving validated abstinence
E2 group (96 women): USD 75 voucher (local department store) for achieved abstinence
Control group (95 women): standard care as above
Outcomes Abstinence at 8 months gestation, + phone call post-partum and a salivary cotinine test
for self-reported non-smokers
Biochemical confirmation: salivary cotinine < 30 ng/ml; CO < 5 ppm at monthly tests
Notes New for 2015 update
Funding: grant from Robert Wood Johnson Foundation Smoke-Free Families Program
Too little information to adequately assess risk of bias; emails to the author elicited no
responses
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not stated
Allocation concealment (selection bias) Unclear risk Not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information. 298 reported enrolled,
but results given for only 293
Drummond 2014
Methods Randomised factorial 4-arm controlled trial, subset of a prospective, longitudinal cohort
study (ALIVE: AIDS linked to the Intravenous Experience study)
Country: USA
Setting: Baltimore, MD
Study conducted March 2011 to February 2012
Participants 100 injecting drug-using patients randomised to 4 groups: Usual care (26); Lung age
(24); Contingency management (26); Lung age + contingency management arm (24).
47% women, median age 50 (IQR 45 to 56); median FTND 4 (IQR 2 to 5); median
pack years 19 (IQR 12.5 to 31); Ethnicity % African-American: UC 92; LA 75; CM
100; LA+CM 88
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Interventions 6-month programme. Cotinine blood test at 6 months for everyone
1. Usual care (UC; control) group: Baseline visit, + visits at 1, 2, 4 weeks, and then 2, 3
and 6 months. Participants completed questionnaires, self-efficacy, motivation to quit,
level of addiction, eCO testing, spirometry
At all visits participants reviewed their spirometry results, and got guidance on quitting
based on this
2. Lung age (LA) group: As UC, + written report giving their chronological age and their
lung age. ‘Abnormal’ = lung age exceeding chronological age
3. Contingency management (CM) Group: As UC, + monetary compensation for veri-
fied cessation. On each visit, CO < 7 ppm = USD 25 at 1st visit, increasing by USD 5
for each consecutive negative sample, to a maximum of USD 50. If negative sample, no
payment and schedule reverted to starting point
4. Combined (LA + CM) group: Combined the CM and lung age elements
Outcomes Primary: 7-day PPA at 6 months, cotinine-confirmed
Secondary: N of visits attended, smoking rates, N of quit attempts, change in FTND
score, change in self-efficacy score
Notes New for 2015 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “120 sequen-
tially numbered opaque sealed envelopes
were externally prepared that included ran-
dom assignment to one of four interven-
tions. Randomization sequence was com-
puter-generated using a block randomiza-
tion approach with randomly ordered four
and eight sample blocks”
Allocation concealment (selection bias) Low risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk > 80% followed up at 6m across all groups
Other bias Unclear risk Ethnicity significantly different for LA
group from others (P = 0.03), but no report
of interaction with key outcomes. Authors
stated they had predetermined to combine
CM and non-CM arms if they found no
interaction between lung age and CM
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Etter 2016
Methods 2-arm, parallel-group, individually randomised controlled trial. 2011 to 2016
Country: Switzerland
Participants 805 regular smokers, smoking at least 5 CPD for at least 1 year. Baseline CO reading of
at least 10 ppm. Baseline saliva cotinine reading of NicAlert level 1 or higher (≥ 10 ng/
mL). Age > 18 years old
CG n = 404, IG n = 401
Mean age 42, Mean CPD = 16. Median annual income, CG: USD 20,700 IG: USD
19,200. Occupation, % Unemployed CG: 18 IG: 20 Student CG: 45 IG: 42 Mother
at home CG: 3 IG: 1 Manual CG: 12 IG: 15 Clerical, administrative CG: 13 IG: 12
Professional CG: 9 IG: 10. Mean years of education: 15
Interventions Control Group: Internet-based support
Experimental Group(s): financial rewards of up to CHF 1,500 (USD 1650 in 2013) were
paid to those participants biochemically verified as abstinent. Incentives given 6 times
during 6 months: CHF 100, 150, 200, 300, 350, and 400 at 1, 2, and 3 weeks, and 1,
3, and 6 months, respectively (USD 110, USD 165, USD 220, USD 330, USD 385,
and USD 440, respectively). If participants smoked or missed an assessment, the value
of the next reward was reset to the value of the previous reward they had received
Theoretical basis for intervention: not reported
Duration of intervention: 6 months
Length of follow-up: 18 months
Outcomes Continuous abstinence between 6 and 18 months, CO-verified (0 to 3 ppm) and coti-
nine,10 ng/ml
Quit attempts during the intervention phase (number, duration and dates), cigarette
consumption, motivation to quit, confidence in ability to quit, Use of the online smoking
cessation programme
Notes New for 2019 update
Previously listed as ongoing. Relatively affluent population compared to other countries
Funding: “From the Institute of Global Health, Faculty of Medicine, University of
Geneva, Geneva, Switzerland. The study was funded by the Swiss Tobacco Prevention
Fund (Swiss Federal Office of Public Health), grant 11.001733. Dr. Etter’s salary was paid
by the University of Geneva. The authors have reported that they have no relationships
relevant to the contents of this paper to disclose.”
Decarations of interest: “The Swiss Tobacco Prevention Fund, which funded the study,
suggested that the follow-up should be extended to 12 instead of 6 months after the final
incentives were received, but had no other role in the conduct of the study.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “sealed opaque envelopes drawn by
participants. Neither the researchers nor
the participants could know in advance
the content of the envelopes. We did not
use blocks for randomization. Participants
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could not be blinded to their assignment
group. Researchers were not blinded, but
online data collection at follow-up was
computerized”
Allocation concealment (selection bias) Low risk Sealed opaque envelopes
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically verified
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “very high follow-up rates.” “All
randomized participants were included in
the denominator and participants with
missing data at follow-up were counted as
smokers.”
Fraser 2017
Methods 2-group randomised clinical trial. 2013 to 2017
Country: USA
Setting: recruited from Wisconsin Quit Line, primary care clinics, and community ad-
vertisements
Participants 1900 community-dwelling smokers accessing a quit line or recruited from primary care
or advertising
CG: n = 952; IG: n = 948
60% women. Mean age 45. Mean CPD = 16. 51% and 41% black and white respectively.
Education: 61% high school or less
Interventions Control Group: All participants were incentivised for participating in baseline and 6-
month follow-up biochemical assessment visits
Quit line coaching included a pre-quit call that typically occurred at study enrolment
and 4 additional proactive calls. Participants could also initiate calls to the WTQL for
additional assistance. WTQL quit coaches made 3 attempts (per protocol) on different
days to reach a participant for each proactive call, leaving messages at least twice if pos-
sible. Those callers not reached on the first 2 proactive calls were sent a letter urging
them to call. Study participants also received a mailed quit guide, access to recorded
medication information (by phone), and access to Web Coach®, an online cessation
programme maintained by the quit line. WTQL quit coaches routinely recommended
that participants obtain a prescription for a Medicaid-approved smoking cessation med-
ication from their primary care provider (at minimal or no co-pay). Participants in the
control condition could receive a total incentive of USD 80: USD 40 each for attendance
at the baseline and 6-month follow-up biochemical assessment visits. Compensation was
in the form of prepaid Visa gift cards and took 2 to 4 weeks from the point of contact
Experimental Group(s): All participants were incentivised for participating in baseline
and 6-month follow-up biochemical assessment visits. Incentive condition participants
were additionally incentivised for participating in WTQL calls and for biochemically
determined abstinence at the 6-month follow-up visit. Participants in the Incentive
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condition could receive a total payment of USD 270: USD 30/call for up to 5 WTQL
calls, USD 40/visit for attending the baseline and 6-month follow-up assessment visit,
and USD 40 for producing biochemical evidence of abstinence at the 6-month follow-
up visit
Theoretical basis for intervention: None specified
Duration of intervention: 6 months
Length of follow-up: 6 months
Outcomes PPA at 6 months. CO ≥ 7 ppm. Clinics chose different cut-scores for the urine cotinine
test; Almost all the clinics chose to define smoking as a value that exceeded either 50 ng/
mL, 100 ng/mL, or 200 ng/mL, depending on the clinic. 4 clinics used 300 ng/mL as
the smoking cut-score. Treatment engagement, medication use
Notes New for 2019 update
Funding: “This research was supported by Funding Opportunity Number
1B1CMS330876 from the Centers for Medicare & Medicaid Services.”
Decarations of interest: “No financial disclosures were reported by the authors of this
paper.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation occurred by computer-
generated lists (Appendix, available online)
, with order stratified by county and race
Allocation concealment (selection bias) Unclear risk Quote: “These randomization lists were
supplied by the research team to the Wis-
consin Tobacco QL and then programmed
to automatically determine randomization
at the time required in the consent proto-
col”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 552 intervention (58%) and 562 control
followed up at 6 months (59%)
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Gallagher 2007
Methods Randomised 3-arm controlled trial
Country: USA
Setting: 3 psychiatric case management sites in La Frontera, Arizona
Participants 180 smokers, aged 18+, English-speaking, smoked at least 10 CPD for at least 3 years,
CO > 10 ppm. Diagnosed with DSM-IV Axis 1 psychotic-spectrum or affective disor-
ders resulting in long-term mental illness and experiencing significant symptoms and
functional impairment.
48% women, 76% Anglo, av age 43, av FTQ 6.1, av CPD 24.8
Not required to commit to cessation, but 98% expressed interest either in quitting or in
reducing
Randomised to contingent reinforcement (CR, n = 60), contingent reinforcement +
NRT patches (CR+NRT, n = 60), or self-help (Control, n = 60)
Interventions 1. CR: Weekly visits weeks 1 to 4 (Phase 1), fortnightly weeks 6 to 12 (Phase II), monthly
weeks 16 to 24 (Phase III). Payments USD 25 for baseline assessment and USD 5 per
visit, plus USD 20 per abstinent visit in Phase I, USD 40 in Phase II, USD 60 in Phase
III, and USD 80 if abstinent at 36-week follow-up. Maximum payable USD 580 for
attendance + abstinence. At each visit weight, pulse rate, smoking status, intention to
quit, withdrawal symptoms, CO, BP measured
2. CR+NRT: As CR Group, plus 16-week course of 21 mg NRT patches, plus supporting
instructions
3. Control: Visits at baseline and weeks 20 and 36, plus encouraged to use the community
smoker helpline, ALA and ACS self-help information.
In all groups, salivary cotinine measured at baseline and at weeks 20 and 36; brief
symptom inventory (psychiatric symptoms) at baseline and weeks 6, 16 and 36; FTND
at baseline and at weeks 10, 24, 36
Outcomes Abstinence at weeks 20, 36
Verified by expired CO < 10 ppm and by salivary cotinine < 15 ng/mL
Other outcomes: smoking reduction, change in psychiatric symptoms
Notes Additional information supplied by the author
New for 2008 update
Study funded by Arizona Biomedical Research Commission
Risk of bias
Bias Authors’ judgement Support for judgement





Allocation concealment (selection bias) High risk Study staff oversaw allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No significant differences between groups:
Attrition for CR at weeks 20 and 36 was
37% and 43%; CR+NRT at weeks 20 and
36 was 35% and 36%; and Controls 52%
at both time points
Ghosh 2016
Methods 2-arm RCT (dates not reported)
Country: USA
Setting: Head and Neck Surgery clinic at the Philadelphia Veterans Affairs Medical
Center
Participants 14 patients with a previous diagnosis of head and neck cancer who had completed
treatment or were undergoing treatment. Age 18+. Actively smoking at least, on average,
five cpd. CG: n = 8 IG: n = 6. ’the majority’ male gender. Mean age 60. all black/African
American
Education: 1 to 3 years at college. Income: $30,000 to 39,999. CPD reported as packs
per day CG; 1, IG: 1.5 to 2
Interventions Control Group: Participants in each study arm were offered free enrolment in a Veterans
Administration-sponsored smoking cessation course. Attendance was recorded at each
of the 3 classroom sessions. For all participants, a payment of USD 50 was made for
each class attended. Payments for attendance at each class took place at the conclusion
of the class on that day
Experimental Group(s): information about smoking cessation and financial incentives
in the form of cash payments at specific time intervals if class attendance or smoking
abstinence was confirmed
At 30 days: USD 150; At 3 months: USD 150; At 6 months USD 150
Theoretical basis for intervention: not reported
Duration of intervention: 6 months
Length of follow-up: 6 months reported but methods state 12 months
Outcomes PPA CO-confirmed at 6 months, but cut-off not defined
Notes New for 2019 update
Contacted author to request clarification on some issues but did not hear back
Funding: not reported
Decarations of interest: none declared
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomisation was performed, at the time
of study enrolment, by the physician or
clinical staff (physician assistant), accord-
ing to a specific schema. Slips of paper were
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sequentially numbered with integers from
100 to 299, and for each person enrolling
in the study 1 slip was selected at random.
The number on the slip of paper in the en-
velope became the participant’s study iden-
tification number. Group assignment was
as follows: even numbers were assigned to
the control group (information only), while
odd numbers were assigned to the experi-
mental group (financial incentives plus in-
formation)
Allocation concealment (selection bias) High risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Biochemically verified, but cut-off level was
not defined
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 24 randomised, only 14 included in
analysis (others were post-randomisation
exclusions but numbers not reported by
group). All lost to follow-up at 6 months
apart from 2 in intervention group
Other bias High risk Inconsistent reporting of length of follow-
up. Methods state 12 month follow-up but
only 6-month follow-up reported
Giné 2010
Methods Randomised 3-arm controlled trial. Study conducted between August 2006 and May
2007
Country: Philippines (Mindanao); the CARES study (Committed Action to Reduce and
End Smoking), described as randomised
Participants 2000 smokers aged ≥ 18, identified as “obvious smokers”, and approached in the street
by Green Bank marketing employees
3 waves of recruitment:
1) and 2) Butuan city; August 2006 to December 2006;
3) Ampayon; February 2007 to May 2007.
Totals were 418 smokers enrolled from waves 1 and 2, and 515 from wave 3
Allocation distributed as:
Wave 1: 1a: 45%; 1b: 45%; cue cards: 5%; controls: 5% (to verify acceptability of CARES
offer)
Wave 2: 1a: 15%; 1b: 15%; cue cards: 30%; controls: 40% (to balance up numbers of
cue card and control participants)
Wave 3: presumably roughly 1:1:1 (no without-deposit CARES assignments)
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Interventions All individuals approached were given a pamphlet on dangers of smoking, and a quitting
tip sheet
People agreeing to participate were given a brief baseline survey (age, smoking status)
1a: CARES + deposit collection (most were visited weekly by a bank employee to collect
the money)
1b: CARES without deposit collection (pt had to go to a bank to deposit money)
Both the CARES groups were encouraged to deposit the money they would normally
spend on cigarettes (minimum 50 pesos (~USD 1)) in a non-interest-bearing account
2: Cue cards: pocket-sized graphic depictions of negative health consequences of smok-
ing; choice of 1 from 4 different images
3. Control (no additional intervention)
Outcomes All participants contacted and tested (NicCheck urine test for nicotine and cotinine) for
smoking status; those proved abstinent received their deposit money back at 6-months
test. Those who could not be reached, did not attend, or who failed the test, forfeited
their money to charity
Pre-stated assessment at 6 months (PPA), and ’surprise’ test at 12 months; continuous
abstinence defined as abstinent at both time points
All non-CARES participants received 30 pesos for attending for testing at 6 months; all
participants, including CARES, received 30 pesos for attending 12 months test
Notes New for 2015 update. Study was funded by the World Bank, and implemented by
marketers of the Green Bank of Caraga
Additional information supplied by the authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Randomised with stickers on backs of base-
line questionnaires for waves 1 and 2;
for wave 3, researchers used a calculation
(residual of (birth date (dd+mm+yy)/3)) to
allocate participants, 0s to CARES, 1s to
cue cards, and 2s to control
Allocation concealment (selection bias) Unclear risk Researchers revealed allocation concealed
under a sticker on the back of the baseline
face-to-face questionnaire for waves 1 and
2. Algorithm effectively concealed alloca-
tion for wave 3. Change in methods may
have compromised concealment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
62Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Giné 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No differences between the groups; 36%
attrition across the board in Wave 3 at 12
months. Nothing reported for waves 1 and
2
Glasgow 1993
Methods Cluster-randomised controlled trial
Country: USA
Setting: 18 Oregon worksites (8 experimental, 10 control), stratified on number of
employees and estimated smoking prevalence
Participants Smokers defined as ≥ 7 cigs/week. Smoking prevalence av 21.5%; av age 40.5, 37%
M, av 18.5 CPD. Smokers in intervention sites had higher education levels, and rated
themselves more likely to try and quit smoking within next 6 months. 23% of baseline
smokers in intervention sites joined the programme. 474 participants in intervention
sites, 623 in control sites
Interventions 1. Experimental: USD 10 for each monthly PPA over 1 year of programme + monthly
worksite lottery (USD 5 to USD 20 first 6 months, then minimum USD 50 for 2nd 6
months). 12-month sweepstake for USD 200, USD 100 and USD 50 at each worksite.
Also ’good buddy’ nonsmokers’ lottery prize. No formal quitting support
2. Control: Baseline and follow-up surveys at 1 year, 2 years
Outcomes PPA at 1 year, 2 years
Validation: CO < 9 ppm and salivary cotinine
Notes This is the HIP study (Health Incentives Program). Great variability in outcome across
sites (2-year follow-up cessation rates Int: 14 to 33%, Control: 9 to 27%), with 30%
lost to follow-up at 2 years
Study was funded by National Cancer Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “the worksites were then random-
ized”. Method not stated
Allocation concealment (selection bias) Unclear risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 12 months, 19% of incentives group had
left, vs 24% of no-incentives group
At 24 months, 27% of incentives group
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had left, vs 32% of no-incentives group; No
statistically significant differences
Other bias Unclear risk Data extrapolated from percentages
Halpern 2015
Methods 5-arm randomised controlled trial. Study conducted between February and October
2012
Country: USA
Setting: Web-based and worksite-based across the USA
Participants Employees of CVS/Caremark (retail pharmacy outlets) and their families and friends.
Aged 18+, smoking at least 5 cpd, with internet access, and interested in learning about
ways to quit
Mean age 33, 63% women, 74% income < USD 60,000, 79% white, mean CPD 15,
64% in preparation stage of change (ready to quit within 30 days)
Interventions All participants were paid for completing questionnaires and submitting samples, and
all used the Way to Health web-based portal for communicating, and accounting
A random sample of 5% of enrolled participants were invited for cotinine screening and
offered USD 100 for completing the cotinine assay, to discourage non-smokers from
signing up
Control Group (N = 468): Usual care, i.e. information about local SC services, ACS
cessation guides, and for the 41% on health benefits free access to behavioural support
and NRT
1. Individual rewards (N = 498): usual care, plus participants received USD 200 for
sustained abstinence at each of 14 days, 30 days and 6 months, + a 6-month USD 200
bonus for sustained abstinence at that point
2. Collaborative rewards (N = 519): usual care, plus participants grouped into teams of
6, linked by proximal TQDs. Rewards for sustained abstinence were given at 14 days,
30 days and 6 months, calculated at USD 100 per successful quitter in the group, i.e. up
to USD 600 per person at each time point if all 6 remained quit, + USD 200 sustained
abstinence bonus at 6 months. Linked by a web-based chat room throughout study, for
mutual support
3. Individual deposits (N = 582): usual care, plus participants put up USD 150 of their
own money (by debit or credit card) within 60 days of enrolment or prior to the TQD,
whichever came first. They received USD 200 for confirmed abstinence at each of 14
days, 30 days and 6 months, + a 6-months USD 200 sustained abstinence bonus
4. Competitive deposits (pari-mutuel principle) (N = 471): usual care, plus participants
put up USD 150 of their own money (by debit or credit card) within 60 days of enrolment
or prior to the TQD, whichever came first. Participants were grouped into teams of 6,
linked by proximal TQDs. USD 600 per person was available, distributed at 14 days, 30
days and 6 months to successful quitters only, + USD 200 sustained abstinence bonus at
6 months. So USD 1200 potentially available at each time point for sustained abstinence,
e.g. if 2 people quit at 14 days but relapsed by 30, the 2 quitters would get USD 600
each at 14 days and then no more rewards for anyone in the group. Participants got
anonymised descriptions of their team-mates to encourage competitive interaction
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All intervention arms offered potentially the same financial returns, i.e. USD 800 per
quitter, but for the 2 deposit arms this includes USD 150 of the participants’ own money
Outcomes Primary: Sustained abstinence (14 days, 30 days, 6 months) at 6 months, cotinine-
verified (anabasine/anabitine for NRT users)
Biochemical verification: salivary cotinine < 10 ng/ml (urinary anabasine/anabitine < 3
ng/ml)
Secondary outcomes: initial quit rate at 14 days, sustained abstinence at 30 days and
at 12 months; self-reported quit rates at 12 months; rates of acceptance of the assigned
intervention
Notes New for 2015 update
Funding was from National Cancer Insitute grant R01 CA159932 (SDH) and National
Institute of Aging grant RC2 AG036592 (DAA and KGV), and through in-kind support
from the host company
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomized individually”, strati-
fied on 2 variables: access to full company-
sponsored healthcare benefits; household
income (USD 60,000 [median company
income])
“We developed an adaptive randomiza-
tion algorithm that updated the assignment
probabilities to the five arms after every
third enrolled patient. Updated probabili-
ties reflected the inverse of the proportion
of participants assigned to that arm who
accepted the intervention, relative to total
acceptance across arms”
Allocation concealment (selection bias) Low risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses not reported; ITT analyses included
all randomised. Compliance rates were re-
wards 89.9%, deposits 13.9%
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Methods 5-arm RCT. 2015 to 2017
Country: USA
Setting: Employees of companies using wellness programme
Participants N = 6006 employees and spouses of company wellness programmes. CG; n overall =
3600, consisting of n = 813 usual care; n = 1588 free cessation aids; n = 1199 free e-
cigarettes. IG: Reward group n = 1198, redeemable deposit n = 1208
Interventions Control Group: access to information about benefits of smoking cessation and motiva-
tional text message service plus free cessation aids (NRT, bupropion or varenicline with
NJOY EC if standard therapies tried and did not work)
Experimental Groups: REWARD Group: as control, plus USD 600 in rewards for sus-
tained abstinence. eligible to earn USD 100, USD 200, and USD 300 if at 1, 3, and
6 months after the quit date, respectively, they submitted blood or urine samples for
testing and the samples were negative for nicotine metabolites
REDEEMABLE DEPOSITS group: as control, plus USD 600 in redeemable funds
deposited in separate account for each participant with money removed from account if
cessation milestones not met (same schedule as rewards group)
Theoretical basis for intervention: not reported
Duration of intervention: 6 months
Length of follow-up: 12 months
Outcomes PPA at 12 months. “Co verified cut off 20 ng per milliliter was the primary method for
confirming abstinence”. Urine sample with an anabasine level of < 3 ng per milliliter
or a blood carboxyhaemoglobin level of less than 4%. For users of e-cigarettes who had
a positive cotinine sample (cotinine level ≥ 20 ng per milliliter), also accepted a blood
carboxyhaemoglobin level of < 4%. PPA for quitting at 1 month and sustained abstinence
rates at 3 months and 6 months
Notes New for 2019 update
Funding: “Supported by a grant from the Vitality Institute to the University of Pennsyl-
vania Center for Health Incentives and Behavioral Economics.”
Decarations of interest: none reported by authors
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not stated
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated, but low levels of
completion. However, “Because the defini-
tion of the primary outcome was biochem-
ically confirmed sustained abstinence, par-
ticipants who did not submit samples were
coded as not having met the primary out-
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come”
Incomplete outcome data (attrition bias)
All outcomes
High risk Poor post-randomisation intervention en-
gagement. 6006 randomised and included
in ITT analysis. Only 1191 followed up
as ’engaged’ cohort, included in secondary
analysis. At 12 months, very few partici-
pants completed self-report assessment: 6/
1588 control; 21/1198 rewards; 33/1208
redeemable
Harris 2015
Methods Pilot RCT. Dates not stated
Country: USA
Setting: rural Appalachia Ohio and Kentucky prenatal clinics
Participants 17 pregnant women (mean = 10¾ weeks pregnant) aged 18+, daily smokers (reporting
smoking at least 2 CPD verified by breath CO readings and urinary cotinine levels).
IG: CM (n = 7) CG: SCHB (phone-delivered counselling) (n = 10). Mean age 24. 88%
identified as white. Mean CPD = 12. SES and education not reported
Interventions Control Group: SCHB participants received 5 telephone calls from a registered nurse,
and as many as 5 check-in calls
Experimental Group(s): a 6-week web-based CM programme, with 2 follow-up sessions
that occurred after the 6-week programme ended but before birth. The web-based CM
programme was used to verify breath CO measurements. Each participant was loaned
a piCO Smokerlyzer, web camera, and if necessary a laptop computer with Internet
access. The Motiv-8 portion of the CM programme lasted 6 weeks and consisted of 5
phases: Baseline (7 days), Shaping (4 days), Abstinence (21 days), Thinning (5 days)
, and Return to Baseline (5 days). During each phase, participants submitted video
recordings of themselves twice a day (at least 8 hours apart) giving breath samples using
the Smokerlyzer. They could earn vouchers exchangeable for online purchases with major
retailers (e.g. Best Buy, Wal-Mart) for criterion breath samples based on programme
phase. For the Abstinence phase, participants were required to have breath CO levels 4
ppm to indicate abstinence and to earn vouchers
Escalating pay schedule: 1st sample that met criteria earned voucher of USD 1; vouchers
then increased in value by USD 0.25 for each consecutive breath sample that met the
abstinence criterion. USD 5.00 bonus for every 6 consecutive breath samples that met
the abstinence criterion. Participants could earn a maximum of approximately USD 800
during study participation. If sample did not meet criterion, then the participant did
not receive reinforcement and the value of the next voucher was reset to USD 1.00.
However, if, after a reset, the participant provided 3 consecutive samples that met the
criterion for recent abstinence, then the voucher returned to the value at which the reset
occurred
In addition, 2 spot checks (at random times, participants aware in advance) during
remaining months of pregnancy following programme end - if abstinent, participant
received USD 100 in cash
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Participants were aware these follow-up sessions would occur. These appointments were
intended to extend incentives for abstinence later into pregnancy
Theoretical basis for intervention: not reported
Duration of intervention: 6 weeks but with pre-birth follow up (intervention) appoint-
ments
Length of follow-up: Until end of pregnancy. Mean 8.47 months
Outcomes PPA at end of pregnancy verified by urinary cotinine (cut-off not defined). Smoking
reduction (time line follow-back method),
Stages of Change Ladder (SCL), Modified Fagerström Test of Nicotine Dependence
(mFTND); Post-treatment assessments measured birth outcomes (e.g. gestational age at
birth, birth weight, and time spent in NICU) and smoking-related variables
Notes New for 2019 update
Funding: Not reported
Decarations of interest: “The authors report no conflict of interest or relevant financial
relationships”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random-number generator available via
the Internet (Research Randomizer, n.d.)
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants reported as followed up
Heil 2008
Methods Study design: RCT; conducted between 2001 and 2003
Country: USA
Setting: 4 group obstetric practices and the Women, Infants, and Children (WIC) pro-
gramme in Burlington, VT
Participants 82 women, gestational age ≤ 20 weeks, smoked at all in the previous 7 days, locally
resident, English-speaking
Mean age 24, Education 11.8 years, mean CPD 18.6; mean gestation 9 weeks
Interventions Abstinence monitoring for first 5 days (Monday to Friday) for all participants, then twice
weekly (Mondays, Thursdays) for next 7 weeks, then once a week (Wednesday) for 4
weeks, then every other Wednesday until delivery. In post-partum period, monitoring
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increased to every Wednesday for first 4 weeks, then bi-weekly (every other Wednesday)
for next 8 weeks to week 12. Final 24-week post-partum testing
All participants received standard care from their clinic, over and above trial conditions.
Also a pamphlet from study staff at baseline, plus another for those not smoking at end
of pregnancy. NRT was discouraged for all participants, as it might contaminate testing
Experimental Group (40 women): Contingent vouchers: awarded for proven abstinence
during first 5 days. From 2nd week vouchers given for urine cotinine ≤ 80 ng/ml.
Vouchers entirely contingent on biochemical specimens, not on self-report. Values started
at USD 6.25, increasing by USD 1.25 per consecutive negative sample, to a maximum
of USD 45, where they stayed until a missed visit or a positive test. If reset required,
value went back to start point, but 2 valid tests restored to previous level
Control Group (37 women): Vouchers delivered independent of smoking status, at USD
15 per visit antepartum and USD 20 per visit post-partum. This would average the mean
payments earned in the other group
Voucher-based reinforcement therapy (VBRT) applied until 12 weeks post-partum
Outcomes Abstinence at end of pregnancy, 12 and 24 weeks post-partum
Biochemical confirmation by urine cotinine < 80 ng/ml, apart from CO ≤ 6 ppm for
first week
Notes New for 2015 update
Funding was from research grants R01DA14028 (STH) and GCRC M01RR109
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Randomization was stratified
based on the clinic where participants re-
ceived their pre-natal care”. Participants
“were assigned randomly”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Relatively high compliance (83% to 95%)
with assessment schedules, and no differ-
ences between groups. Withdrawals only
for termination or foetal death. 3 interven-
tion and 2 control participants removed
from the denominators
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Methods Cluster-randomised controlled trial
Country: USA
Setting: 24 Minneapolis-St Paul worksites; 2 x 3 factorial design, stratified by gender
and education
Participants 2402 current smokers (smoked at least 100 cigs in lifetime). Mean age 39, 56.2% women,
62% married/partner
Interventions 1. Group: 13 group sessions over 2 months.
2. Phone: sent printed materials, inc ALA Freedom from Smoking + 3 to 6 telephone
counselling sessions
3. Choice: free choice between group or phone programmes. All programmes offered
3 times over 18 months; smokers could join more than once. Half of the sites in each
intervention were offered direct incentives for participation and for quitting: Quitters at
1 month won USD 20 and entered lottery for grand prize (USD 500 as 1 prize (5 sites)
, 2 x USD 250 (6 sites) or 4 x USD 125 (1 site)). Drawn about every 6 months
Outcomes Baseline, 7-day PPA at 12 months, 24 months
Validation: self-report, countersigned by friend or family member for monthly absti-
nence. Grand draw prize winners + 24 months random sample of quitters (paid USD
25 for compliance) tested for salivary cotinine
Notes Study was funded by the National Heart, Lung, and Blood Institute. Data extrapolated
from percentages
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Four worksites were randomly as-
signed to each of the 6 experimental con-
ditions”. Method not stated
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not all participants had abstinence bio-
chemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 12 months 14.5% lost, and at 24 months
18.3% lost
Other bias High risk Group dropouts were not followed up;
phone dropouts were rung for up to 10
times for each counselling session, and were
then left messages or sent letters
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Methods Study design: 3-arm RCT; December 2006 to June 2012
Country: USA
Setting: Group obstetric practices and the WIC office in Burlington, VT
Participants 130 women; mean age 24; mean gestational age 10 weeks; mean CPD pre-pregnancy
18; while pregnant 8
12 women (RCV: 4; UCV: 5; NCV: 3) withdrawn from denominators because of ter-
mination or foetal death
Interventions All participants received standard antenatal care for smoking; study staff delivered addi-
tional counselling as 4 sessions over first 2 weeks, at final antepartum visit and during
3 post-partum study visits. Those who quit during pregnancy got brief counselling at
routine visits whenever they reported temptations to smoke. Study staff used a printed
booklet tailored for pregnant smokers, Need help putting out that cigarette? (ACOG 2001,
URL in study report)
Women chose one of next 2 Mondays as a quit date; were then monitored from Monday
to Friday that week, Monday and Thursday next 7 weeks, then every Wednesday for
4 weeks, then every other Wednesday until delivery for the UCV and NCV groups; in
the RCV group it was every other week to week 12 and then every 3rd week through to
delivery. After delivery all 3 groups were on weekly monitoring for 4 weeks, then every
other week through to 12 weeks post-partum. 1 final assessment at 24 weeks. Relapsers
could continue the schedule or recycle back round the entire process (only offered once
per woman). This was used fairly equally by all 3 groups (RCV 40%, UCV 46% and
NCV 41%)
Experimental Groups:
1. Usual contingent voucher (39 women): First 5-day week validated by CO, thereafter by
urine cotinine. Vouchers based exclusively on valid biotesting, not self-report. Vouchers
began at USD 6.25 and rose by USD 1.25 each time to a max of USD 45. Missed or
positive results meant schedule was reset, but 2 passes reset the schedule to former point
2. Revised contingent voucher (40 women): Same pattern as above, but with potentially
USD 296.25 available early in weeks 1 to 6 by maintaining a ≤ 4 ppm breath CO in
week 1 (i.e. USD 18.75 day 1 to USD 33.75 day 5 (going up by USD 3.75 per day)),
testing cotinine-negative on 2nd Monday for an additional USD 87.50 and thereafter
testing negative twice a week to week 6. The 2nd test each week increased by USD 15.
50 if it was negative and the first had also been negative. This was meant to reinforce
early continuous abstinence
Non-contingent voucher [Control Group] (39 women): Voucher value was USD 15 per
antepartum and USD 20 per post-partum visit, irrespective of smoking status. Total
available earnings were comparable across all 3 groups
Duration: to 24 weeks post-partum
Outcomes 7-day PPA at baseline, 1 month, end of pregnancy, 2, 4, 8, 12 and 24 weeks post-partum
Biochemical validation: CO ≤ 4 ppm or 6 ppm, + urine cotinine ≤ 80 ng/ml
Notes New for 2015 update
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not stated; they were “randomly assigned”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses not reported, apart from with-
drawals and foetal demise, but ITT analy-
ses conducted
Lasser 2017
Methods Unblinded, randomised clinical trial. 1 May 2015 to 4 September 2017
Country: USA
Setting: Boston Medical Center, a large urban hospital
Participants 352 low-SES and minority daily smokers. Age of 18+, smoking 10 or more CPD in the
past week; in contemplation or preparation stage of readiness to quit smoking; having
a primary care clinician in the Section of General Internal Medicine or Department of
Family Medicine
CG n = 175; IG n = 177. 54% women. Mean age 50. Mean cpd = 15. ’majority reported
belonging to a racial/ethnic minority group’. SES: ≤ $20 000 193 (55%); > $20 000
90 (26%); Refused/do not know 69 (20%). Education: ≤ High school 80 (23%); High
school or GED 137 (39%); > High school 133 (38%)
Interventions Control Group: Enhanced traditional care control participants received a low-literacy
smoking cessation brochure and a list of hospital and community resources for smoking
cessation
Experimental Group(s): up to 4 hours of participant navigation delivered over 6 months,
and financial incentives for biochemically-confirmed smoking cessation at 6 and 12
months following enrolment. USD 250 for smoking cessation 6 months after study
enrolment, as confirmed by a salivary cotinine, and an additional $500 for an additional
6 months after the initial cessation (12-month time point), confirmed by a salivary
cotinine. Participants who did not quit smoking at 6 months and who had been unaware
of the exact dollar amount of the incentive were given a ’second chance’ to quit smoking
and earn USD 250 at 12 months, having been notified of the exact amount of the
incentive
Theoretical basis for intervention: The Social Contextual Model; operant conditioning
for incentives
Duration of intervention: 12 months
Length of follow-up: 12 months
Outcomes Continued abstinence biochemically verified by saliva or urine cotinine (≥ 10 ng/ml) or
anabasine test (for those on NRT, < 3 ng/mL). Receipt of counselling, medications
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Notes New for 2019 update
In terms of misreport or no measurement 21 out of 41 self-reported at 12 months
confirmed quit from Int group versus 4/19 control group
Funding: “This study was supported by American Cancer Society (grant No. 125785-
RSG-14-034-01CPPB). The funder/sponsor had no role in the design and conduct of
the study; collection, management, analysis, and interpretation of the data; preparation,
review, or approval of the manuscript; and decision to submit the manuscript for publi-
cation.”
Decarations of interest: “Dr Quintiliani was a consultant on a research grant to Partners
HealthCare Inc unrelated to the work presented in this article. No other conflicts are
reported.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “We randomized participants using
a random number generator with alloca-
tion concealment to a research assistant us-
ing sealed envelopes. Randomization was
stratified by stage of change (contempla-
tion vs preparation) with regard to smok-
ing cessation”
Allocation concealment (selection bias) Low risk Sealed envelopes given to research assistant
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically verified
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intervention: 48 lost to follow-up, Control:
53 lost to follow-up (at 12 months). ITT
analyses used
Ledgerwood 2014
Methods Randomised controlled trial; conducted December 2007 to January 2011
Country: Michigan, USA
Setting: University clinic
Participants 81 smokers, aged ≥ 18, FTND ≥ 4, literate in English; recruited through newspaper
ads, bulletin boards, health fairs, broadcast messages in a health centre and a university
All participants had to submit 5+ CO samples during 1st week, to qualify to enter the
study. Received USD 1 per sample, + a bonus of USD 20 if all 10 samples submitted in
week 1
N = Standard care (SC): 17; Traditional contingency management (TCM): 28; Enhanced
contingency management (ECM): 36; 61% women, mean age 44.8, mean FTND 6.3
73Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Ledgerwood 2014 (Continued)
Interventions 1. SC: Weeks 2 to 5: Monitoring of CO and cotinine + brief counselling (≃ 5 mins)
twice a day, 5 days a week for 4 weeks; participants received USD 1 per sample, regardless
of result, + weekly bonus of USD 20 for submitting all 10 samples
2. TCM: as SC, + chances to win prizes for every negative CO or cotinine or both. On
Day 1, participant drew for a prize if CO down by at least 3 ppm; thereafter draws only
if CO ≤ 6ppm. Weekly N of draws increased by 1 a day for every day (2 tests) abstinent,
up to 5 daily draws by end of week. TCM urn contained 250 slips of paper: 50% had
some kind of reward, i.e. 44.8% small (worth around USD 1, e.g. snacks, toiletries);
4.8% large (worth around USD 20, e.g. gift certificates, electronics); and 0.4% jumbo
(worth USD 100, e.g. DVD player, gift certificate). In weeks 3 to 5, if Monday cotinine
≤ 100 ng/ml (i.e. weekend abstinence), participant had 5 draw chances. In whole 5-
week study course 180 draws and 15 bonus draws were possible
3. ECM: as TCM, but in 1st week prizes were guaranteed for negative tests. In week 1,
ECM urn had 91.2% small, 8% large, and 0.8% jumbo rewards. For remaining 3 weeks,
urn contained 65.8% no prize, 30% small, 4% large, and 0.2% jumbo
Outcomes PPA, cotinine-verified, at 2 months and 6 months
Other outcomes: Prize money won; differences between TCM and ECM schedules
Notes New for 2015 update
Funding by NIH grant, and Helene Lycaki/Joe Young Sr funding through the State of
Michigan
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All participants had to have submitted at
least 5 samples to qualify for entry
Quote: “Statistician-prepared sequentially
numbered randomization envelopes con-
cealed group assignment until assigned”.
Stratified by gender and by any CO ≤
6ppm (none vs 1 or more) on treatment
day 1 (quit date). Randomised in a ratio of
2:1 CM:control
Allocation concealment (selection bias) Low risk Envelopes concealed allocation until as-
signed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 months: SC 1/17; TCM 6/28; ECM 5/
36 lost
6 months: SC 2/17; TCM 7/28; ECM 10/
36 lost
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All analyses conducted as ITT, and differ-
ences non-significant
Ondersma 2012
Methods Study design: 4-arm factorial RCT; July 2008 to November 2009
Country: USA
Setting: 4 prenatal clinics in Detroit, MI
Participants 110 pregnant smokers, aged 18+, gestation < 27 weeks. Allocated to CD-5As (N = 26);
CM-Lite (N = 28); CD-5As+CM-Lite (N = 30): TAU (N = 26)
Mean age 27.9 years, 81.8% B; mean CPD 8.
Interventions Control (TAU): Standard care from prenatal clinic staff, without any input from research
team. Participants used PC tablets to complete a brief series of questions about their
musical preferences, watched a series of tailored music videos, and answered questions
about the videos, i.e. computer time was blinded, and comparable with intervention
groups
All participants completed a baseline 11-item assessment of ease of use, enjoyment,
helpfulness, satisfaction
Experimental Groups:
1. CD-5As: PC tablet, with interactive software; participants accessed with headphones,
for privacy. Content was 5As programme (Ask, Advise, Assess, Assist, Arrange), or 5Rs
(Relevance, Risks, Rewards, Roadblocks, Repetition) for those unwilling to set a quit date.
Included a 4- to 6-minute professional video of black male obstetrician + 3 testimonials
, tailored to participant’s reactivity, defensiveness, quit status. All gave positive advice to
quit. Programme led participant through advice, feedback, plan development, support
options
Participants at baseline completed 5-item additional assessment of likelihood of quitting,
intention to quit, confidence in ability to quit, readiness to quit, desire to quit
2. CM-Lite: designed for non-treatment-seeking participants in a healthcare setting. No
proactive tracking, but relying on participant to request verification of smoking status.
Testing offered only at antenatal visits, rather than multiple times a day. Participants eli-
gible for unlimited incentivisation attempts, but only 5 reinforcement vouchers available
(retail gift cards worth USD 50)
Programme was delivered by a website, which took participants through verification
process and recorded result (urinary cotinine test)
3. Combination of CD-5As and CM-Lite
Outcomes Follow-up at 10 weeks
7-day PPA, 30-day CA, validated by CO < 4 ppm, urinary cotinine (Nicalert strips) <
100 ug/ml
Mean N of samples submitted, and modal N of negative samples; mean amount of gift
vouchers earned; mean amount earned among those submitting a sample; help-seeking
behaviour
Notes New for 2015 update
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk By computer for brief intervention (1:
1), then by random-number generator (
www.randomization.com) for CM compo-
nent
Allocation concealment (selection bias) Low risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk CD-5As: 3/26 lost; CM-Lite 6/28 lost;
CD-5As+CM-Lite 4/30 lost; TAU 3/26
lost. All participants included in ITT anal-
yses
Rand 1989
Methods Quasi-randomised 3-arm controlled trial.
Country: USA
Setting: Employees at a Baltimore hospital
Participants 51 smokers, av age 38.1, 74.5% women, CPD 26
Interventions Introductory lecture, ACS brochure Clearing the Air, baseline measures taken. After
confirmed 5-day abstinence (USD 25 reward), participants assigned either to:
1. Contingent Group: Contingent payment/frequent monitoring: checked twice a week
at random times, paid USD 4 per CO < 11 ppm
2. Non-contingent Group: Non-contingent payment/frequent monitoring: checked twice
a week at random times, paid USD 4 per CO sample, regardless of reading
3. Control Group: Non-contingent payment/infrequent monitoring: checked monthly
at random times, paid USD 40 per CO sample, regardless of reading. Programme lasted
26 weeks
Outcomes 3 x daily CO samples < 11 ppm to confirm 5-day qualifying abstinence. Monthly survival
analysis (continuous cessation) to 6 months. Dropouts and relapsers treated as continuing
smokers
Notes Study funded by National Institute on Drug Abuse
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Randomisation method not stated; “sub-
jects were randomly assigned to one of three
follow-up groups” after 5 days confirmed
abstinence
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
High risk 4/51 participants dropped out in absti-
nence week; by 6 months, 6 contin-
gents, 1 non-contingent and 4 controls had
dropped out. Although dropout reasons
were generally unrelated to participation (e.
g. heart attack, pregnancy, work move), sig-
nificantly more contingents dropped out
(Chi2 = 13.63, P = 0.005)
Rettig 2018
Methods Pilot RCT. 2014 to 2018
Country: USA
Setting: Johns Hopkins Cancer Treatment Centers
Participants 30 smokers with head and neck or thoracic malignancies undergoing radiation therapy.
Age 18+. Reported smoking cigarettes within the previous 14 days. CG: n = 11; IG: n
= 19.
Mean age = 55. Mean CPD = 8. N = 11 women (38%). Ethnicity: white: 18 (62%);
black or other non-white 11 (38%). Education: Did not finish high school n = 7 (24%);
High school graduate or GED n = 11 (38%); Post-high school n = 11 (38%). Income: <
USD 15,100: 11 (38%); USD 15,000 to USD 49,999: 6 (21%); USD 50,000 to USD
99,999: 4 (14); > USD 100,000: 7 (24%)
Mental health history: anxiety: 3 (10%) depression: 6 (21%) bipolar disorder: 2 (7%)
HADS-D score < 8 (not depressed): 20 (69%); 8+ (depressed): 9 (31%). Ever used
injection drugs No: 23 (79%) Yes: 6 (21%)
Interventions Control Group: ‘Enhanced usual care’: single counselling session at the baseline visit. The
baseline visit for the control group comprised 4 intervention components to constitute
enhanced usual care: (1) brief counselling by a trained tobacco treatment specialist con-
sistent with the ’5 As’ recommended by the United States Department of Health and
Human Services37; (2) a smoking cessation workbook tailored to people with cancer; (3)
contact information for local and national smoking cessation resources, including some
offering free nicotine replacement therapy; and (4) mental health screening to evaluate
depressive symptoms
Experimental Group: Usual care plus up to 4 additional daily visits during the first week.
At baseline, the intervention group received the smoking cessation workbook and un-
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derwent intensive tobacco treatment specialist motivational interviewing, with brief fol-
low-up motivational interviewing sessions at subsequent study visits, daily for the first
week, then weekly for 8 weeks. Other additional interventions received included: enrol-
ment in the National Cancer Institute’s free smokefreetxt text-messaging programme (
smokefree.gov); contingency management at each visit, by which participants received
USD 5 gift cards for biochemically-confirmed smoking abstinence; and guided pharma-
cotherapy. Pharmacotherapeutic options offered were combination nicotine replacement
therapy (patch/gum, patch/lozenge, or patch/nasal spray), bupropion, and varenicline.
Participants were permitted to opt out of intervention components
Theoretical basis for intervention: not reported
Duration of intervention: 8 weeks
Length of follow-up: 12 months
Outcomes PPA at 12 months, CO-verified, confirmed as exhaled CO 8 ppm. Smoking abstinence
at 1, 2, 3, 4, 5, 6, 7 and 8 weeks, and at 3 and 6 months. Smoking intensity (total
cigarettes per previous 7 days), reduction from baseline, and total cigarettes smoked
Notes New for 2019 update
Funding: “This work was supported by the National Institute of Dental and Craniofacial
Research and National Institutes of
Health Research Training in Otolaryngology grant (grant number 2T32DC000027026)
and the Maryland Department of Health and Mental
Hygiene Cigarette Restitution Fund (grant number PHPA-G2034). The study sponsors
had no role in study design or in the collection, analysis, or interpretation of data”
Decarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised to enhanced
usual care (“control”) or intervention
groups using 1:1 block randomisation with
stratification by cancer site (head and neck
versus thoracic) and sex. Randomisation
was generated using SAS software (Cary,
NC)
Allocation concealment (selection bias) Low risk Allocation concealed in sequentially-num-
bered opaque envelopes until study group
assignment
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One participant in the control
group was lost to follow-up after the base-
line visit; therefore, the analytic cohort
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comprised 29 participants (19 intervention
and 10 control)”
Rohsenow 2015
Methods 4-arm RCT. Recruitment: June 2002 to June 2006. End date not reported
Country: USA
Setting: a state-funded inner-city 28-day residential substance abuse treatment pro-
gramme
Participants 184 people meeting current DSM-IV substance-use disorder (SUD) criteria, smoking
at least 10 CPD for the past 6 months, not engaged in smoking treatment. CG: n = 86;
IG (CV): n = 98.
Gender N = 102, 55.4% women. Mean age = 34.5. Mean CPD = 22.3. Ethnicity: 83.
2% (n = 153) were white, 9.2% (n = 17) were black, 7.5% (n = 14) were of other
races; 6.6% (n = 12) were Hispanic. SES: mean legal income was USD 9487 in the past
year, mean education level was 12.2 years. 71.2% alcohol abuse or dependence, 73.9%
cocaine abuse or dependence, 52.8% opiate abuse or dependence, and 37% marijuana
abuse or dependence
Interventions Control Group: BA (Brief advice): 1 x 15-minute session to promote motivation to quit,
adapted for SUD recovery issues. Advice given re: quit date, NRT, support groups,
resources, smoking cessation pamphlets and corrective information, if needed. Followed
up after first session at 7, 14 and 19 days (10 to 15 minutes each). Progress asked and
revision of goals, if necessary
Experimental Group(s): MI (motivational interviewing): 1 x 45-minute session providing
education re: smoking cessation, discussion of pros and cons, health risks and costs,
corrective information, goal-setting + written smoking cessation pamphlets. Followed
up after first session at 7, 14 and 19 days (15 to 30 minutes each). Progress asked and
revision of goals, if necessary
Intervention and control groups then randomised into receiving either Contingency
Vouchers (CV) or Non-Contingency vouchers (NCV)
Contingent voucher procedures were provided during a 5-day reduction phase plus a
14-day abstinent phase. CO monitoring used an EC50 Micro III Smokerlyzer. In NCV
participants could earn the same payments a day for 19 days as those randomised to CV,
simply for providing breath samples as scheduled
Theoretical basis for intervention: MI
Duration of intervention: 4 sessions for MI; 4 sessions for BA. 19 days
Length of follow-up: MI: 12 months
Outcomes PPA at 12 months. CO level ≤ 4 ppm and salivary cotinine level ≤ 15 ng/ml. Timeline
follow-back method to assess smoking reduction (number of CPD), number of heavy-
drinking days, number of drug-use days, and relapse to any heavy drinking or drug use
over the 12 months
Notes New for 2019 update
Funding: “Supported by 1 RO1 DA13616 from the National Institute on Drug Abuse;
two Senior Career Research Scientist Awards from the Department of Veterans Affairs
(DJR and PMM); and K05AA019681 from the National Institute on Alcohol Abuse
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and Alcoholism. The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans Affairs.”
Decarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified random assignment, using urn
randomisation
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated. CO verification
not required for those in prison at follow-
up
Quote: “At follow-up, people with a CO
4 ppm, cotinine 15 ng/mL (if not using
NRT), or missing CO or cotinine data, or
with self-reported smoking were coded as
having smoked with the following excep-
tion: if the participant was in prison, self-
report was accepted since biological verifi-
cation equipment was not allowed so lack
of verification was unrelated to participant
decision (Number of prisoners claiming ab-
stinence: n = 2 at 3 months, n = 1 at 6
months, n = 3 at 12 months.)”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 12-month follow-up was completed by 139
(75.5%)
Rohsenow 2017
Methods RCT. Initial start date not reported
Country: USA
Setting: 2 inner-city state-funded residential SUD treatment programmes
Participants 340 smokers who had not sought smoking treatment in a residential SUD treatment
programme, meeting current DSM-IV SUD criteria and
smoking at least 10 CPD for the past 6 months. CG (NV) n = 168. IG (CV) n = 172.
Gender: 33% women. Mean age: 37.58. Mean CPD = 19.48. Ethnicity: white: 86%;
black/ African American: 10%; Asian: < 1%; multi-racial: 2%. Annual Income: USD 0
to USD 9999: 59%; USD 10,000 to USD 29,999: 26%; USD 30,000 to USD 49,999:
9%; USD 50,000+ 6%. Education years, mean = 12.09. Alcohol use disorder: 76%;
opiate use disorder: 49%; cocaine use disorder: 60%; marijuana use disorder: 36%
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Interventions Control Group: NV: vouchers not contingent on smoking status. (USD 8 per sample)
, plus a USD 40 bonus for providing all 33 samples (total possible = USD 304). All
received BA, a standard of care for smokers not seeking smoking treatment, then 7, 14,
and 19 days later (subsequent sessions, 10 to 15 minutes). 4 sessions in total. and up to
8 weeks of NRT. To encourage participants to provide a breath CO sample regardless of
whether they had been smoking, USD 1 was provided simply for providing the sample
(non-contingent) regardless of results (total possible = USD 33)
Experimental Group(s): CV: 14 days of vouchers for smoking abstinence (based on CO
readings twice a day) after a 5-day smoking reduction period
Reduction phase. USD 2 per test for a 25% reduction from baseline CO, USD 4 for
50% reduction, and USD 6 for a 75% or greater reduction
Abstinence phase. Escalating schedule of payments provided increasing levels of pay-
ments in vouchers for each successive CO reading ≤ 6 ppm. USD 3 for the first sample,
increasing by USD 0.50 for each consecutive negative test to USD 16.50 for the 28th
consecutive abstinent breath sample, plus USD 10 bonuses provided every time 3 consec-
utive readings showed abstinence. Whenever a breath sample did not meet the criterion
for abstinence, the participant earned no voucher and the payment schedule reverted to
the initial USD 3 level, then after 3 consecutive abstinent samples the schedule returned
to the payment level at which the reset occurred
Total possible payment. Participants who completed all 19 days of samples and missed
no more than 3 of the scheduled breath tests earned a USD 40 bonus voucher (total
possible = USD 433 plus USD 33 for showing up = USD 466)
Theoretical basis for intervention: not reported
Duration of intervention: 19 days vouchers plus 8 weeks NRT
Length of follow-up: 12 months
Outcomes PPA at 12 months, CO level ≤ 4 ppm and salivary cotinine ≤ 15 ng/ml
At 1, 3, 6 months, the Timeline Followback interview for number of cigarettes each day,
number of days of drug use, and number of heavy drinking days. At pretreatment and
at 1 month, participants completed a Smoking Self-Efficacy Questionnaire
Notes New for 2019 update
Funding: “Supported by 1 R01 DA023995 from the National Institute on Drug Abuse;
a Senior Career Research Scientist Award from the Department of Veterans Affairs to
the first author; and K05AA019681 from the National Institute on Alcohol Abuse and
Alcoholism. The views expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans Affairs or the
official views of the National Institutes of Health.”
Decarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Urn randomisation
Allocation concealment (selection bias) Unclear risk Not reported
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Incomplete data for Intervention: 27%
(CV) and 32% (NCV). Judged low as be-
low 50% and ITT used
Romanowich 2015
Methods RCT June 2005 to November 2010
Country: USA
Setting: San Antonio
Participants 146 volunteers who worked at the University of Texas Health Science Center at San
Antonio, lived near that centre, or both
Smoking > 15 CPD, regularly for at least 1 year, and planning to quit smoking within
the next month. Age 18+ with CO > 15 ppm
All participants were classified as early success (ES) from the results of a 5-visit baseline
fixed reinforcement period before randomisation Participants were all classified as ES
based on their performance during a 5-visit abstinence trial. During this trial, participants
received USD 5.00 for each breath sample. CG: n = 47, IG HTT percentile criterion: n
= 37; IG HTT fixed n = 40; IG-ES Escalating: n = 59, IG-ES Fixed: n = 58.
Mean age 41. Mean CPD = Control: 21.9 (6.3), Escalating: 21.7 (5.3), Fixed: 24.3 (6.
9). Gender (% female) = Control:16 (55), Escalating: 25 (42), Fixed: 26 (45). Ethnicity:
white: Control: 16 (55%), Escalating: 43 (73%), Fixed 39 (67%). Income: < USD 15,000
Control: 8 (28%), Escalating: 26 (44%), Fixed: 29 (50%); USD 15,000 to USD 24,999
Control: 7 (24%), Escalating: 12 (20%), Fixed: 13 (22%); USD 25,000 to USD 34,999
Control: 7 (24%), Escalating: 6 (10%), Fixed: 6 (10%); > USD 35,000 Control: 7 (24%)
, Escalating: 15 (25%), Fixed: 10 (17%). Education: GED or high school: Control: 11
(38%), Escalating: 21 (36%), Fixed: 23 (40%); Vo tech or associated: Control: 12 (41%)
; Escalating: 21 (36%); Fixed: 22 (38%); Bachelors+: Control: 6 (21%), Escalating: 17
(29%), Fixed: 13 (22%)
Interventions Control Group: Payments for CO tests, not contingent on abstinence. a two-in-three
chance of receiving a payment on any visit (the probability for each visit was independent
of other visits), regardless of their breath CO sample
Experimental Group(s):
Escalating reinforcement group: Specifically, the value of the payment available started
at USD 5.00 and increased by USD 0.50 with the delivery of each breath CO sample
Fixed reinforcement group: the value of the potential payment for these participants was
always USD 19.75, regardless of how many consecutive criterion breath CO samples
they had previously submitted
For both escalating and fixed reinforcement groups, the total payment amount possible
was USD 1185.00 over the 60-visit intervention period
Theoretical basis for intervention: not reported
Duration of intervention: 60 visits, approximately 12 weeks
Length of follow-up: 6 months
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Outcomes PPA at 6 months. CO criterion of < 4 ppm . saliva cotinine level < 20 ng/ml. Use of
smoking cessation medication. CPD in past 6 week at 6 months
Notes New for 2019 update
CO cut-off of < 3 ppm stated in NCT entry but < 4 ppm stated in e-mail correspondence
with author
Funding: “The research reported in this paper was supported by Grant DA013304 to
R. J. Lamb.”
Decarations of interest: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not computer-generated
Quote: “Random assignment to one of the
three groups was accomplished by assign-
ing two participants to the escalating re-
inforcement group, two to the fixed rein-
forcement group, and one to the control
group from each group of five participants
who completed the abstinence trial”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk > 80% follow-up across all conditions (data
supplied by authors)
Quote: “All participants randomly assigned
to one of the study conditions were in-
cluded in the analysis. All missing data
points were counted as not meeting the
breath CO criterion (i.e. positive) for that
visit.”
Secades-Villa 2014
Methods Randomised controlled trial
Country: Spain
Setting:Community-based, conducted in Addictive Behaviors Clinic at Oviedo Univer-
sity
Participants 92 smokers of > 10 CPD, aged > 18, motivated to quit, recruited by flyers, local media
ads and word of mouth
Mean 64.1% women; mean age 45.8 (SD 12.1); mean CPD 21.7 (SD 8.7); mean FTND
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5.7 (SD 1.8); CBT 35.4% in full-time work, CBT+CM 55.8%
Interventions 1. CBT (control) group: Group-based counselling, 5 to 6 participants. 1-hour sessions,
weekly over 6 weeks. Main technique nicotine fading, based on weekly 30% reduction,
with abstinence required from week 5 onwards. Also info about tobacco, a behavioural
contract, self-monitoring, withdrawal strategies, physiological feedback, social reinforce-
ment, relapse prevention
Cotinine and CO collected twice a week, i.e. 11 samples over the 6 weeks
2. CBT + CM: As CBT, plus voucher system, beginning in week 5 CBT session; negative
≤ 80 ng/ml. First negative specimen earned 80 points (1 point = EUR 1), with a 20-
point increase for each subsequent and consecutive negative sample. Missing samples
counted as negative, and missing or failed set the reward back to 80 points. Max value
EUR 300 (3 consecutive negative specimens)
Points could be exchanged for vouchers for “leisure activities, cinema, theatre, muse-
ums, sports events, gyms, adventure sports, meals in restaurants, training, purchases in
department stores, bookshops, clothes shops and art shops, and spa and beauty services”
Outcomes Primary: 7-day PPA at EoT, at 1 month and at 6 months; CA at 6 months (all 3 time
point tests to be negative)
Biochemical validation by CO < 4 ppm, cotinine < 80 ng/ml
Secondary: Treatment retention; % attending throughout the 6-week course
Testing was twice a week, rather than daily+
Notes New for 2015 update
Funding was from Spanish Ministry of Science and Innovation grant PS12011-22804,
and predoctoral grants BP12-037; FOundation for the Promotion of Applied Science
Research and Technology in Asturias; and Spanish Ministry of Economy and Competi-
tiveness (BES-2012-053988)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Eligible participants were ran-
domly assigned …, in accordance with
a computer-generated randomization list”
(p. 64)
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Attrition at 6 months not reported (at 1
month, 10 control and 1 intervention lost
to follow-up)
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Methods Randomised 4-arm controlled trial
Country: USA
Setting: 3 narcotic treatment centres in LA
Participants 175 smokers (≥ 10 CPD, expired CO > 8 ppm, cotinine > 30 ng/mL), av age 44, 39.
5% women, av 22.1 CPD. No significant differences between groups, except group 3
reported higher cocaine use than other groups
Interventions 2-week baseline and randomisation period, then 12 weeks treatment with NRT patches,
tapered from 21 mg for 8 weeks, to 14 mg for 2 weeks and 7 mg for 2 weeks. CO and
urine samples taken x 3/week. Randomised to:
Group 1. NRT patch only
Group 2 NRT patch + RP
Group 3. NRT patch + CM: USD 2 for 1st CO sample < 8 ppm; each consecutive sample
rewarded with voucher increased by USD 0.50, + bonus USD 5 for every 3 consecutive
samples. If a sample > 8 ppm, reward process reverted to USD 2 level again, but was
restored to previous scale after 1 round of 3 consecutive samples < 8 ppm. Participants
could earn up to USD 447.50
Group 4. NRT patch + RP + CM (see group 3 procedure)
Outcomes Baseline measures, + thrice-weekly breath and urine samples throughout 12 weeks treat-
ment, + weekly self-report, and same measures at 6 months and 12 months. Participants
with missing data were counted as continuing smokers
Notes Additional outcome data supplied by the authors
Study funded by National Institute on Drug Abuse, and National Cancer Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “an urn randomization procedure”.
A randomised 2 x 2 repeated measures de-
sign
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Group A (patch only): 6 months 5/43, 12
months 7/43 dropped out; Group B (patch
+ CM): 6 months 6/43, 12 months 8/43
dropped out
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Methods Phase II single-blind randomised controlled trial, conducted July 2012 to September
2013
Country: UK
Setting: Large health board area, inner city, Greater Glasgow and Clyde (Scotland)
Participants 612 pregnant smokers, aged 16+, English-speaking, gestation 24+ weeks, exhaled CO >
7 ppm. Intervention n = 306, control n = 306
Interventions Control: Standard care: All smokers identified at maternity booking referred to the stop-
smoking services (SSS), who attempted to contact them. SSS set up a 1-hour session to
discuss cessation, + 4 weekly phone calls to support, and 10 weeks free NRT if wished.
SSS contacts at 4 weeks, 12 weeks (if quit at 4), 34 to 38 weeks gestation, and 6 months
post-natal if quit at 34 to 38 weeks
Experimental Group: As control, plus: up to GBP 400 of shopping vouchers (Love2shop)
, for engagement or for quitting, or both:
GBP 50 for attending the 1-hour face-to-face and setting a TQD (engagement).
At 4-week phone check-up, if self-reported no smoking for past 2 weeks had a researcher
visit and CO breath test < 10 ppm; if OK, another GBP 50 voucher
Routine phone call at 12 weeks (for those quit at 4) + CO test, GBP 100 voucher if
validated
Some time between 34 and 38 weeks gestation, all participants contacted by helpline
staff. Researchers visited self-reported quitters for CO and cotinine, and gave GBP 200
for confirmed intervention quitters
To minimise losses to follow-up, all participants (intervention and control) reporting
smoking status and with saliva or urine sample at final follow-up given a GBP 25 shopping
voucher (engagement)
Outcomes Abstinence at 4 weeks for all participants (2-week PPA, CO < 10 ppm); 12 weeks, if
quit at 4, intervention only (4-week PPA, CO < 10 ppm); 34 to 38 weeks gestation, all
participants (< 5 cigs in past 8 weeks, CO < 10 ppm, cotinine (urine < 44.7 ng/ml; saliva
< 14.2 ng/ml) if self-reported quit); 6 months post-natal for confirmed quitters at 34 to
38 weeks: still quit or < 5 cigs since quit date, cotinine-confirmed
Notes Published after last search date
Change to protocol meant that research team were allowed to collect routine blood
samples (residual) in late pregnancy (32 to 42 weeks) from the last 200 women enrolled
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The Glasgow clinical trials unit
embedded the randomisation in the
trial database using randomised permuted
blocks, with a block length of four”
Allocation concealment (selection bias) Low risk Quote: “Allocation was concealed from
staff and clients until after consent and
recruitment.” “The helpline … contacted
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women, confirmed that all selection crite-
ria had been met, enrolled participants us-
ing telephone consent, and conducted con-
cealed random allocation”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Attrition equal across groups: 43/303
(14%) control, 46/306 (15%) incentives.
ITT analysis assumed all lost to follow-
up were continuing smokers, and cross-
checked this where possible by residual
blood samples
Tevyaw 2009
Methods Randomised controlled trial
Country: USA
Setting: Public and private colleges and universities
Participants 110 young adult smokers, with a baseline CO ≥ 10 ppm. Mean age 19.7, 38.2% women,
av 12 CPD, 77% white. No significant differences between groups on any demographic
variables. Motivation to quit not required (51% reported no plans to quit)
Interventions 2 x 2 psychosocial condition x reinforcement condition
1. 3 sessions motivational enhancement therapy (MET) counselling over 2 weeks, with
either contingent or non-contingent rewards
2. 3 sessions of progressive muscle relaxation control (REL), with either contingent or
non-contingent rewards
3 weeks of reinforcement, with CO samples collected in person twice daily from each
participant
All participants received USD 75 for completion of baseline interview, and cash payments
for follow-ups, i.e. USD 25 at 1 month, USD 35 at 3 months, USD 75 at 6 months, +
USD 40 for timely completion of all 3 follow-ups
(i) Non-contingent rewards: USD 5 for each sample, + USD 10 per week for attending
≥ 80% of sample collections. Total available USD 240
(ii) Contingency management rewards: Week 1: USD 1 for reduction of 25% to 49%,
USD 2 for 50% to 74%, USD 3 for > 75%. Weeks 2 to 3: Payments for abstinence (< 5
ppm): USD 3 for 1st abstinent sample, increasing by 50c for each subsequent abstinent
sample. Additional USD 1 for 2 consecutive abstinent samples. Non-abstinent sample
meant no bonus for that reading and the clock set back to USD 3 for next abstinent
reading. After a reset, 4 consecutive abstinent samples reset the bonus to the pre-reset
level. Total available USD 285.50
Outcomes 7-day PPA at 6 months.
Validation: CO < 5 ppm for daily samples; cotinine < 15 ng/mL for non-attenders
sending in samples at follow-up
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Notes New for 2011 update.
Additional information supplied by the authors
Study funded by National Institute on Drug Abuse, and Dept of Veterans Affairs
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “participants were randomly as-
signed”
Allocation concealment (selection bias) Unclear risk See above
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6 months
attrition: CM+MET: 2/28; CM+REL: 2/
27; NR+MET: 1/27; NR+REL 1/27
Tuten 2012
Methods Study design: 3-armed RCT; May 2005 to January 2009
Country: USA
Setting: Center for Addiction and Pregnancy, Baltimore, MD
Participants 102 pregnant, methadone-maintained smokers, aged 18+, ≤ 30 weeks gestation, nico-
tine-dependent or smoking 10+ CPD
Contingent behavioural incentives (CBI): 42; non-contingent behavioural incentives
(NCBI): 28; treatment as usual (TAU): 32
Mean age 30.7; mean CPD 18; % unemployed 94.8; mean gestational age 16.5 weeks
Interventions All participants completed an initial 8-day residential course, then went to outpatient
status. In 1st week, all completed an Addiction Severity Test (ASI), a structured clinical
interview for DSM-IV disorders (SCID), revised FTND. CO testing 3 times a week,
urine samples 3 times a week (cotinine) + random cocaine testing once a week
ASI repeated at 1 month and 3 months and at 6 weeks post-partum, + CO and urine
tests. At each testing all participants received brief (10 mins) MI feedback.
Standard info on adverse effects of smoking for mother and baby
All this was classified as ‘Treatment as usual (TAU)’.
Experimental Group:
CBI: 12 weeks of eligibility for CBI rewards contingent on reduction or abstinence.
Incentives for each negative breath test on Mondays, Wednesdays and Fridays, as follows:
week 1: any reduction; weeks 2 to 4 10% reduction; weeks 5 to 7: 25% reduction; weeks
8 to 9: 50% reduction; weeks 10 to 11: 75% reduction; week 12 - delivery: abstinence
(CO < 4 ppm)
88Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Tuten 2012 (Continued)
Voucher started at USD 7.50 and increased by USD 1 a day up to USD 41.50. If negative
sample missed through the 12 weeks, schedule was reset to USD 7.50. If she achieved 5
consecutive negative tests, the voucher value was restored to former level
NCBI: “pseudo-yoked” schedules. NCBI participants were each yoked to a random
participant in the pilot study (i.e. had submitted CO samples for at least 2 weeks)
. Participants were told that their behaviour did not determine rewards received, but
that they would receive incentives in line with a previously established schedule. NCBI
participants had to give breath and urine samples to receive their scheduled incentive.
They were eligible for 12 weeks or until delivery
Outcomes Primary target outcome was reduction. Abstinence measured at end of 12-week pro-
gramme, and 6 weeks post-partum
Cessation was PPA, biochemically verified (CO < 4 ppm; urinary cotinine < 300 ng/ml)
Notes New for 2015 update
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were assigned randomly”
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk CBI: 8/42 lost; NCBI 4/28 lost; TAU 7/
32 lost, but all included in ITT analyses
Van den Brand 2018
Methods Cluster-RCT; 2016 to 2018
Country: The Netherlands
Setting: Companies of varying size and from different industry types in the Netherlands.
Companies were required to facilitate a smoking cessation training programme at the
workplace during or directly after working hours
Participants 604 employed smokers, aged 18+, had smoked tobacco for at least 1 pack year. Mean
age 45. IG n = 319; CG n = 285.
CPD at baseline ≤ 10 IG n = 58 (18%) CG n = 55 (19%); 11 to 20 IG n = 179 (56%)
CG n = 159 (56%); 21 to 30 IG n = 59 (18%) CG n = 58 (20%); ≥ 31 IG n = 9
(3%) CG n = 3 (1%); missing IG n = 14 (4%) CG n = 10 (4%). Ethnicity not reported.
Income level: low IG n = 111 (35%), CG n = 68 (24%); middle IG n = 91 (29%), CG
n = 84 (29%); high IG n=76 (24%) CG n = 105 (37%); missing IG n = 41 (13%) CG
n = 28 (10%). Education level low: IG n = 97 (30%); CG n = 62 (22%); middle IG n =
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136 (43%); CG n = 119 (42%); high IG n = 75 (24%); CG n = 90 (32%); missing IG
n = 11 (3%); CG n = 14 (5%)
Interventions Experimental Group(s): Participants could earn 4 vouchers with a total worth of EUR
350. The first EUR 50 voucher was received on the condition of biochemically validated
smoking abstinence at the end of the smoking cessation training programme. The second
and third EUR 50 vouchers could be earned when participants were abstinent 3 and 6
months after finishing the cessation programme. At the end of the study (12 months after
completion of the cessation programme), participants could earn an additional EUR
200 voucher
The vouchers were sent by email in the form of a digital code that could be exchanged
in a web shop for a large range of products or activities
Control Group: A smoking cessation group training programme consisting of a 90-minute
session each week for 7 weeks. The pre-existing training programme was designed to
help participants to initiate a quit attempt and guide them through the first few difficult
weeks of quitting smoking, with an important role for group dynamics and peer support.
Participants quit together at the start of the third session, and had quit smoking for about
1 month at the last session
Outcomes Primary: continuous abstinence at 12 months. Cut-off point 9 ppm
Secondary outcomes: 3 and 6 months biochemically validated abstinence, and self-
reported abstinence
Notes New for 2019 update
Funding: “This study is funded by the Dutch Cancer Society (grant number: UM 2015-
7943)”
Decarations of interest: “DK received an unrestricted grant from Pfizer for an inves-
tigator-initiated trial on the effectiveness of practice nurse counseling and varenicline
for smoking cessation in primary care (Dutch Trial Register NTR3067). OS received
institutional research grants from Pfizer for investigator-initiated trials.”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The randomisation sequence was generated
by a digital programme using the biased urn
method, in order to maintain allocation to
intervention groups as balanced as possible
The randomisation programme was writ-
ten by a statistician (BW), but companies
were randomly allocated by an indepen-
dent research assistant not involved in the
study
Allocation concealment (selection bias) Low risk Group allocation was not revealed to par-
ticipants or employers until the start of the
first training session
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 post-randomisation exclusion (re-
ported)
Volpp 2006
Methods Randomised controlled trial
Country: USA
Setting: Philadelphia VA Medical Center
Participants All outpatient self-identified smokers invited to complete baseline survey. 404 surveyed,
179 eligible: 92 invited to join Incentives group, 87 to join Control group
Mean age 52, 6% women, 25% white, 41.7% completed high school or GED, av 22
CPD, mean years smoking 30, 35% Fagerström score > 7, 17% smoking > 2 packs a day
Interventions 1. 5 free fortnightly sessions of SC programme, standardised group counselling, plus
NRT patches every 2 weeks (4 weeks x 21 mg, 2 weeks x 14 mg, 2 weeks 7 mg)
2. As 1, plus USD 20 per session attended, + USD 100 if quit ~ 30 days after programme
completion (75 days post-quit date)
Incentives and control groups conducted separately, to avoid contamination, but same
instructor, blinded to assignment and not involved in rewards distribution
Outcomes Primary: Initial enrolment within the programme (= attended 1st session)
Secondary: Cumulative attendance, programme completion
7-day PPA at ~ 1 month post-completion (75 days post-quit date), and at 6 months
post-completion (~ 7.5 months post-quit date) among those who had quit at earlier time
point. ITT analysis, included all 179 eligible smokers, whether or not they had joined
the cessation programme
Validation: urinary cotinine (< 500 ng/mL). USD 20 reimbursement for attending for
validation procedure
Notes Sample size estimate of 100 per group would give > 80% power to test enrolment at 5%
level of significance, with a 1-sided test of equality of proportions
New for 2008 update.
Study funded by VA Health Services Research and Development; Center for Health
Equity Research and Promotion; Leonard Davis Institute of Health Economics of the
University of Pennsylvania School of Medicine; National Institute on Drug Abuse; Na-
tional Cancer Institute
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Randomisation by permuted blocks of 4,
stratified by level of smoking (± 2 packs per
day)
Allocation concealment (selection bias) Low risk Sequentially-numbered surveys by com-
puter-generated lists of random numbers
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Losses at 1 month: Intervention 29/92,
Control 25/87; Losses at 6 months: Inter-
vention 31/92, Control 26/87
Enrolled in SC programme: Intervention
38, Control 17; Completion rates Inter-
vention 23/38, Control 10/17
Volpp 2009
Methods Randomised controlled trial
Country: USA
Setting: Multiple worksites of General Electric Energy Company
Results were adjusted for stratification variables, i.e. worksite, income and amount
smoked
Participants 878 smokers, randomised to Int (436) or control (442). Av age 45, 35% women, av 20
CPD, 25% high school or lower, 65% income > 500% of poverty level. Motivation to quit
not required. No significant baseline differences between groups on any demographic
variables
Interventions All participants given information on local community-based SC services, + received
standard employee benefits, e.g. physician visits, SC pharmacotherapies. All received
USD 20 per telephone interview at baseline and at 3 follow-ups, plus USD 25 per
confirmatory sample returned
Intervention: Told they would receive USD 100 for completing an SC course, USD 250
for confirmed abstinence at 6 months, and USD 400 for confirmed sustained additional
6-month abstinence
Outcomes Prolonged abstinence at 9 months or 12 months. Those not abstinent at 3 months were
retested at 6 months , and followed from then if abstinent All abstinent at both follow-
ups were assessed again 6 months later, i.e. at 15 months or 18 months
9 to 12 months endpoint used in 6-month MA, and 15 to 18 months endpoint in 12-
month MA
Validation: Cotinine by saliva or urine
Notes New for 2011 update.
Additional information supplied by the author
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Volpp 2009 (Continued)
Study was funded by Centers for Disease Control and Prevention and by Pennsylvania
Dept of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “performed in permuted blocks of
four”, stratified by level of smoking (± 2
packs per day), income and worksite
Allocation concealment (selection bias) Low risk Quote: “assignments were concealed until
all eligible criteria had been entered”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk At 6 months 50/436 (Intervention) and 47/
442 (Control) lost to follow-up, and 16 and
12 withdrew;
At 6 to 12 months 43/436 (Intervention)
and 35/442 (Control) lost to follow-up,
and 13 and 12 withdrew
At 12 to 18 months 4/436 (Intervention)
and 2/442 (Control) lost to follow-up, and
1 and 0 withdrew
White 2013
Methods Randomised controlled trial; conducted from December 2010 to March 2011
Setting: Thailand rural villages
Participants 215 smokers (10.5% of eligible smokers in 30/42 villages)
Participants grouped in 2-person teams, either choosing their own partner or being
randomly assigned based on village and gender. Controls also paired up
N = 128 experimental; 68 control; 13% women, mean age 51, mean CPD 13.5
Interventions All participants received an initial group counselling session, and a further session at 3-
month follow-up
Intervention Grp: signed a ’team commitment’ contract:
a) Opened a savings account, with a minimum deposit of THB 50 (USD 1.67), and a
starter bonus of THB 150 (USD 5), with an extra bonus of THB 150 if the account
balance reached THB 150 over the 10-week deposit period. Community Health Workers
visited weekly for the 10-week duration, to try to elicit additional voluntary contributions
b) Cash bonus of THB 1200 (USD 40) to each partner if both were abstinent at 3
months
c) Weekly supportive text messages
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Intervention group received deposits back if verified quit at 3 months
Outcomes 7-day PPA at 3 months, 6 months, 13 to 16 months (“14 months”); urine cotinine
verified at 3 months and 6 months , but 14 months self-report only Participants not
attending at 3 months and 6 months were contacted by CHW or by phone, and tested
at home if claimed abstinent
Other outcomes: % receiving 3-month bonus; %s quit as teams at 3 months, 6 months
and 14 months; partner choice vs random assignment; team vs individual enhancing
likelihood of quitting; impact of text messages; cost effectiveness
Notes New for 2015 update;
Funded by grants from the US National Institute on Aging and the US National Institute
for Child Health and Development
Additional information supplied by the author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated random
numbers” by an independent programmer
Allocation concealment (selection bias) Low risk Quote: “...concealing the sequence from
other field staff and participants”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intervention: 1/128 death, 3/128 missing
baseline data; Control: 1/68 missing base-
line data
White 2018
Methods Cluster-RCT; 2015 to 2017
Country: Thailand
Setting: Large workplaces in the Bangkok metropolitan area
Participants 4190 employees at large workplaces in the Bangkok metropolitan area (101 worksites
from 84 Bangkok area companies)
Age 18+; Healthy volunteers. Motivated to quit smoking. Smoker of 100+ cigarettes
during lifetime and at least 10+ cigarettes a week.
CG: n = 444. IG(s): 2) USD 20 individual bonus n = 508; 3) USD 40 individual bonus
n = 482; 4) team bonus n = 495; 5) deposits n = 397; 6) deposits plus teammate (no
bonus) n = 364; 7) deposits plus USD 20 individual bonus n = 515; 8) deposits plus
USD 40 individual bonus n = 489; 9) deposits plus team bonus n = 496. Gender: the
per cent male varied from 94.9% to 99.3%. Age: The per cent over age 45 varied from
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6.5% to 18.5%. Mean CPD = 8. Ethnicity: not reported
Interventions Control Group: Participants in the control group (1) received usual care only, consisting
of 2 elements: in-person group counselling on smoking cessation and text messaging
support with quitting. The group counselling consisted of 90 minutes of counselling
delivered at each worksite by a trained smoking cessation counsellor. The text messaging
programme, developed by the Thai Health Professional Alliance against Tobacco, pro-
vided 1 to 3 messages a day for 28 days, with advice, support, and encouragement for
quitting smoking
Experimental Group(s): 9 randomisation groups (8 experimental) consisting of a combi-
nation of 4 intervention components: usual care, refundable deposits, a teammate, and
a cash bonus:
2) USD 20 individual bonus,
3) USD 40 individual bonus,
4) team bonus,
5) deposits,
6) deposits plus teammate (no bonus),
7) deposits plus USD 20 individual bonus,
8) deposits plus USD 40 individual bonus,
9) deposits plus team bonus.
”Deposits. Participants in deposit programmes (groups 5 to 9) were asked to provide
refundable deposits contingent on smoking abstinence. These participants made an min-
imum initial contribution of USD 3 (THB (Thai baht)100) at the enrolment meeting,
which was kept under the care of an appointed company representative. Participants
then received a personal deposit box, made out of metal and designed to be tamper-
proof (pictured in Supplemental Figure S1). Participants were free to make additional
voluntary contributions in the box until the 3-month follow-up assessment. Study per-
sonnel encouraged participants to contribute at least as much as they had typically spent
on tobacco. Participants gave the project an additional USD 5 as collateral for the safe
return of the box, in order to prevent tampering or theft. At the 3-month follow-up
assessment, study personnel opened each box using a can opener and recorded the total
balance. All deposits were returned to the participant if the person was confirmed to be
abstinent during the 3-month assessment. Deposits were forfeited to the project if the
person was found to have smoked
Teammate. Participants in team-based programmes (groups 4, 6, and 9) were randomly
assigned to another participant from the same worksite as a teammate. Team assignment
was stratified by work shift and native language in order to facilitate opportunities for
communication. Pairings were announced at the enrollment meeting at each worksite
Cash bonus. Participants in groups 2 and 7 were eligible for a cash bonus of USD 20
(THB 600) for abstaining from smoking at 3 months. Participants in groups 3 and 8
were eligible for a bonus of USD 40 for abstinence at 3 months. On average, this amount
was roughly equivalent to 1 or 2 days’ wages, respectively. Participants in groups 4 and
9 were eligible for a team bonus of USD 40 only if both team members abstained from
smoking at 3 months“
Theoretical basis for intervention: not reported
Duration of intervention: 3 months
Length of follow-up: 12 months
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Outcomes 7-day point prevalence. Biochemically verified by urine cotinine test. cut-off level of 200
ng/mL. PPA at 3 and 6 months. Programme acceptance
Notes New for 2019 update
Results data are from manuscript in preparation provided by the author. Home-based
depositing strategy did not appear to lead to consistent use (Supp. Table S7), especially
in the absence of regular reminders.The size of the worksites did not lend itself to the
strategy we employed for pairing teammates. Many teammates did not know each other,
and did not interact during the study period
Funding/declaration of interest: sponsors and collaborators: University of California,
Berkeley, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA)
, Mahidol University
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Worksites were digitally
cluster-randomised to usual care or one of
8 incentive designs
Allocation concealment (selection bias) Low risk A co-author implemented the random al-
location sequences using computer-gener-
ated random numbers, concealing the se-
quence from field staff, company employ-
ees, and participants until after the baseline
survey was completed
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis.
Quote: ”Eight smokers (< 0.02%) were
omitted from the analyses due to missing
baseline covariate data, providing a denom-
inator of 4182 for all intent-to-treat analy-
ses“
Per protocol analyses presented and yield
consistent results. Follow-up rates ranged
between 57 to 70% across all arms at 12m”
(data supplied by author)
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Windsor 1988
Methods Study design: 2 x 2 factorial pretest/post-test control group design
Country: USA
Setting: University of Alabama, Birmingham
Participants 378 smokers over 21 months recruitment, mean age 37, CPD 25; sex ratio not stated
Interventions Baseline survey, ALA Freedom from smoking in 20 days self-help manual and A lifetime of
freedom from smoking maintenance manual at quit date.
Method 1: Controls: manuals only, brief chat
Method 2: Cessation skills training (diary, deep breathing), contract to quit, and quit
smoking ’buddy’ (with buddy education)
Method 3: Monetary incentives: USD 25 after 6 weeks confirmed cessation, and after 6
months confirmed cessation
Group A: Method 1 only
Group B: Methods 1 and 2
Group C: Methods 1 and 3
Group D: Methods 1, 2 and 3
Outcomes 6 weeks, 6 months, 1 year. Baseline measure and saliva were obtained for thiocyanate
(SCN) analysis of smoking status (≤ 100 ng/mL) Participants smoking > 2 cigs more
than once in a follow-up period counted as a smokers. Lost to follow-up counted as
continuing smokers
Notes As no significant effect of incentives was detected after 6 weeks, the authors collapsed
Groups A and C for comparison with Groups B and D collapsed, to test programme
efficacy
Our MAs were conducted using Group C vs Group A (Windsor 1988), and Group D
vs Group B (Windsor (B) 1988)
Study funded by National Heart, Lung, and Blood Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “computer-generated assignment
method”.
Allocation concealment (selection bias) Low risk Quote: “labels were placed in separately
sealed envelopes”.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Abstinence biochemically validated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “Employees lost to follow-up were
counted as smokers. The data indicate that
these individuals were equally distributed
among groups”. N lost to follow-up in each
group not provided
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Other bias Unclear risk The last scheduled rewards were paid out
to coincide with the final assessment, and
may therefore have confounded that result
Data extrapolated from percentages
ACS: American Cancer Society; ALA: American Lung Association; av: average (mean); B: black; CA: continuous abstinence; CBT:
cognitive behavioural therapy; CHW: community health worker; CM: contingency management; CO: carbon monoxide; COPD:
chronic obstructive pulmonary disease; CPD: cigarettes per day; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders,
Edition 4; EoT: end of treatment; ICC: Intra-class correlation coefficient; FEV: forced expiratory volume; FTND: Fagerström test
for nicotine dependence; FVC: forced vital capacity; NICU: neonatal intensive care unit; NRT: nicotine replacement therapy; pp:
post-partum; PPA: point prevalence abstinence; ppm: parts per million; QTW: quit to win; RP: relapse prevention; SC: smoking
cessation; SCN: saliva thiocyanate; TAU: treatment as usual
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alessi 2008 Outcome was reduction rather than smoking cessation, and participants were followed for 12 weeks only
New for 2011 update
Berg 2014 Too short; follow-up to 12 weeks
New for 2015 update
Bowers 1987 Outcomes were reduced CO and changes in blood pressure, not smoking cessation
Businelle 2014 Too short, 5 weeks duration
New for 2015 update
Cavallo 2007 Randomised trial of school children, lasting 1 month
New for 2008 update
Chivers 2008 RCT of variable contingency management schedules; programme lasted for 2 weeks only.
New for 2011 update.
Correia 2006 3-week trial of college students, randomised to high or low payments for abstinence
New for 2008 update
Crowley 1991 Study 1 was not a controlled trial. Studies 2 and 3 did not give detailed 6-month follow-up
Crowley 1995 Intervention is a competition (lottery ticket) rather than an incentive
Cummings 1988 Follow-up was only 3 months
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Curry 1991 Incentives were for use of the materials, not for smoking cessation
Dallery 2008 RCT of deposit vs vouchers for abstinence; programme lasted only 20 days
New for 2011 update
De Paul 1989 Incentives component cannot be evaluated separately from the other components of the intervention
Donatelle 2000c SOS II Programme: Non-randomised; used the control group from Donatelle 2000a as historical controls
New for 2015 update; pregnancy trial
Dunn 2008 RCT of contingency management; study only lasted 2 weeks
New for 2011 update
Dunn 2010 Same intervention as Dunn 2008, but with bupropion an added option
Elliott 1968 No control group, and followed up for 3 months only
Emont 1992 Aim of the study was to enhance recruitment, not smoking cessation
Fortmann 1995 Intervention being tested was self-help versus nicotine gum. All participants could receive quitting incentive
payment
Gadomski 2010 Cohort study, not an RCT
New for 2011 update
Gilbert 1999 Long-term incentives were for attending follow-up, not for smoking cessation
Gilbert 2002 No long-term follow-up outcomes beyond 31 days
Glover 2015 Trial only 8 weeks duration, not necessarily to end of pregnancy or beyond
New for 2015 update; pregnancy trial
Gottlieb 1990 Competition was used as a recruitment tool, not for smoking cessation
Graham 2007 No control group; incentives were paid for recruitment rather than cessation
New for 2011 update
Gulliver 2004 Participants randomised to partner support or no partner support; everyone attending follow-up got a raffle
ticket, regardless of smoking status
New for 2015 update; pregnancy trial
Hanewinkel 2007 Smoking prevention trial among school children in Germany, Finland and Netherlands. See Schools prevention
review
New for 2008 update
Haug 2017 Intervention targets both smoking and alcohol use
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Hertzberg 2013 CM RCT in PTSD patients, only followed up for 3 months
New for 2015 update
Higgins 2004 Study previously included, but excluded from the 2019 update because only 16 out of 53 participants were
randomly allocated
Hunt 2010 Not randomised; only followed up for 3 months
New for 2015 update
Jason 1990 Some baseline differences between (non-randomised) experimental and control companies, and intervention
included several programme options as well as the incentive component
Jeffery 1988 Intervention being tested was reduction versus cessation. Incentives were available to both groups
Jeffery 1989 Not a controlled trial. All participants were eligible for incentives
Jeffery 1993 Incentives were for attendance, not for cessation
Kassaye 1984 Objectives were cessation and reduction, and long-term follow-up outcomes were not fully reported
Kendzor 2015 Follow-up only 3 months
New for 2015 update
Kollins 2010 Not a randomised trial, and participants were followed for 24 days
New for 2011 update
Lamb 2004 Trial of 102 adult smokers, rewarded for reduced CO in daily breath samples. Lasted 3 months, and outcome
was lowered CO rather than cessation
New for 2008 update
Lamb 2007 Aim was reduction, not cessation; only followed up for 3 months
New for 2015 update
Lamb 2010 RCT of contingency management; followed for 3 months
New for 2010 update
Lussier 2005 Trial of 63 adult smokers randomised to 14-, 7- or 1-day contingency payments for abstinence. Lasted 2 weeks
MacKillop 2009 Only followed up for 8 weeks
New for 2015 update
Mantzari 2012 Qualitative report; not an RCT
New for 2015 update; pregnancy article
McDonell 2013 Intervention targets psycho-stimulant use
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Meredith 2011 Followed up only for 2 weeks
New for 2015 update
Monti 2006 50 adult smokers randomised to MET+contingency payment, relaxation+contingency payment, MET+ non-
contingency reinforcement or relaxation+noncontingency reinforcement. Followed for 3-week treatment pe-
riod
New for 2008 update
Mooney 2004 97 adult smokers randomised to standard care, information or information+contingent payment. Lasted 15
days, and outcome was increased use of nicotine gum, not cessation
New for 2008 update
NCT00508560 Study terminated before completion
NCT00718835 Follow-up less than 6 months
NCT00807742 Follow-up less than 6 months
NCT00960375 Follow-up less than 6 months
NCT01040260 Competition rather than incentives as intervention
NCT01145001 Follow-up less than 6 months
NCT01303081 Follow-up less than 6 months
NCT02195570 Study terminated before completion
Nowicki 1984 Complex intervention, including monthly lottery; cannot separate out the effect of the components
New for 2015 update; pregnancy trial
Olsen 1990 Incentives could not be evaluated separately from other components
Ormston 2015 Not an RCT; report on the “quit4u” stop smoking service
New for 2015 update; pregnancy study
Pardell 2003 No baseline measurements reported, and incentives could not be separated from other programme components
Parker 2007 Complex intervention, including USD 100 lottery for 30-day abstinence. Cannot separate out the components
New for 2015 update; pregnancy trial
Paxton 1980 Study previously included, but excluded from the 2019 update because participants were not randomised
Paxton 1981 Study previously included, but excluded from the 2019 update because participants were not randomised
Paxton 1983 Study previously included, but excluded from the 2019 update because participants were not randomised
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Perkins 2010 Cross-over RCT, lasted for 6 weeks
New for 2011 update
Poole 2001 Prospective cohort study, not a controlled trial
Radley 2013 Not an RCT; report on the ’Give it up for baby’ programme
New for 2015 update; pregnancy study
Rohsenow 2005 187 substance abusers randomised to contingency reinforcement or non-contingent reinforcement for 19 days.
No results reported for CR group
New for 2008 update
Roll 2008 RCT of deduction CM vs incremental CM; Trial only lasted 5 days, and abstinence was for 48 hours
New for 2011 update
Romanowich 2010 No non-incentive control group, and only followed up for 3 months
New for 2015 update
Romanowich 2013 No non-incentive group, and only followed up for 3 months
New for 2015 update
Romanowich 2014 No non-incentive group, and only followed up for 3 months
New for 2015 update
Sheikhattari 2016 Less than 6 months follow-up
Sigmon 2012a No non-incentive group, and only 3 months follow-up
New for 2015 update
Sloan 1990 Non-experimental design, with no control group
Spring 1978 Long-term follow-up outcomes not fully reported
Stitzer 1985 Outcome was reduced CO, and only 6 weeks follow-up
Stoops 2009 RCT of contingency management; programme lasted 6 weeks
New for 2010 update
Strecher 1983 No long-term outcomes, and no control group
Tanaka 2006 Complex intervention, in which impact of incentive cannot be isolated
New for 2011 update
Tidey 2011 Only followed up for 2 weeks
New for 2015 update
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Wagner 2013 Ineligible interventions in comparison study of two RCTs (no incentives)
New for 2015 update
Walsh 1997 Complex intervention, including a lottery for quitters. Cannot separate out the lottery component
New for 2015 update; pregnancy study
Winett 1973 Incentives were paid for attendance, reduction and cessation; no true control group (no incentives)
Winhusen 2014 Unable to establish length of follow-up (no response from author)
New for 2015 update
Wiseman 2005 20 cocaine users randomised to contingent or non-contingent payments. Treatment period and follow-up lasted
2 weeks
New for 2008 update
Yi 2008 Outcome was reduction rather than smoking cessation, and duration of study only 5 days
New for 2011 update
Yoon 2009 RCT of variable contingency payments for abstinence; followed up for 2 weeks
New for 2011 update
CO: carbon monoxide
Characteristics of studies awaiting assessment [ordered by study ID]
NCT02713594
Methods Open-label, parallel assignment randomised controlled trial
Participants 1900 Medicaid smokers
Interventions Control: “Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant
to help them successfully quit tobacco use, plus ad hoc calls at the participant’s initiation; also, WTQL coaches
encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications
to help them quit smoking.”
Experimental: Control intervention plus financial incentives. “Participants in the Incentive condition received $30
per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing
biochemical evidence of abstinence at the 6-month follow-up visit.”
Outcomes Primary outcome: biochemically verified smoking abstinence (measured by urine cotinine or expired CO) assessed
at 6 months follow-up
Secondary outcomes: engagement in treatment (number of calls completed) and cost-effectiveness
Notes
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Berlin 2016
Trial name or title Financial incentives for smoking cessation in pregnancy (FISCP): randomised, multicentre study
Methods Single-blind, randomised, 2 parallel groups, national superiority trial run in 16 maternity wards all over France
Participants 398 pregnant smokers aged ≥18years, smoking at least 5 manufactured or 3 roll-your-own cigarettes a day,
and pregnant for < 18weeks of amenorrhoea
Interventions Control group: After a predefined quit date, participants in the control group will receive EUR 20 vouchers
at the completion of each visit but no financial incentive for smoking abstinence
Intervention group: participants will be rewarded for their abstinence by vouchers on top of the EUR 20
show-up fee. The amount of reward for abstinence will increase as a function of duration of abstinence to
stimulate longer periods of abstinence
Outcomes Complete abstinence from quit date to the last predelivery visit
Starting date April 2016




Trial name or title ENtiCe Project - Encouragement for Nicotine Cessation in pregnant smokers
Methods 3-armed randomised trial (smaller incentives, larger incentives, control (no incentive)); non-concealed allo-
cation, randomising by day and antenatal session. No blinding
Participants 90 pregnant women who smoke, aged 16+, < 31 weeks gestation
Interventions 1; Small (AUD 20) incentives; 2. Large (AUD 40) incentives; 3. (Control) usual care. Incentive starts at AUD
20/AUD 40, and increases by AUD 20/AUD 40 for every consecutive abstinent check. Up to AUD 720/
AUD 1440 available if quit throughout programme
Outcomes Primary: Consenting to participate; acceptance of cash incentives; 7-day PPA, self-reported and cotinine-
verified, over 8 routine a/n sessions (10 weeks)
Secondary: abstinence confirmed by cotinine content of hair.
Starting date Registered April 2012
Contact information Dr Marita Lynagh (marita.lynagh@newcastle.edu.au)
Notes Pregnancy trial
ACTRN12612000399897
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Meyer 2015
Trial name or title Financial incentives promote smoking abstinence among patients with pulmonary disease
Methods Randomised controlled trial
Participants 30 daily smokers diagnosed with chronic obstructive pulmonary disease (COPD) (FEV1/FVC < 70%)
Interventions “Participants visit the clinic daily for 14 days and provide breath and urine samples for biochemical verifica-
tion of smoking status. Incentive participants earn financial incentives delivered contingent upon smoking
abstinence. Controls receive vouchers of the same value but independent of smoking status.”
Outcomes “Abstinence is defined as a breath CO level 6 ppm during Study Days 1-5 and a urinary cotinine level 80 ng/
ml on Days 6-14.”
Starting date Not stated




Trial name or title Incentive program for female substance abusers who smoke
Methods 3-arm intervention trial (not clear if randomised or not)
Participants 90 substance-abusing women, aged > 15
Interventions 2 voucher incentive programmes; 1 targeting abstinence alone, and the other additional incentives for negative
BAL and urinalysis
Outcomes Not stated; would include abstinence
Starting date January 2002
Contact information Leslie Amass (leslie.amas@uchsc.edu)
Notes
NCT00079469
Trial name or title Contingency management to enhance smoking cessation for cancer survivors: a proof of concept trial
Methods Multicentre RCT
Participants Smokers of at least 2 years who had been diagnosed and completed treatment for cancer at least 6 months,
but not more than 5 years, before study entry
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NCT00079469 (Continued)
Interventions 12 weeks bupropion + 6 weeks counselling for all participants; intervention arm get CM payments for
abstinence in weeks 1 to 6
Outcomes Primary: Feasibility of study; 7-day PPA at weeks 12, 24
Secondary: Characteristics of participants determining success
Starting date February 2004 to August 2004
Contact information Glen D Morgan
Notes
NCT00273793
Trial name or title Increasing contingency management success in smoking cessation
Methods Open-label RCT
Participants 240 adult smokers
Interventions Contingent and non-contingent incentives, with fixed and variable schedules, for hard-to-treat and easy-to-
treat smokers
Outcomes CO-verified abstinence at 6-month follow-up
Starting date June 2005
Contact information Richard J Lamb, University of Texas
Notes
NCT00408265
Trial name or title Smoking cessation in substance abuse treatment patients: a feasibility study
Methods Open-label RCT
Participants Substance-abusing men (N not given)
Interventions Self-help materials vs self-help materials + CM component, i.e. rewards equivalent to USD 1, USD 20, USD
100 for validated abstinence
Participants checked 4 times a week in weeks 1 to 4, twice a week in weeks 5 to 8, weekly in weeks 9 to 12.
Follow-ups at 1, 3 and 6 months following TQD
Outcomes Primary: % negative CO readings; % negative cotinine readings; longest period of continuous abstinence
Secondary: Self-reported smoking; objective substance use; self-reported substance use; treatment retention
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NCT00408265 (Continued)
Starting date January 2004 to March 2007
Contact information Sheila M Alessi (salessi@uchc.edu)
Notes
NCT00683280
Trial name or title Contingency management and pharmacotherapy for smoking cessation
Methods Open-label Phase II RCT
Participants 70 adult smokers, motivated to quit (59 recruited)
Interventions 12-week course of varenicline alone vs 12-week course of varenicline + CM rewards for validated abstinence
at weeks 5, 12 and 24
Outcomes Primary: Abstinence validated by CO, cotinine
Secondary: Changes from baseline in ambulatory 24-hour BP
Starting date May 2008 to August 2010
Contact information Prof Sheila M Alessi (salessi@uchc.edu)
Notes
NCT00690131
Trial name or title An integrated approach to smoking cessation in severe mental illness (SMI)
Methods Open-label RCT
Participants 50 adult smokers with severe and persistent mental illness
Interventions Group counselling, pharmacotherapies and CM with financial incentives for reductions in smoking
Outcomes Smoking abstinence and number of quit attempts at 3-month follow-up
Starting date June 2008
Contact information Melanie E Bennett, University of Maryland
Notes
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NCT01484717
Trial name or title Interactive voice response technology to mobilise contingency management for smoking cessation
Methods Open-label RCT
Participants 90 smokers motivated to quit
Interventions NRT (8 weeks of patches) + brief telephone counselling for all participants. Intervention arm also receives
chance to win prizes for negative breath tests
Outcomes Primary: Longest duration of abstinence (up to 24 weeks)
Secondary: not stated
Starting date January 2012
Contact information Shelia M Alessi (salessi@uchc.edu)
Notes
NCT01736982
Trial name or title Contingency management for smoking cessation in the homeless
Methods Open-label RCT
Participants 70 homeless smokers
Interventions Standard care: 8 weeks NRT, breath sample monitoring, standard SC counselling; Intervention: as standard
care + prizes for negative breath samples
Outcomes Longest duration of abstinence (Week 4)
Starting date October 2012
Contact information Eileen M Ciesielski (echiesielski@uhc.edu)
Notes
NCT01789710
Trial name or title Contingency management for smoking cessation in homeless smokers
Methods Single-arm trial
Participants 30 homeless smokers
Interventions Internet-based smoking cessation programme, plus NRT and bupropion, plus 4 counselling sessions. Partic-
ipants will use smartphone to relay images of verification. Payment contingent on CO readings
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NCT01789710 (Continued)
Outcomes Breath CO, throughout study to 12 months
Starting date January 2013
Contact information Jean C Beckham
Notes
NCT01826331
Trial name or title Incentives for participation versus outcomes
Methods Single-blind randomised controlled trial
Participants 880 smokers
Interventions 1. Those incentivised for participation in an evidence-based treatment designed for smokers at each stage of
change
2. Those incentivised for biologically validated prolonged abstinence at 6 and 12 months who could also
choose to participate in the TTM (Transtheoretical Model)-tailored intervention
3. An assessment-only control condition
Outcomes Smoking abstinence at 24 months
Starting date March 2014
Contact information James O Prochaska, Ph.D, University of Rhode Island jop@uri.edu
Notes
NCT01965405
Trial name or title Smoking cessation for people living with HIV/AIDS
Methods Open-label RCT
Participants 400 smokers with HIV/AIDS
Interventions Standard care (controls): bupropion + brief counselling; Phase 1: as standard care + high-value prize con-
tingency management for validated abstinence; Phase 2a: Non-responders A: bupropion, brief counselling +
monitored support to quit; Phase 2a: Non-responders B: as A, + chance to win prizes for validated abstinence.
2b: Responders A: Bupropion, no additional treatment; 2b: Responders B: bupropion, continued monitoring
+ low-intensity prize contingency management
All participants received USD 35 for intake, and USD 25 for each follow-up interview at post-phase 1, post-
phase 2, 6 and 12 months
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NCT01965405 (Continued)
Outcomes Primary: Urinary cotinine at all test points, up to 12 months; Longest duration of continuous abstinence; 7-
day PPA at all time points; CO result at all time points
Starting date August 2013
Contact information Lisa Sulkowski (lulkows@med.wayne.edu)
Notes
NCT02210832
Trial name or title Financial incentives for smoking cessation among disadvantaged pregnant women
Methods Open-label RCT
Participants 345 pregnant smokers
Interventions Controls: Best practice (5As) + referral to pregnancy-specific quit line; Intervention: as controls, + financial
incentives for validated abstinence (vouchers, available through to 12 weeks post-partum)
Also a group of never-smoker pregnant women matched to smokers on key demographic variables, for
comparison through to 12 months
Outcomes Primary: validated 7-day PPA at final ante-partum appointment (around 28 weeks gestation)
Secondary: validated 7-day PPA post-partum, i.e. weeks 4, 8, 12, 24 and 48; birth outcomes; maternal and
baby heath utilisation measures; cost effectiveness
Starting date January 2014
Contact information Mary Ellen Lynch (mlynch1@uvm.edu) and Kylie N Johnson (kjohns@uvm.edu)
Notes Pregnancy trial
NCT02237898
Trial name or title Harnessing the power of technology: MOMBA for post-partum smoking
Methods Phase 1 RCT
Participants 40 pregnant smokers
Interventions Controls; traditional office-based CM programme, delivering financial incentives to abstinent post-partum
women; Intervention: MOMBA smart-phone Sensodrone app to relay CO monitoring of abstinence
N.B. All participants receive financial incentives; mode of delivery was the variable being tested
Outcomes Primary: Acceptability; feasibility
Secondary: short-term abstinence; long-term (7-day PPA)
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NCT02237898 (Continued)
Starting date September 2014
Contact information Ruth M Arnold (ruth.arnold@yale.edu) and Heather Howell (heather.howell@yale.edu)
Notes Pregnancy trial (pilot)
NCT02245308
Trial name or title Abstinence Reinforcement Therapy (ART) for homeless veteran smokers
Methods Open-label RCT
Participants 165 veteran homeless smokers
Interventions Controls: VA smoking cessation clinic for standard care treatment, including group counselling, individual
counselling, self-help materials. Intervention: tele-health programme, combining CBT-based support, tele-
medicine clinic for pharmacological aids (nicotine patches, bupropion), and mobile contingency management
Outcomes Primary: validated 6-month abstinence
Secondary: QALY, resource utilisation, intervention delivery costs and participant time costs
Starting date September 2014
Contact information Jean C Beckham
Notes
NCT02266784
Trial name or title Contingency management, quitting smoking, and ADHD (ADQUIT)
Methods Phase 1 open-label RCT
Participants 40 smokers with ADHD
Interventions Controls: Supportive counselling + NRT patches, 8-week programme; Intervention: as for controls, + es-
calating financial rewards for continuous abstinence, reset in case of failure or missed visits; all participants
checked at 3 and 6 months
Outcomes Primary: Change in motivation to quit; change in readiness to change behaviour
Secondary: Chamge in smoking behaviour in ADHD population at 3 months, 6 months; decreasing effects
of quitting smoking
Starting date October 2014
Contact information Joseph S English (engli009@mc.duke.edu) and Denny A Hood (denny.hood@dm.duke.edu)
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Trial name or title Financial Incentives for Smoking Treatment (FIESTA)
Methods Parallel-assignment randomised controlled trial
Participants 182 urban veteran smokers
Interventions Financial incentives intervention: “Usual care in hospital, referral to a smoking cessation Quitline on discharge
from hospital. Financial incentives for: a) speaking with a coach from the Smoker’s Quitline ($50), b) com-
pletion of another community-based smoking-cessation program ($50), and/or c) use of pharmacotherapies
for smoking cessation at 2 weeks ($50); and d) for smoking cessation, confirmed with the use of a cotinine
test at 2 months ($150); and e) for smoking cessation, confirmed with the use of a cotinine test at 6 months
after study enrollment ($250).”
Control: “Usual care in hospital, referral to a smoking cessation Quitline on discharge from hospital.”
Outcomes Primary: Self-report and biochemically verified (by salivary cotinine) smoking abstinence at 6 months
Secondary: Self-report smoking abstinence at 6 months; use of evidence-based treatments; quality of life
(measured with EQ5-D); short- and long-term return on investment (cost analysis)
Starting date July 2015
Contact information Dr Joseph Ladapo JLadapo@mednet.ucla.edu
Dr Scott Sherman Scott.Sherman@nyumc.org
Notes
NCT02596061
Trial name or title In It To Quit: commitment contracts for smoking cessation (I2Q)
Methods Open-label parallel-assignment 3-group randomised controlled trial
Participants 311 low-moderate income smokers
Interventions Intervention 1 - Rewards Only :Participants have access to a website where they can self-report smoking
status, add virtual supporters, and submit journal entries. Participants receive incentives for completing these
activities and for using counselling services at the clinic. At the 2-month mark, these participants come to
the clinic for a biochemical verification of their smoking status. Their rewards are contingent on passing this
verification test. They are also asked to return to the clinic 6 and 12 months after enrolment to complete the
smoking tests and are compensated for these 2 visits
Intervention 2 - Pre-Committment: In addition to activities in intervention group 1, at enrollment, partic-
ipants are offered the chance to set aside some of their future rewards for a deposit contract that lasts for 4
months and starts 2 months after the rewards contract. If at the end of 6 months the participants pass the
second verification test, their rewards are returned to them
112Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02596061 (Continued)
Control: No intervention
Outcomes Primary outcome: continuous abstinence from smoking between months 2 and 12, i.e. biochemically verified
abstinence at all 3 measurements
Starting date November 2015
Contact information Dr Daren Anderson: andersd@chc1.com
Notes
NCT02737566
Trial name or title Small financial incentives to promote smoking cessation (Prevail II)
Methods Open-label parellel-assignment randomised controlled trial
Participants 320 English-speaking adult smokers of at least 5 cigarettes a day, in receipt of Medicaid or uninsured
Interventions Experimental: standard care plus financial incentives (“the opportunity to earn small gift cards for biochem-
ically-verified abstinence through 12 weeks post-quit. The amount of the gift cards will escalate each week
from the quit date through 4 weeks post-quit with continuous abstinence. Participants who are non-abstinent
at any visit may earn incentives for abstinence at the next visit, but the amount will reset to the starting level.
Participants may additionally earn an additional gift card for abstinence at the 8 and 12 weeks post-quit visits.
”
Control: standard care (weekly smoking cessation counselling and pharmacotherapy)
Outcomes Primary outcome: biochemically verified 7-day point prevalence smoking cessation at 26 weeks
Secondary outcome: biochemically verified 7-day point prevalence smoking cessation at 12 weeks
Starting date January 30th 2017




Trial name or title Disseminating and implementing a smoking cessation program for pregnant and postpartum women
Methods Single-blind parallel-assignment randomised controlled trial
Participants 185
Interventions Intervention: “Striving to quit”. Includines “additional pre-natal counseling (in-person and telephonic); post
delivery counseling (in-person and telephonic) and incentives”
Control: Brief pre-natal smoking cessation counselling
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NCT02952703 (Continued)
Outcomes Primary outcome: biochemically verified smoking abstinence (breath CO < 9ppm, 6 months post-interven-
tion)
Secondary outcome: motivation to quit/remain quit meausred on a 5-point Likert scale at 6 months
Starting date May 2018




Trial name or title Smoking cessation treatment for depressed smokers
Methods Open-label parallel-assignment randomised controlled trial
Participants 150 adult smokers of 10+ cigarettes a day for at least 1 year, meeting diagnostic criteria for current unipolar
major depression and nicotine dependence
Interventions Control group 1: group-based cognitive behaviour treatment for smoking cessation
Control group 2: as per control group 1 plus behavioural activation strategies
Intervention group: as per groups 1 and 2 plus contingency management. From the 5th session onwards
“Participants providing negative specimens of both CO (≤4 ppm) and cotinine (80 ng/ml) earned points
exchangeable for rewards (e.g. cinema tickets) on a schedule of escalating magnitude of reinforcement (from
10EURO voucher value with maximum possible earnings of 175EURO in vouchers).”
Outcomes Primary outcomes: 7-day point prevalence smoking abstinence biochemically verified with CO and cotinine
(longest follow-up 6 months)
Secondary outcomes: depression; behavioural activation; environmental reward; cigarette craving; anxiety;
impulsivity
Starting date January 26th 2015
Contact information Dr Roberto Secades-Villa: secades@uniovi.es
Notes
NCT03528304
Trial name or title Native Women’s Wellness: contingency management for tobacco cessation and weight loss (NWW)
Methods Open-label factorial assignment randomised controlled trial
Participants 125 women aged 18 - 44 of American Indian or Alaska Native heritage, currently smoking and overweight
and not interested in using NRT
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NCT03528304 (Continued)
Interventions No-intervention control
Intervention 1: contingency management for smoking cessation. As part of the CM intervention, women
attend visits for smoking are rewarded with prizes for abstaining from smoking
Intervention 2: contingency management for smoking cessation and weight loss. As part of the CM interven-
tion, women attend visits for smoking and weight loss assessment and are rewarded with prizes for abstaining
from smoking and for losing some weight
The study also included a third arm which does not meet the inclusion criteria for this review, involving
contingency management alone
Outcomes Primary outcome: smoking abstinence at 16 weeks
Starting date September 2010
Contact information Dr Dedra Buchwald
Email: dedra.buchwald@wsu.edu
Notes Pregnant women and those planning to become pregnant in the next 4 months were excluded
NCT03551704
Trial name or title Smoking cessation treatment for substance use dependents
Methods Open-label parallel-assignment randomised controlled trial
Participants 120 adults who have smoked at least 10 cigarettes a day for the past year undergoing outpatient cocaine or
alcohol treatment and meeting diagnostic criteria for nicotine dependence
Interventions Control group: cognitive behavioural therapy plus episodic future thinking
Intervention group: as per control group, plus contingency management. Participants will be provided with
“incentives to promote and reinforce abstinence contingent on biochemical verification. The schedule will
incorporate an increasing magnitude of reinforcement.”
Outcomes Primary outcomes: 1. Changes in smoking abstinence (period of at least 24 hours without smoking or not
smoking in the last 7 days, assessed with CO and cotinine samples) 2. Changes in continuous abstinence (not
smoking even a puff since the quit date, verified with CO and cotinine samples)
Secondary outcomes: Changes in other substance abstinence; changes in drug demand; changes in health-
related quality of life; changes in depression; changes in impulsivity; cost-analysis
Starting date January 15th 2018
Contact information Dr Roberto Secades-Villa: secades@uniovi.es
Notes
115Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Secades-Villa 2015
Trial name or title CM of smoking abstinence vs CM with shaping for smoking cessation among treatment-seeking patients
Methods Randomised controlled trial
Participants 47 smokers in a community setting
Interventions Contingency management (CM) intervention where participants earned voucher-based incentives contingent
on providing biochemical evidence (a negative urine cotinine test) of smoking abstinence
Contingency management with shaping (CMS): participants were set intermediate criteria for incentive de-
livery between the present behaviour and total abstinence. “CMS reinforce progressive reductions in smoking
according to a percentile schedule.”
Outcomes Smoking abstinence at post-treatment assessment; treatment completion; total days abstinent
Starting date Not reported
Contact information Dr Roberto Secades-Villa: secades@uniovi.es
Notes
Wilson 2016
Trial name or title Abstinence Reinforcement Therapy (ART) for rural veterans
Methods Randomised control trial
Participants 310 rural Veteran smokers
Interventions Intervention: Abstinence Reinforcement Therapy (ART) which combines evidence-based cognitive-be-
havioural telephone counselling (TC), a tele-medicine clinic for access to NRT and mobile contingency man-
agement (mCM), in which compensation is given based on smoking abstinence
Control condition: TC and NRT alone
Outcomes Primary outcome: self-report and biochemically validated prolonged smoking abstinence at 6 months and 12
months
Starting date Not reported
Contact information Sarah Wilson: sarah.wilson@duke.edu
Notes
116Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Incentives in mixed populations




participants Statistical method Effect size
1 Smoking cessation (subgrouped
by when incentives were
provided)
30 20060 Risk Ratio (M-H, Random, 95% CI) 1.49 [1.28, 1.73]
1.1 Incentives provided at
longest follow-up
6 3039 Risk Ratio (M-H, Random, 95% CI) 1.66 [1.33, 2.07]
1.2 Incentives not provided at
longest follow-up
24 17021 Risk Ratio (M-H, Random, 95% CI) 1.40 [1.16, 1.69]
2 Smoking cessation (grouped by
substance misuse)
31 20097 Risk Ratio (M-H, Random, 95% CI) 1.49 [1.28, 1.73]
2.1 Substance misusers 8 1055 Risk Ratio (M-H, Random, 95% CI) 1.24 [0.81, 1.89]
2.2 Non-substance misusers 23 19042 Risk Ratio (M-H, Random, 95% CI) 1.52 [1.29, 1.80]
Comparison 2. Incentives in pregnant women




participants Statistical method Effect size
1 Smoking cessation at longest
follow-up
9 2273 Risk Ratio (M-H, Random, 95% CI) 2.38 [1.54, 3.69]
2 Abstinence at end of pregnancy 7 1244 Risk Ratio (M-H, Random, 95% CI) 2.79 [2.10, 3.72]
3 Contingent rewards vs
guaranteed payments
3 225 Risk Ratio (M-H, Random, 95% CI) 3.33 [0.97, 11.38]
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Analysis 1.1. Comparison 1 Incentives in mixed populations, Outcome 1 Smoking cessation (subgrouped by
when incentives were provided).
Review: Incentives for smoking cessation
Comparison: 1 Incentives in mixed populations
Outcome: 1 Smoking cessation (subgrouped by when incentives were provided)








1 Incentives provided at longest follow-up
Drummond 2014 3/50 1/50 0.4 % 3.00 [ 0.32, 27.87 ]
Fraser 2017 205/948 131/952 10.4 % 1.57 [ 1.29, 1.92 ]
Gallagher 2007 4/60 3/60 1.0 % 1.33 [ 0.31, 5.70 ]
Ghosh 2016 2/6 0/8 0.3 % 6.43 [ 0.36, 113.52 ]
Lasser 2017 21/177 4/175 1.8 % 5.19 [ 1.82, 14.81 ]
Van den Brand 2018 (1) 120/292 69/261 9.5 % 1.55 [ 1.22, 1.99 ]
Subtotal (95% CI) 1533 1506 23.4 % 1.66 [ 1.33, 2.07 ]
Total events: 355 (Incentives), 208 (No incentives)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.26, df = 5 (P = 0.28); I2 =20%
Test for overall effect: Z = 4.54 (P < 0.00001)
2 Incentives not provided at longest follow-up
Alessi 2014 3/24 5/21 1.2 % 0.53 [ 0.14, 1.94 ]
Cheung 2017 30/764 17/379 4.4 % 0.88 [ 0.49, 1.57 ]
Cooney 2017 5/42 2/41 0.9 % 2.44 [ 0.50, 11.88 ]
Dallery 2016 11/48 6/46 2.3 % 1.76 [ 0.71, 4.36 ]
De Paul 1994 (2) 34/259 27/259 5.6 % 1.26 [ 0.78, 2.02 ]
Etter 2016 39/401 19/404 5.0 % 2.07 [ 1.22, 3.52 ]
Gin 2010 86/781 55/616 8.1 % 1.23 [ 0.89, 1.70 ]
Glasgow 1993 (3) 35/243 35/301 6.2 % 1.24 [ 0.80, 1.92 ]
Halpern 2015 (4) 50/1053 8/234 3.2 % 1.39 [ 0.67, 2.89 ]
Halpern 2015 (5) 82/1017 8/234 3.3 % 2.36 [ 1.16, 4.81 ]
Halpern 2018 29/2406 5/1588 2.1 % 3.83 [ 1.48, 9.87 ]
Ledgerwood 2014 4/64 1/17 0.5 % 1.06 [ 0.13, 8.90 ]
Rand 1989 1/17 0/14 0.2 % 2.50 [ 0.11, 56.98 ]
Rettig 2018 4/19 0/11 0.3 % 5.40 [ 0.32, 91.76 ]
0.002 0.1 1 10 500
Favours no incentives Favours incentives
(Continued . . . )
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Rohsenow 2015 4/97 4/86 1.1 % 0.89 [ 0.23, 3.44 ]
Rohsenow 2017 6/172 3/168 1.1 % 1.95 [ 0.50, 7.68 ]
Romanowich 2015 15/193 6/47 2.3 % 0.61 [ 0.25, 1.48 ]
Secades-Villa 2014 17/43 13/49 4.3 % 1.49 [ 0.82, 2.70 ]
Shoptaw 2002 (6) 1/47 2/42 0.4 % 0.45 [ 0.04, 4.75 ]
Shoptaw 2002 (7) 2/43 4/43 0.8 % 0.50 [ 0.10, 2.59 ]
Tevyaw 2009 1/55 3/55 0.4 % 0.33 [ 0.04, 3.11 ]
Volpp 2006 6/92 4/87 1.3 % 1.42 [ 0.41, 4.86 ]
Volpp 2009 41/436 16/442 4.6 % 2.60 [ 1.48, 4.56 ]
White 2013 58/131 13/69 5.0 % 2.35 [ 1.39, 3.98 ]
White 2018 (8) 403/2631 29/312 7.4 % 1.65 [ 1.15, 2.36 ]
Windsor 1988 (9) 9/94 17/94 3.0 % 0.53 [ 0.25, 1.13 ]
Windsor 1988 (10) 5/95 6/95 1.5 % 0.83 [ 0.26, 2.64 ]
Subtotal (95% CI) 11267 5754 76.6 % 1.40 [ 1.16, 1.69 ]
Total events: 981 (Incentives), 308 (No incentives)
Heterogeneity: Tau2 = 0.07; Chi2 = 40.47, df = 26 (P = 0.04); I2 =36%
Test for overall effect: Z = 3.53 (P = 0.00041)
Total (95% CI) 12800 7260 100.0 % 1.49 [ 1.28, 1.73 ]
Total events: 1336 (Incentives), 516 (No incentives)
Heterogeneity: Tau2 = 0.05; Chi2 = 48.05, df = 32 (P = 0.03); I2 =33%
Test for overall effect: Z = 5.13 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.31, df = 1 (P = 0.25), I2 =23%
0.002 0.1 1 10 500
Favours no incentives Favours incentives
(1) Cluster-randomised; adjusted data used here
(2) Cluster-randomised; adjusted data used here
(3) Cluster-randomised; adjusted data used here
(4) Deposit arms versus control; control split to avoid double-counting
(5) Rewards versus control. Control split to avoid double-counting
(6) Four-armed study, two arms involve relapse prevention (RP). RP arms listed here.
(7) Four-armed study, two arms involve relapse prevention (RP). Non-RP arms listed here.
(8) Cluster-randomised; adjusted data used here
(9) Study includes four arms; 2 with cessation skills training (CST). CST arms listed here. Control groups split to avoid double counting.
(10) Study includes four arms; 2 with cessation skills training (CST). Non-CST arms listed here. Control groups split to avoid double counting.
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Analysis 1.2. Comparison 1 Incentives in mixed populations, Outcome 2 Smoking cessation (grouped by
substance misuse).
Review: Incentives for smoking cessation
Comparison: 1 Incentives in mixed populations
Outcome: 2 Smoking cessation (grouped by substance misuse)









Ainscough 2017 0/19 0/18 Not estimable
Alessi 2014 3/24 5/21 1.2 % 0.53 [ 0.14, 1.94 ]
Cooney 2017 5/42 2/41 0.9 % 2.44 [ 0.50, 11.88 ]
Drummond 2014 3/50 1/50 0.4 % 3.00 [ 0.32, 27.87 ]
Rohsenow 2015 4/97 4/86 1.1 % 0.89 [ 0.23, 3.44 ]
Rohsenow 2017 6/172 3/168 1.1 % 1.95 [ 0.50, 7.68 ]
Secades-Villa 2014 17/43 13/49 4.3 % 1.49 [ 0.82, 2.70 ]
Shoptaw 2002 (1) 1/47 2/42 0.4 % 0.45 [ 0.04, 4.75 ]
Shoptaw 2002 (2) 2/43 4/43 0.8 % 0.50 [ 0.10, 2.59 ]
Subtotal (95% CI) 537 518 10.2 % 1.24 [ 0.81, 1.89 ]
Total events: 41 (Incentives), 34 (No incentives)
Heterogeneity: Tau2 = 0.0; Chi2 = 5.89, df = 7 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
2 Non-substance misusers
Cheung 2017 30/764 17/379 4.4 % 0.88 [ 0.49, 1.57 ]
Dallery 2016 11/48 6/46 2.3 % 1.76 [ 0.71, 4.36 ]
De Paul 1994 (3) 34/259 27/259 5.6 % 1.26 [ 0.78, 2.02 ]
Etter 2016 39/401 19/404 5.0 % 2.07 [ 1.22, 3.52 ]
Fraser 2017 205/948 131/952 10.4 % 1.57 [ 1.29, 1.92 ]
Gallagher 2007 4/60 3/60 1.0 % 1.33 [ 0.31, 5.70 ]
Ghosh 2016 2/6 0/8 0.3 % 6.43 [ 0.36, 113.52 ]
Gin 2010 86/781 55/616 8.1 % 1.23 [ 0.89, 1.70 ]
Glasgow 1993 (4) 35/243 35/301 6.2 % 1.24 [ 0.80, 1.92 ]
0.01 0.1 1 10 100
Favours no incentives Favours incentives
(Continued . . . )
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Halpern 2015 (5) 82/1017 8/234 3.3 % 2.36 [ 1.16, 4.81 ]
Halpern 2015 (6) 50/1053 8/234 3.2 % 1.39 [ 0.67, 2.89 ]
Halpern 2018 29/2406 5/1588 2.1 % 3.83 [ 1.48, 9.87 ]
Lasser 2017 21/177 4/175 1.8 % 5.19 [ 1.82, 14.81 ]
Ledgerwood 2014 4/64 1/17 0.5 % 1.06 [ 0.13, 8.90 ]
Rand 1989 1/17 0/14 0.2 % 2.50 [ 0.11, 56.98 ]
Rettig 2018 4/19 0/11 0.3 % 5.40 [ 0.32, 91.76 ]
Romanowich 2015 15/193 6/47 2.3 % 0.61 [ 0.25, 1.48 ]
Tevyaw 2009 1/55 3/55 0.4 % 0.33 [ 0.04, 3.11 ]
Van den Brand 2018 (7) 120/292 69/261 9.5 % 1.55 [ 1.22, 1.99 ]
Volpp 2006 6/92 4/87 1.3 % 1.42 [ 0.41, 4.86 ]
Volpp 2009 41/436 16/442 4.6 % 2.60 [ 1.48, 4.56 ]
White 2013 58/131 13/69 5.0 % 2.35 [ 1.39, 3.98 ]
White 2018 (8) 403/2631 29/312 7.4 % 1.65 [ 1.15, 2.36 ]
Windsor 1988 (9) 5/95 6/95 1.5 % 0.83 [ 0.26, 2.64 ]
Windsor 1988 (10) 9/94 17/94 3.0 % 0.53 [ 0.25, 1.13 ]
Subtotal (95% CI) 12282 6760 89.8 % 1.52 [ 1.29, 1.80 ]
Total events: 1295 (Incentives), 482 (No incentives)
Heterogeneity: Tau2 = 0.05; Chi2 = 41.32, df = 24 (P = 0.02); I2 =42%
Test for overall effect: Z = 4.97 (P < 0.00001)
Total (95% CI) 12819 7278 100.0 % 1.49 [ 1.28, 1.73 ]
Total events: 1336 (Incentives), 516 (No incentives)
Heterogeneity: Tau2 = 0.05; Chi2 = 48.05, df = 32 (P = 0.03); I2 =33%
Test for overall effect: Z = 5.13 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.78, df = 1 (P = 0.38), I2 =0.0%
0.01 0.1 1 10 100
Favours no incentives Favours incentives
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(1) Four-armed study, two arms involve relapse prevention (RP). RP arms listed here.
(2) Four-armed study, two arms involve relapse prevention (RP). Non-RP arms listed here.
(3) Cluster-randomized; adjusted data used here
(4) Cluster-randomized; adjusted data used here
(5) Rewards versus control. Control split to avoid double-counting
(6) Deposit arms versus control; control split to avoid double-counting
(7) Cluster-randomized; adjusted data used here
(8) Cluster-randomized; adjusted data used here
(9) Study includes four arms; 2 with cessation skills training (CST). Non-CST arms listed here. Control groups split to avoid double counting.
(10) Study includes four arms; 2 with cessation skills training (CST). CST arms listed here. Control groups split to avoid double counting.
Analysis 2.1. Comparison 2 Incentives in pregnant women, Outcome 1 Smoking cessation at longest follow-
up.
Review: Incentives for smoking cessation
Comparison: 2 Incentives in pregnant women
Outcome: 1 Smoking cessation at longest follow-up








Baker 2018 74/505 47/509 27.8 % 1.59 [ 1.12, 2.24 ]
Donatelle 2000a 22/103 6/102 14.6 % 3.63 [ 1.54, 8.58 ]
Donatelle 2000b 13/67 7/60 14.8 % 1.66 [ 0.71, 3.89 ]
Harris 2015 1/7 3/10 4.0 % 0.48 [ 0.06, 3.69 ]
Heil 2008 3/37 1/40 3.5 % 3.24 [ 0.35, 29.82 ]
Higgins 2014 7/40 3/39 8.7 % 2.28 [ 0.63, 8.17 ]
Ondersma 2012 7/48 1/23 4.1 % 3.35 [ 0.44, 25.68 ]
Tappin 2015a (1) 47/306 12/303 20.2 % 3.88 [ 2.10, 7.16 ]
Tuten 2012 13/42 0/32 2.3 % 20.72 [ 1.28, 336.01 ]
Total (95% CI) 1155 1118 100.0 % 2.38 [ 1.54, 3.69 ]
0.005 0.1 1 10 200
Favours no incentives Favours incentives
(Continued . . . )
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(. . . Continued)








Total events: 187 (Incentives), 80 (No incentives)
Heterogeneity: Tau2 = 0.15; Chi2 = 13.61, df = 8 (P = 0.09); I2 =41%
Test for overall effect: Z = 3.89 (P = 0.00010)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours no incentives Favours incentives
(1) 12 months post-TQD
Analysis 2.2. Comparison 2 Incentives in pregnant women, Outcome 2 Abstinence at end of pregnancy.
Review: Incentives for smoking cessation
Comparison: 2 Incentives in pregnant women
Outcome: 2 Abstinence at end of pregnancy








Donatelle 2000a 34/105 9/102 17.5 % 3.67 [ 1.85, 7.26 ]
Donatelle 2000b (1) 13/67 7/60 11.3 % 1.66 [ 0.71, 3.89 ]
Heil 2008 15/37 4/40 8.0 % 4.05 [ 1.48, 11.11 ]
Higgins 2014 18/40 7/39 14.4 % 2.51 [ 1.18, 5.33 ]
Ondersma 2012 (2) 7/48 1/23 2.0 % 3.35 [ 0.44, 25.68 ]
Tappin 2015a 69/306 26/303 45.8 % 2.63 [ 1.72, 4.01 ]
Tuten 2012 (3) 13/42 0/32 1.1 % 20.72 [ 1.28, 336.01 ]
Total (95% CI) 645 599 100.0 % 2.79 [ 2.10, 3.72 ]
Total events: 169 (Incentives), 54 (No incentives)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.90, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 7.05 (P < 0.00001)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours no incentives Favours incentives
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(1) extrapolated from %
(2) Results reported only to end of 10-wk programme (end of pregnancy)
(3) Results reported only to end of 12-wk programme (end of pregnancy)
Analysis 2.3. Comparison 2 Incentives in pregnant women, Outcome 3 Contingent rewards vs guaranteed
payments.
Review: Incentives for smoking cessation
Comparison: 2 Incentives in pregnant women
Outcome: 3 Contingent rewards vs guaranteed payments








Heil 2008 3/37 1/40 25.8 % 3.24 [ 0.35, 29.82 ]
Higgins 2014 6/39 3/39 56.8 % 2.00 [ 0.54, 7.43 ]
Tuten 2012 13/42 0/28 17.4 % 18.21 [ 1.13, 294.43 ]
Total (95% CI) 118 107 100.0 % 3.33 [ 0.97, 11.38 ]
Total events: 22 (Contingent), 4 (Guaranteed)
Heterogeneity: Tau2 = 0.24; Chi2 = 2.45, df = 2 (P = 0.29); I2 =18%
Test for overall effect: Z = 1.92 (P = 0.055)
Test for subgroup differences: Not applicable
0.002 0.1 1 10 500
Favours guaranteed Favours contingent
A D D I T I O N A L T A B L E S
Table 1. Results of included studies: mixed-populations
Study ID Denomina-
tor
Abstinence Time point Biological
criterion







PPA 6 months CO < 10
ppm




124Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


















Alessi 2014 24 (CM)
21 (control)















































































125Incentives for smoking cessation (Review)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Results of included studies: mixed-populations (Continued)




















































PPA 24 months CO < 9 ppm 13.2% (I)
10.3 %(SH)





















50 (CM x 2)
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Fraser 2017 948 (IG)
952 (CG)
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but not at 8
ppm
Rettig 2018 8 (CG)
13 (IG)
PPA 12 months 8 ppm 0 (CG)
4 (31%)
(!G)
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Volpp 2006 92 (I)
87 (C)
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Volpp 2009 436 (I)
442 (C)





















White 2013 131 (I)
69 (C)
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Table 2. Results of included studies: pregnancy
Study ID Denomina-
tor
Abstinence Time point Biological
criteria
Quit rate Stat sig? Other out-
comes
Comment
Baker 2018 505 (IG)
509 (CG)
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CO < 5 ppm
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Heil 2008 37 (I)
40 (C)
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A P P E N D I C E S









9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
W H A T ’ S N E W
Date Event Description
21 January 2019 New citation required and conclusions have changed Certainty of evidence for studies in mixed populations
upgraded from low to high. Previously included non-
randomised studies now excluded
21 January 2019 New search has been performed Search run 30th July 2018. Review updated with 16 new
included studies in mixed populations and 2 new in-
cluded studies in pregnant women
H I S T O R Y
Protocol first published: Issue 2, 2003
Review first published: Issue 2, 2005
Date Event Description
6 January 2015 New citation required and conclusions have changed Review split into ’Incentives and contingency man-
agement’ (this update) and ’Competitions’ (compan-
ion update). 5 trials transferred to the Competitions
update, and 7 new trials added, plus a complete new
section (9 trials) on pregnant women
16 December 2014 New search has been performed New searches conducted, and entire review reformat-
ted and expanded. 16 new trials added. Non-ran-
domised trials excluded. Analysis changed from OR to
RR
14 April 2011 Amended Minor typographical errors corrected
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(Continued)
24 November 2010 New search has been performed 15 new trials added: 2 included, 13 excluded.
24 November 2010 New citation required and conclusions have changed New included study (Volpp 2009) found long-term
positive effects of their incentive-based trial. Risk of
bias tables added for all studies
6 August 2008 Amended Source of support added
29 April 2008 New citation required but conclusions have not
changed
Name change for first author
2 April 2008 New search has been performed Two new included studies, nine new excluded studies,
conclusions unchanged
2 April 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
CN (guarantor of the review) extracted data, conducted the analyses and wrote the review.
SG double-data extracted and contributed to the analysis and writing of the review.
JHB contributed to the design of the update, double-data extracted, checked data extraction and contributed to the writing of the
review.
RP checked the statistical analysis and commented on the review.
JLB ran the searches, checked the inclusion/exclusion and critical appraisal and contributed to the writing of the review.
LB contributed to the writing and editing of the review.




LB: is co-author of one of the trials included in the review (Tappin 2015a) and some of the studies cited as supporting evidence in the
Background and Discussion sections (Berlin 2018; Hoddinott 2014).
RP: none known.
JHB: none known.
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S O U R C E S O F S U P P O R T
Internal sources
• Nuffield Department of Primary Care Health Sciences, University of Oxford, UK.
• JHB is funded by the National Institute of Health Research School for Primary Care Research (NIHR SPCR), UK.
External sources
• NHS Research and Development Fund, UK.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
For this 2019 update, we removed the separate six-month follow-up time point analysis for studies of mixed populations, as long-term
follow-up was our focus for this review.
For this 2019 update we excluded non-randomised studies and changed the analysis from odds ratios to risk ratios, in accordance with
standard methods of the Cochrane Tobacco Addiction Group. We also introduced a new subgroup analysis within mixed-population
studies of trials recruiting from substance misuse populations (community or inpatient clinics), since a number of new studies included
in this update recruited from this specific population and there is reason to believe the effect of incentives could be different in this
population.
For the 2019 update we changed the ’Risk of bias’ assessments from evaluating performance and detection bias in one domain, to
assessing detection bias alone, based on whether studies biochemically validated abstinence. We did this because the interventions being
studied preclude effective blinding of participants and study personnel, and in order to simplify and clarify the assessment of detection
bias.
We included sensitivity analysis to explore the relative size of incentives offered, and sub-group analysis to explore potential impact of
studies where incentives were continually offered up until the long term follow up point.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Motivation; ∗Reward; Health Facilities; Health Promotion [methods]; Randomized Controlled Trials as Topic; Smoking Cessation
[methods; ∗psychology]; Workplace
MeSH check words
Female; Humans; Male; Pregnancy
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